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Graft-versus-tumor reactivity after hematopoietic stem cell transplantation 
 
Allogeneic stem cell transplantation (SCT) has evolved to a specialized form of 
immunotherapy for treating numerous hematological malignancies like 
leukemia, malignant lymphoma, multiple myeloma and some solid tumors (1, 
2). Initially, the infusion of donor hematopoietic stem cells was applied to rescue 
bone-marrow toxicity after the high dose chemotherapy and total body 
irradiation for the eradication of malignant cells. However, several clinical 
studies have demonstrated decreased relapse rates after allogeneic SCT 
compared to autologous SCT and SCT between genotypically identical 
syngeneic twins (3, 4). Moreover, some studies showed that allogeneic SCT 
using T cell-depleted grafts results in an increased relapse rate (5, 6). These 
clinical observations indicated that tumor eradication after allogeneic SCT is 
primarily mediated by a donor T cell-dependent immune reaction collectively 
referred to as the graft-versus-tumor (GVT) reactivity (7-9). The hypothesis that 
donor-derived T cells are key mediators of the GVT reactivity was confirmed by 
successful treatment of patients with recurrent hematopoietic malignancy with 
donor lymphocyte infusions (DLI) (10, 11). This is best illustrated by the 
induction of durable molecular remissions for relapsed chronic myeloid 
leukemia (CML) in chronic phase (12-15). In addition, objective responses can 
be achieved in patients with relapsed acute myeloid leukemia (AML), acute 
lymphoid leukemia (ALL) and multiple myeloma (MM) (13, 14, 16-19). 
Unfortunately, the beneficial GVT reactivity is often accompanied by graft-
versus-host-disease (GVHD). This adverse immune response, which is also 
mediated by donor-derived T cells, results in destruction of healthy normal 
tissues of the recipient, such as skin, gut, liver and lung. Therefore, GVHD is a 
major complication leading to significant morbidity and mortality after 
allogeneic SCT (20-22). In general, patients are transplanted with stem cell 
grafts from a major histocompatibility complex (MHC)-identical donor. This 
implies that recognition of non-MHC-encoded minor histocompatibility antigens 
(mHAg) and/or tumor-associated antigens by donor-derived T cells play a 
crucial role in de induction of GVT and GVHD (Figure 1; 23, 24). Selective 
induction of GVT without causing GVHD requires separation of both T cell-
mediated immune responses from eachother. Therefore, knowledge of the 
molecular identity of mHAg with expression restricted to cells of the 
hematopoietic lineage, including hematopoietic tumor cells, is essential (Figure 
1). In the past decades, a significant number of mHAg-specific T cell lines and 
clones have been established from the peripheral blood of recipients after 
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allogeneic SCT, which have been used as tools to obtain information regarding 
MHC-restriction, tissue distribution, expression frequency and the molecular 
identity of the recognized mHAg (25, 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Separation of GVHD and GVT reactivity according to the tissue distribution of 
mHAg. Induction of mHAg-specific immune responses by donor CTL is based on the 
ubiquitous or tissue-restricted mHAg expression on recipient target cells resulting in GVHD 
and GVT, respectively.  
 
Antigen recognition by T lymphocytes 
 
The immunological synapse 
Donor-derived T lymphocytes, responsible for the induction of GVT and 
GVHD, recognize antigens via the T cell receptor (TCR), which is a heterodimer 
molecule composed of an α and β chain. The TCR is associated with the CD3 
molecule, composed of four invariant polypeptides γ, δ, ε and ξ to form a 
TCR/CD3 complex responsible for stable expression at the cell surface and 
signal transduction after antigen recognition (27). T cells have distinct functions 
based on the expression of CD8 or CD4 co-receptor molecules. CD8+ cytotoxic 
T lymphocytes (CTL) have the capacity to destroy target cells after recognition 
of foreign intracellular peptides presented in the context of MHC class I 
molecules. Following recognition, the content of granules containing perforines 
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and granzymes is released by the CTL in the direct presence of the plasma 
membrane of the target cell. Perforines polymerize in the presence of Ca2+ into 
transmembrane channels, which are subsequently used for the transfer of toxic 
substances, like granzymes, to induce cellular damage. Granzymes are serine-
esterases which influence the intracellular metabolism of the target cell by 
activation of apoptosis and DNA degradation (28). In contrast, CD4+ T cells 
provide help during the activation of other immune cells, like B cells and 
macrophages, by specific cytokine release after recognition of foreign 
extracellular peptides presented by MHC class II molecules on professional 
antigen presenting cells (APC). 
Interaction of the TCR and CD4/CD8 co-receptor molecules with the MHC-
peptide complex is necessary but this interaction is not sufficient for full T cell 
activation. Therefore, several additional interactions are required to provide a 
stable binding between cytotoxic and helper T cells and their target cells, which 
is accomplished by interactions between leukocyte function associated antigen 
(LFA) 2 (CD2)/LFA3 (CD58) and LFA1 (CD11a)/intracellular adhesion 
molecule 1 (ICAM-1) (CD54) (29, 30). In addition to these interactions, 
professional APC also express co-stimulatory molecules such as CD80/CD86 
and CD40 which interacts with CD28 and CD40L molecules on T cells, 
respectively (31). These interactions not only strengthen T cell binding but also 
provide required co-stimulatory signals to promote adequate T cell stimulation 
by the target cells. 
 
Antigen processing and presentation 
Antigenic peptides are presented to T lymphocytes by human leukocyte antigen 
(HLA) molecules, which are encoded by genes located within two major regions 
of the MHC complex on the short arm of chromosome 6 (32). Region I contains 
polymorphic MHC class I genes which encode for the membrane-anchored 
heavy chain molecules. A stable and functional HLA molecule is expressed at 
the cell-surface when these heavy chains are combined with the light chain, β2-
microglobulin, which is encoded by a gene located on chromosome 15. MHC 
class I molecules are constitutively expressed on all nucleated cells. 
Polymorphic genes located in region II encode for MHC class II molecules, 
which are heterodimers composed of membrane-anchored α and β chains. These 
MHC class II molecules are only constitutively expressed by APC, such as 
dendritic cells (DC) and B cells.  
Before foreign peptides are presented in the context of MHC molecules to T 
cells, these antigens must be generated by the protein degradation machinery. 
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Two distinct antigen processing mechanisms are involved for the generation of 
MHC class I-bound intracellular proteins and MHC class II-bound extracellular 
proteins (33, 34). Endogenous proteins are degraded into peptides by the 
proteasome, which is a specialized organel with proteolytic activity. After 
proteasomal cleavage, peptide fragments are transported to the endoplasmic 
reticulum (ER) via transporter associated with antigen processing (TAP) 1 and 
TAP2 molecules. Also the HLA class I heavy chain and β2 microglobulin 
molecules are translocated into the lumen of the ER, where a stable HLA-
peptide complex is assembled and subsequently transported to the cell surface 
via the Golgi system. In contrast, endocytosed extracellular proteins are 
degraded by endosomes and lysosomes. Simultaneously, synthesized HLA class 
II α and β proteins are translocated into the ER, where the assembled HLA 
molecules interact with invariant chain molecules for stabilisation and 
prevention of early binding of antigenic peptides. Next, these protected HLA 
class II molecules are transported via the Golgi system to endocytic vesicles, 
which contain the endosomal and lysosomal degraded peptides. Within this 
specialized MHC class II compartment the invariant chain is degraded by HLA-
DM and the class II associated invariant peptide (CLIP) is replaced by an 
antigenic peptide. Subsequently, the HLA-peptide complex is transported to the 
plasma membrane for T cell surveillance. 
 
Target antigens of the graft-versus-tumor response 
 
The induction of GVT responses without the occurrence of significant GVHD 
requires the knowledge of the T cell target antigens expressed on malignant 
cells. At present, a variety of antigenic epitopes recognized by T lymphocytes 
have been elucidated at the molecular level, which can be classified in tumor-
specific antigens, tumor-associated antigens and mHAg.  
 
Tumor-specific antigens 
Tumor-specific antigens are derived from mutated proteins or aberrantly 
expressed fusion proteins as a result of chromosomal translocations. 
Consequently, these antigens are exclusively presented by malignant cells and 
are excellent candidates for the induction of cellular anti-tumor reactivity. 
However, only a limited number of tumor-specific antigens have been identified, 
for example Bcr-Abl. The generation of the Bcr-Abl oncogene, encoding a 
protein with tyrosine kinase activity, is the result of a chromosomal translocation 
between the Bcr gene and the c-Abl gene in CML (35, 36). Peptides derived 
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from the fusion region of Bcr-Abl are able to bind several MHC class I and II 
molecules and shown to induce T cell responses in vitro, thereby demonstrating 
the immunogenicity of these breakpoint peptides (37, 38). In addition, it has 
been shown that Bcr-Abl-specific CD4+ and CD8+ T cell lines recognize Bcr-
Abl+ CML tumor cells (39, 40). Interestingly, Bcr-Abl fusion peptide 
vaccination trials generated specific cellular immune responses in CML patients, 
but a correlation between vaccination and clinical responses has not been 
observed yet (41, 42). 
 
Tumor-asssociated antigens 
Tumor-associated antigens are derived from self-proteins which are expressed at 
low levels in certain normal cells and overexpressed by tumor cells. Therefore, 
these antigens are candidate targets to elicit allogeneic anti-tumor responses. A 
significant number of tumor-associated self-antigens have been identified, 
including WT1 and Proteinase 3 (43). The WT1 gene encodes a zinc finger 
transcription factor involved in cell proliferation and differentiation and is 
overexpressed in leukemia (44-46). Several immunogenic MHC class I and II-
restricted WT1-derived antigens have been described. (47-52). In addition, 
analysis of peripheral blood samples of patients with hematopoietic 
malignancies demonstrated the natural occurrence of high-affinity WT1-specific 
CTL with effective lytic capacity towards leukemic cells (53, 54). Furthermore, 
significant inhibition of colony formation was observed, which demonstrated 
specific cytotoxicity against malignant CD34+ progenitors cells (48, 55). A 
phase I clinical vaccination study demonstrated that vaccination with WT1 
peptides in AML patients induce WT1-specifc CTL which correlated with tumor 
regression without damage to normal tissues (56). 
Another potential target to contribute to GVT is Proteinase 3, which is a 
differentiation antigen overexpressed in myeloid leukemias (57). The HLA-A2-
restricted PR1 peptide derived from this serine protease is able to elicit specific 
CTL responses in healthy donors after in vitro stimulation with peptide-loaded 
APC. These anti-PR1 CTL efficiently lyse myeloid leukemia and specifically 
inhibit colony formation of CML targets (58-60). Furthermore, it was shown by 
ELISPOT assays that PR1-specific CD8+ T-cell responses develop 
spontaneously in AML patients, but are absent in healthy individuals (53). 
Recently, ex vivo characterization of CTL responses in CML patients detected 
CML-specific CD8+ T lymphocytes directed against PR1 and WT1 epitopes 
(61). PR1/HLA-A2 tetramers demonstrated a strong correlation between the 
emergence of PR1-specific T cells and the elimination of tumor cells in CML 
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patients after allogeneic SCT (62). Taken together, these results provide a 
rationale for the development of WT1- and Proteinase 3-based immunotherapy.  
 
Minor histocompatibility antigens 
mHAgs are MHC-restricted antigenic peptides derived from cellular proteins 
that differ in amino acid sequence between recipient and donor due to non-
synonymous single nucleotide polymorphisms (SNP) in their encoding genes 
(63). mHAg can be classified based on chromosomal location of the encoding 
gene (autosomal or Y-specific) or based on their tissue distribution (ubiquitous 
versus hematopoietic-restricted). Ubiquitous mHAg are expressed by normal 
and malignant (non)-hematopoietic cells and cellular immune response may 
result in both GVHD and GVT. In contrast, mHAg selectively expressed by 
normal hematopoietic cells as well as their malignant counterparts may induce 
GVT without GVHD (Figure 1; 23). Recently, another classification of human 
mHAg was proposed by Spierings et al. (64). This system classifies mHAg into 
two groups, designated malignancy-associated and normal mHAg, based on the 
function of the corresponding proteins rather than tissue distribution or 
chromosomal location of the mHAg-encoding gene. For instance, it was shown 
that the proteins of genes encoding mHAg HA-1, HA-2 and HA-3 are involved 
the Rho signal transduction cascade responsible for cytoskeletal rearrangements 
(65). Several studies revealed that a disturbance in the Rho signal cascade 
results in oncogenic transformation of cells (66, 67). However, it remains to be 
proven whether alloreactive donor CTL target preferentially mHAg encoded by 
genes that are (over)expressed as a consequence of malignant transformation. 
 
Methods for molecular identification of minor histocompatibility antigens 
 
Approaches which can be used for the molecular identification of mHAg are 
based on the ‘direct immunology’ and ‘reverse immunology’ strategy. The 
‘direct immunology’ strategy uses isolated CD8+ mHAg-specific CTL as 
cellular tools and is further subdivided in biochemical approaches and genetic 
approaches. In contrast, the ‘reverse immunology’ strategy is based on the 
prediction of polymorphic peptides followed by in vitro immunogenicity 
analysis.  
 
Direct immunology strategy 
The biochemical approach for the identification of mHAg relies on the 
purification of peptides, eluted from MHC class I molecules of antigen positive 
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cells, by microcapillary HPLC fractionation. These peptide fractions are loaded 
on antigen-negative target cells expressing the appropriate HLA molecule and 
tested for CTL recognition to identify a positive fraction. Positive fractions are 
analysed by mass spectrometry to identify the amino acid sequence of the 
antigenic peptide recognized by CTL. Finally, a database search is performed 
using the peptide sequence to identify the corresponding antigen-encoding gene. 
Using this approach several MHC class I-restricted mHAg have been identified, 
including the first human mHAg HA-2 (Table 1). However, a major drawback 
of this method is the requirement of expensive specialized equipment. 
cDNA expression cloning is an example of a genetic approach for mHAg 
identification. This method exploits a high-quality cDNA library, which is 
generated from antigen-positive cells using uni-directionally cloning. Next, the 
cDNA library is divided in pools of bacteria and extracted cDNA is transiently 
transfected together with cDNA encoding the appropriate MHC molecule into a 
mammalian expression system (68). Alternatively, library cDNA can directly be 
transfected into a stably HLA-transfected cell line. Subsequently, transfected 
target cells are tested for recognition by mHAg-specific CTL, determined by 
increased  release of cytokines in the supernatant. Positive pools, containing the 
antigen-encoding cDNA, are subcloned and re-screened to eventually identify 
the cDNA that encodes the antigenic epitope. HB-1 was the first example of a 
mHAg identified by this approach (Table 1). Thereafter, cDNA expression 
cloning has been succesfully applied to identify both MHC class I and class II-
restricted mHAg (Table 1). Despite these successes, cDNA expression cloning 
has some pitfalls which may result in mis-identification of the mHAg-encoding 
gene. For instance, when the antigenic epitope is encoded by a large gene that 
has a very low abundance or is absent in the established cDNA library or when 
cDNA library screening is performed using a CTL with a low cytokine 
production. There are several possibilities to improve the expression cloning 
strategy. First, usage of a subtractive cDNA library in which low abundant 
mRNA transcripts are enriched by removal of high abundant housekeeping gene 
transcripts is an option to circumvent a low number of antigen-encoding cDNA 
in the cDNA library. Second, reconstitution of the TCR α and β chains of 
mHAg-specific T cell clones in primary T cells may be a useful tool when low 
levels of cytokines are produced or when the life span of CTL is limited. 
Recently, Ivanov et al. demonstrated the feasibility of TCR transfer for the 
identification of novel mHAg using cDNA library screening (69).  
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Table 1. Current list of identified human minor histocompatibility antigens 
  
mHAg        MHC            Gene      Chr.  Peptide           Tissue            Identification    Refs 
                    restriction                                                            distribution     method 
  
HY A1 HLA-A*0101 DFFRY Y IVDCLTEMY Ubiquitous HPLC                86 
HY A2 HLA-A*0201 SMCY Y FIDSYICQV Ubiquitous HPLC   84 
HY A33 HLA-A*3303 TMSB4Y Y EVLLRPGLHFR Ubiquitous cDNA cloning 87 
HY B7 HLA-B*0702 SMCY Y SPSVDKARAEL Ubiquitous HPLC 83 
HY B8 HLA-B*08 UTY Y LPHNHTDL Ubiquitous  cDNA cloning 88 
HY B52 HLA-B*5201 UTY Y MQQMRHKEV Ubiquitous cDNA cloning 89 
HY B52 HLA-B*5201 RPS4Y Y TIRYPDPVI Ubiquitous cDNA cloning      158 
HY B60 HLA-B*60 UTY Y RESEESVSL Ubiquitous cDNA cloning 90 
 
ACC-1 HLA-A*24 BCL2A1 15 DYLQYVKQI Hematopoietic Genetic linkage 107 
ACC-2 HLA-B*4403 BCL2A1 15 KEFEDDIINW Hematopoietic Genetic linkage 107 
HA-1            HLA-A*0201   KIAA0223  19     VLHDDLLEA   Hematopoietic  HPLC 97 
HA-1 HLA-B*60 KIAA0223 19 KECVLHDDL Hematopoietic Pept. screening 78 
HA-2 HLA-A*0201 MYOG1 7 YIGEVLVSV Hematopoietic HPLC 95 
HA-3 HLA-A*01 LBC 15 VTEPGTAQY Ubiquitous HPLC  46 
HA-8 HLA-A*0201 KIAA0020 9 RTLDKVLEV Ubiquitous HPLC 117 
HB-1 HLA-B*44 HB-1 5 EEKRGSLHVW Hematopoietic cDNA cloning 111 
PANE1 HLA-A*0301 PANE1 22 RVWDLPGVLK Hematopoietic HPLC 115 
LB-ECGF-1 HLA-B*07 ECGF-1 22 RPHAIRRPLAL Hematopoietic cDNA cloning 108 
LRH-1 HLA-B*0702 P2X5 17 TPNQRQNVC Hematopoietic Genetic linkage 109 
UGT2B17 HLA-A*2902 UGT2B17 4 AELLNIPFLY Ubiquitous cDNA cloning 118 
 
HY DRB1 HLA-DRB1* DBY Y SKGRYIPPHLR Ubiquitous Pept. screening  92 
 1501     
HY DRB3 HLA-DRB3* RPS4Y Y VIKVNDTVQI Ubiquitous cDNA cloning 93 
 0301 
HY DQ5 HLA-DQ5 DBY Y HIENFSDIDMGE Ubiquitous cDNA cloning 91 
  
 
Genetic linkage analysis is another genetic identification approach, which 
relies on large Centre d’Etude Polymorphism Humain (CEPH) reference 
families. For each CEPH individual an Epstein-Barr virus (EBV)-transformed 
lymphoblastoid cell line (LCL) is generated and allele-typed for thousands of 
Chapter 1 
 
 18 
genomic markers. These EBV-LCL can be virally transduced with the 
appropriate MHC class I molecule and tested for CTL recognition to obtain an 
informative mHAg segregation pattern. Informative families are subsequently 
used for genome-wide linkage analysis to identify the chromosomal location of 
the mHAg-encoding gene (70, 71). The genetic location is subsequently 
analysed using available public genome databases for known genes and 
information regarding mRNA expression, non-synonymous SNP and potential 
peptide candidates. Finally, the mHAg-encoding gene and the amino acid 
sequence of the antigenic epitope is identified using cDNA transfection and 
peptide reconstitution assays. The feasibility of this approach was shown by a 
retrospective study on the HA-8 antigen (72). Subsequently, it was successfully 
executed for the identification of the MHC class I-restricted mHAg, ACC-1, 
ACC-2 and LRH-1 (Table 1). 
 
Reverse immunology strategy 
In the reverse immunology strategy tumor-associated or hematopoietic-specific 
proteins are analyzed for the presence of polymorphic peptides using prediction 
algorithms for HLA-binding and proteasomal cleavage (73-77). The candidate 
peptides are subsequently tested in vitro for stable HLA binding, proteasomal 
cleavage and CTL recognition. Using this strategy, a novel HLA-B60-restricted 
HA-1 T cell epitope was identified (78). Cellular microarray-based screening is 
a promising alternative approach to accelerate the identification of novel mHAg 
(79). Predicted HLA-restricted polymorphic epitopes, derived from proteins 
which are preferentially expressed in (malignant) hematopoietic cells, are used 
to generate MHC-tetramers. These MHC-tetramers are subsequently arrayed on 
slides and incubated with fluorescent-labeled CD8+ T cells from allogeneic SCT 
patients to evaluate the immunogenicity of these candidate mHAg based on the 
adherence of mHAg-specific T cells to the peptide-MHC complexes. At present, 
we exploit this innovative technology to identify novel HLA-A2-restricted 
mHAg. A preliminary analysis resulted in ∼50 putative HLA-A2-restricted 
mHAg with a hematopoietic-restricted tissue distribution, which are currently 
evaluated for their immunogenicity.  
 
Characteristics of human minor histocompatibility antigens 
 
Using the above described ‘direct immunology’ strategies, a panel of Y-
chromosome encoded (H-Y) mHAg and autosomal chromosome-encoded 
mHAg has been identified at the molecular level. 
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Characteristics of Y-chromosome encoded minor histocompatibility antigens 
Clinical studies indicated that male recipients receiving an HLA-identical sex-
mismatched SCT from a female donor have higher risk of GVHD. In contrast, 
female patients treated with a sex-mismatched graft have a higher risk of graft 
rejection (80, 81). These immune responses are mediated by alloreactive T cells 
of female origin recognizing male-specific H-Y mHAg. These H-Y mHAg are 
encoded by Y chromosome-specific genes, which have homologous genes on 
the X chromosome (82). Disparities in the amino acid sequences between the 
protein isoforms exist due to the presence of numerous SNP in the coding 
sequences of these genes (82). Elucidation of the molecular nature of these 
human H-Y mHAg is of significant importance to reveal the identity of the T 
cell targets responsible for GVHD and graft rejection as well as to expand 
general knowledge of mHAg immunobiology. 
Therefore, several male-specific H-Y mHAg CD8+ and CD4+ T cells have 
been isolated from the peripheral blood of female patients after rejection of the 
male-donor allograft or after sex-mismatched blood transfusions (82). Using 
these H-Y-specific CD8+ and CD4+ T lymphocytes as reagents, eight MHC class 
I-restricted and three class II-restricted H-Y mHAg have been identified at the 
molecular level (Table 1). H-Y.B7 was the first human mHAg identified by the 
biochemical approach and is encoded by the SMCY gene (83). On the same 
gene, an HLA-A*0201-restricted H-Y mHAg was identified, which can be 
recognized both by cytotoxic CD8+ and by CD4+ T cells (84). 
Posttranscriptional modification of this peptide significantly altered the 
recognition of the CD4+ T cells, whereas no difference in recognition was 
observed for the CD8+ T cells (84). Expression cloning studies with a panel of 
Y-specific cDNAs showed that several distinct Y-specific genes encode human 
H-Y mHAg. It was shown that a HLA-A1-restricted CTL isolated from a female 
AML patient during graft rejection recognized a H-Y mHAg derived from the 
DFFRY gene (85, 86). Using the same approach, TMSB4Y and UTY were also 
identified as H-Y mHAg encoding genes (87-90). The UTY-specific HLA-B60-
restricted CTL was isolated together with a SMCY-specific HLA-A2-restricted 
CTL from a female patient with aplastic anemia during graft rejection, which 
clearly demonstrated that cellular immune responses directed against multiple 
H-Y antigens are simultaneously involved in rejection of male donor stem cells 
(90). 
Recently, several MHC class II H-Y antigens have been characterized. The 
first male-specific MHC class II-restricted mHAg was identified as a 12-mer 
peptide recognized by HLA-DQ5-restricted CD4+ T lymphocytes (91). This 
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DBY-encoded epitope differed by three amino acids from its X-homologue, but 
only two polymorphic residues were crucial for T cell recognition (91). In 
addition, the antigen specificity of two CD4+ T cells, which recognized two 
novel H-Y antigens in the context of HLA-DRB1*1501 and HLA-DRB3, was 
elucidated by molecular cloning of known Y genes and peptide screening, 
respectively (92, 93). 
Unfortunately, all identified H-Y mHag exhibit an ubiquitous tissue 
distribution. Consequently, H-Y-based immunotherapy is expected to result in 
GVT reactivity accompanied by GVHD due to cellular immune responses 
against both hematopoietic and non-hematopoietic tissues in male recipients. 
Therefore, these mHAg are less suitable for cellular immunotherapy. To test this 
hypothesis, the clinical relevance of disparities for known H-Y mHAg in the 
occurrence of GVHD was studied in 50 HLA-A1 and 117 HLA-A2 matched 
recipient/donor pairs (94). Strikingly, no significant influence on the GVHD 
frequency was shown in the sex-mismatched combinations (i.e. male 
recipient/female donor) due to a mismatch for H-Y mHAg. A plausible 
explanation for this finding is that the level of expression of these mHAg on 
epithelial cells might be insufficient to induce GVHD. 
 
Characteristics of autosomal chromosome-encoded minor histocompatibility 
antigens 
Polymorphic genes located on autosomal chromosomes have been found to 
encode for mHAg with an ubiquitous or tissue-restricted expression pattern. At 
present, the molecular nature of nine hematopoietic-restricted mHAg including 
their encoding genes have been identified (Table 1).  
The mHAg HA-1 and HA-2 were biochemically identified as peptides 
encoded by the KIAA0223 and MYOG1 genes, respectively (95-97). Sequence 
analysis of these antigenic peptides showed conservation between human and 
non-human primates (98). Functional analysis revealed that the tissue 
distribution of both HA-1 and HA-2 is limited to normal and malignant cells of 
the hematopoietic-lineage, including progenitors cells (25, 96, 99-102). The 
growth of these precursor cells can be inhibited by HA-1 and HA-2-specific 
CTL (100, 101, 103, 104). Furthermore, it was shown that HA-1 is also 
significantly expressed by solid tumors. In vitro analysis demonstrated that 
epithelial tumor cell lines were lysed by HA-1-specific CTL, whereas normal 
epithelial cells were not recognized (105, 106). 
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Two other hematopoietic-restricted mHAgs, designated ACC-1 and ACC-2, 
were identified using the genetic linkage approach (107). The generation of both 
mHAg is the result of two distinct SNP on the autosomal BCL2A1 gene.  
The autosomally encoded mHAg LRH-1 was recently identified by genetic 
linkage (108). The HLA-B*0702-restricted epitope is derived from the P2X5 
gene due to a homozygous frameshift polymorphism within the P2X5 coding 
sequence. Selective expression of the P2X5 gene was only observed in leukemic 
and normal CD34+ progenitor cells, lymphoid cells, and lymphoid tissues. 
Furthermore, P2X5 appeared to be highly expressed in tumor cells from all 
stages of lymphoid development. Interestingly, in vitro assays demonstrated that 
LRH-1-specific CTL were able to efficiently recognize and kill LRH-1+ 
lymphoid tumor cell lines (109). Tetramer analyis showed a direct association 
between in vivo expansion of LRH-1-specific CTL and a complete cytogenetic 
remission of Bcr-Abl-positive CML tumor cells following DLI (108). These 
findings indicate a causative role for LRH-1 in GVT reactivity.  
Another HLA-B7-restricted mHAg, designated LB-ECFG-1, was identified 
by cDNA expression cloning (110). Significant LB-ECFG-1 mRNA levels were 
observed in both myeloid and lymphoid cells. Furthermore, a correlation 
between the emergence of LB-ECGF-1-specifc CD8+ T cells and a significant 
decrease in tumor cells was observed (110). 
The HLA-B44-restricted mHAg HB-1 is encoded by the HB-1 gene with a yet 
unknown function (111). The HB-1 gene is differentially expressed in cells of 
the B lymphoid lineage including tumor cells of all B lineage ALL subtypes and 
EBV-LCL (111). Furthermore, HB-1-specific CTL showed specific cytotoxicity 
toward B-ALL blasts and EBV-LCL (112). HB-1 is the first described human 
mHAg inducing bi-directional CTL responses (113). This reciprocal CTL 
response against both HB-1 allelic peptides is due to TCR discrimination. In 
addition, it was demonstrated that HB-1 is able to induce both CD4+ T helper 
and CD8+ CTL responses in the autologous setting (114). 
Another lymphoid-restricted mHAg, HwA-10, was identified by Brickner et 
al. (115). This HLA-A*0301-restricted mHAg is encoded by an alternative 
transcript of the PANE1 gene, which is selectively expressed in B-lymphoid 
cells, especially resting CD19+ B cells and B-lineage chronic lymphoid leukemia 
(115). 
 
Mechanisms for minor histocompatibility antigen immunogenicity 
The immunogenicity of most human mHAgs is due to the presence non-
synonymous SNP in their encoding genes. This either results in an amino acid 
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disparity in the corresponding protein or in differential protein expression 
between donor and recipient.  
The first mechanism, the amino acid disparity, influences the protein 
degradation by the antigen processing machinery of the cell (Figure 2). It has 
been demonstrated that the amino acid change can affect antigen processing and 
presentation at the different levels, like peptide cleavage by the proteasome (e.g. 
HA-2; 116), TAP translocation of the peptide into the ER (e.g. HA-8; 117), 
binding of the peptide to MHC molecules (e.g. HA-1; 97) and TCR-mediated 
recognition of the MHC-peptide complex (e.g. HB-1; 111) (Figure 2).  
Another mechanism for mHAg immunogenicity is differential protein 
expression due to nucleotide deletion/insertion polymorphisms or non-
synonymous SNP resulting in either a frameshift or stop codon in the open 
reading frame of the mRNA sequence. For instance, expression of the LRH-1 
antigenic epitope is controlled by a homozygous nucleotide deletion 
polymorphism in the P2X5 gene of the donor, which is responsible for a 
frameshift in the nucleotide sequence resulting in a disparate protein sequence of 
9 amino acids in the recipient direction (109). The immunogenicity of PANE1-
encoded mHAg HwA-10 is due to the formation of a stop codon in the donor 
protein (115). A homozygous gene deletion in the donor was recently shown to 
generate a disparity for a mHAg encoded by the UGT2B17 gene. However, the 
genetic basis for this gene deletion remains to be elucidated (118).  
 
Clinical relevance of hematopoietic-restricted minor histocompatibility antigens 
Several retrospective analyses were performed to determine the clinical 
relevance of mHAg incompatibility in recipient/donor pairs. Mismatches for 
HA-1 and/or HA-2 were significantly associated with acute GVHD in adult 
recipients after allogeneic SCT using sibling donors (94). This data was 
supported by the detection of HA-1-specific T cells during acute and chronic 
GVHD in the peripheral blood of HA-1-mismatched recipients (119). This 
correlation was confirmed by additional studies using large panels of HLA-A2 
positive recipient/donor couples (120, 121). Moreover, the occurrence of GVHD 
as a consequence of the HA-1 disparity can be prevented by GVHD prophylaxis 
(121). However, other studies could not confirm that HA-1 disparity was 
significantly associated with GVHD and a lower risk of leukemia relapse (122, 
123).  
The paradoxical observation that expression of the hematopoietic-restricted 
mHAg of HA-1 and HA-2 by recipient cells is associated with GVHD can be 
explained by the presence of professional APC, like DC and epidermal 
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Langerhans cells, in GVHD target organs. This hypothesis is supported by 
evidence that DC and epidermal Langerhans cells have significant expression of 
HA-1 and HA-2 (124). Skin-explant assays demonstrated in situ that only mild 
GVHD is induced by anti-HA-1 and HA-2 CTL responses, which target residual 
recipient cells present in the donor skin (125, 126). This data clearly 
demonstrated that during GVHD HA-1- and HA-2-specific CTL are not 
involved in direct recognition of non-hematopoietic cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Altered antigen processing and presentation due to protein disparity determines 
immunogenicity of mHAg. Amino acid sequence discrepancy between donor and recipient 
due to non-synonymous SNP can affects the antigen processing mechanism at several levels, 
like proteasomal cleavage, TAP translocation, MHC binding and TCR-mediated antigen 
recognition. 
 
Several studies illustrated that mHAg may serve as target antigens during 
GVT reactivity after DLI to induce complete remission of relapsed allogeneic 
SCT patients (109, 127, 128). Using HLA-A2/HA-1 or HA-2 tetramers, it was 
shown that complete remissions of three relapsed CML and MM patients after 
allogeneic SCT and DLI correlates with the emergence of HA-1 and HA-2 
specific CD8+ T cells in the peripheral blood (129). Interestingly, we recently 
showed that expansion of LRH-1-specific CTL was associated with complete 
remission of relapsed CML in accelerated phase following DLI (109). 
Functional analysis of several isolated mHAg-tetramer positive CTL displayed 
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specific lysis against leukemic and normal hematopoietic cells and were capable 
to inhibit the growth of leukemic progenitor cells (129). Furthermore, direct 
cloning of leukemia-reactive T cells from responding patients showed a 
relatively high frequency of HA-1 and HA-2-specific CD8+ T cells within the 
total number of tumor-reactive T cells, which may indicate the relative 
immunodominance of these mHAg (130). This direct cloning approach also 
demonstrated that mHAg-specific T cells with multiple distinct mHAg 
specificities can be isolated from patients with relapsed leukemia responding to 
DLI (131). This data indicate that both CTL specific for known 
immunodominant mHAg, like HA-1 and HA-2, and CTL reactive against novel 
mHAg are present in the peripheral blood of patients at the moment of GVT 
reactivity. These studies illustrate that several CD8+ T cells simultaneously 
recognize multiple mHAg specificities during this beneficial anti-tumor 
response. 
The hematopoietic-restricted expression of the BCL2A1 gene suggests that 
mHAg ACC-1 and ACC-2 are selective targets for GVT responses without the 
occurrence of GVHD in ACC-1 and/or ACC-2 mismatched recipients. To 
address the question whether ACC-1 disparity is associated with GVHD, a 
retrospective analysis was conducted in a panel of 320 patients with HLA-
A*2402 after HLA-identical SCT of unrelated donor. ACC-1 disparity was 
observed in 17.2% donor/recipient pairs. However no statistical differences in 
incidence rates of acute and chronic GVHD were found between patients 
receiving ACC-1 compatible and ACC-1 incompatible transplantation (132). 
Recently, it was demonstrated that BCL2A1 mRNA expression in mesenchymal 
stromal cells was upregulated by inflammatory cytokines, which triggered 
recognition by ACC-2-specific cells (133). This finding indicates that under 
inflammatory conditions BCL2A1-specific T cell responses can be directed 
against target tissues of GVHD. 
 
T cell-based immunotherapy using hematopoietic-restricted minor 
histocompatibility antigens 
 
mHAg which exhibit selective expression on hematopoietic cells including 
malignant cells with no or limited expression on non-hematopoietic cells are 
promising target antigens for the development of specific immunotherapy to 
treat patients with relapsed or residual hematopoietic malignancies after 
allogeneic SCT (134). So far, the molecular identity of a small panel  mHAg has 
been elucidated and these mHAgs are available for immunotherapeutic 
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application (135). Despite this initial panel of mHAg and the rapid discovery of 
novel immunotherapeutic mHAg, the actual number of patients which can be 
treated by mHAg-based immunotherapy remains low. The overall applicability 
of these mHAg is based on the mHAg disparity within transplant pairs in 
combination with the allele frequency of the appropriate MHC restriction 
molecule (136). Currently, mHAg HA-1, ACC-1, ACC-2 and LRH-1 are most 
suitable for the development of immunotherapeutic interventions, due to an 
overall applicability of 10.6%, 5.8%, 2.7% and 2.2%, respectively (136). 
Recently, a PCR-based mHAg genotyping kit for fast and reliable genotyping of 
10 mHAg in a single assay has become available. This kit allows studies with 
respect to the potential development of GVHD and GVT reactivity in certain 
recipient/donor combinations. Furthermore, this genotyping kit can be used to 
select mHAg-disparate recipients for immunotherapy. 
 
Adoptive transfer of donor-derived mHAg-specific CTL 
Cellular immunotherapy, based on the adoptive transfer of donor-derived 
mHAg-specific CTL, is an attractive approach to treat relapsed patients (137-
139). The potency of this strategy to safely induce strong cellular immune 
responses was initially demonstrated by the infusion of EBV and 
cytomegalovirus (CMV) antigen-specific CTL to prevent EBV and CMV-
related diseases in patients after allogeneic SCT (140-143). 
The feasibility of ex-vivo generation of sufficient numbers of HA-1 and HA-
2-specific CTL from HA-1/HA-2 negative healthy donors using peptide pulsed 
autologous DC was demonstrated (144). Functional analysis showed that these 
ex vivo-generated CTL exhibit hematopoietic cell-restricted reactivity, including 
primary AML and ALL cells, comparable with the in vivo-induced HA-1 and 
HA-2-specific CTL (144, 145). The in vitro CTL induction protocol was 
optimized by using DC retrovirally transduced with HA-1-coding cDNA (146). 
These retrovirally transduced DC resulted in a more efficient and rapid 
expansion of HA-1-specific CTL compared to peptide loaded DC. However, 
these induction protocols are only successful when donor-derived DC are 
available in large quantities. Artificial antigen-presenting constructs, like latex 
microbead coated with HLA-A2-peptide complexes, represent an attractive 
replacement to selectively enrich mHAg-specifc CTL (147). 
Adoptive CTL transfer is also a novel promising treatment modality for 
patients with relapsed leukemia after (partially) mismatched SCT. This strategy 
relies on infusion of donor CTL specific for hematopoietic-restricted mHAg 
presented by mismatched HLA molecules on recipient target cells. The 
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feasibility of induction of HA-1-specific CTL in an HLA-A2-mismatchted 
setting was recently shown by stimulation of HLA-A2- PBMC with HLA-A2+ 
HA-1-peptide pulsed T2 cells or HA-1 cDNA transduced DC (148). Generated 
HA-1 specific CTL cultures, restricted by nonself HLA, were subsequently 
enriched by HLA-A2/HA-1 tetramers and functional analysis showed significant 
cytotoxicity towards cells of the hematopoietic lineage, including tumor cells 
(148, 149). 
Despite the optimalization of in vitro induction protocols to generate mHAg-
specific T cells, which are restricted by molecules, the induction of allogeneic 
HLA-specific T cells remains a major challenge. Therefore, mHAg-specifc TCR 
gene transfer into donor T lymphocytes has been investigated as an alternative 
strategy. Successful transfer of mHAg-HA-1 and HA-2 specific TCR genes in 
peripheral T cells was demonstrated recently (150, 151). This TCR transduction 
resulted in T cells with a redirection of cytotoxicity against HA-1 and HA-2 
positive leukemic cells. These TCR-transduced T cells derived from HLA-A2 
and HA-1 and HA-2 negative donors were able to efficiently lyse leukemic cells 
without the presence of anti-HLA-A2 alloreactivity. These results are 
encouraging, but TCR transfer has some difficulties.  First, it is possible that the 
transduced TCR chains forms novel TCR complexes with endogenously 
expressed TCR chains, which may lead to T cells with potential self-reactive 
specificities. Second, a significant number of TCR-transduced T cells may 
survive for a short period in vivo due to the transduction of end-stage effector 
cells with limited proliferative activity. To overcome these problems, the 
possibility was explored to redirect virus-specific T cells into leukemia-reactive 
T cells in order to increase in vivo survival due to the transactivation of the 
endogenous TCR specific for latent viral antigens. Interestingly, CMV-specific 
HA-2-redirected T cells isolated from several donors showed both anti-leukemic 
and anti-CMV reactivity and efficient expansion of these redirected dual-
specific T cells was shown after stimulation with both CMV-specific and HA-2 
specific stimulator cells (152). The development of autoimmune reactivities due 
to the formation of mixed TCR with self-reactive specificities will be minimal 
due to the restricted TCR repertoire usage of the virus-specific T cells. An 
alternative method to prevent the formation of mixed TCR is the use of γδ T 
cells. Transfer of HA-2-specific αβ TCR to γδ T cells, together with the CD8 
coreceptor, resulted in the generation of potent anti-leukemic T cells without the 
expression of hazardous mixed TCR (153). 
The adoptive transfer of (TCR-transduced) mHAg-specific T cells to treat 
relapsed patients after allogeneic SCT may induce GVHD.  The introduction of 
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a conditional suicide gene is an option to control immune responses against 
normal tissues. Activation of the herpes simplex virus (HSV) thymidine kinase 
(TK) suicide gene in polyclonal T cells was able to regulate the GVHD in 
relapsed patients after allogeneic SCT (154). Unfortunately, strong cellular anti 
HSV-TK responses are also induced, which coincide with the elimination of 
transferred cells (155). This observation demonstrates the need for 
nonimmunogenic suicide genes. Recently, a promising nonimmunogenic suicide 
gene was developed based on the expression of chimeric human FAS protein 
(156, 157). This suicide gene is expected to regulate efficiently the immune 
responses caused by transferred T lymphocytes and to ensure the safety of T-cell 
therapy using the adoptive transfer of mHAg-specific T cells. 
Vaccination 
The molecular identified hematopoietic-restricted mHag represent also suitable 
targets for vaccine-based immunotherapy to boost or to induce GVT reactivity 
in patients after allogeneic SCT with residual disease. Vaccinations using DC as 
professional APC provide several interesting possibilities. One direct approach 
is vaccination of the patients directed to one or multiple relevant mHAg using 
donor-derived DC loaded with peptides and/or whole protein. An indirect 
approach is vaccination of the original donor with autologous antigen-loaded 
DC. In vivo generated mHAg-specific donor T lymphocytes can subsequently be 
isolated and transferred to the patient by infusion. Both vaccination strategies 
can be applied to induce potent cellular anti-tumor responses to eradicate tumor 
cells effectively. Unfortunately, no results from clinical trials with vaccination 
approaches using mHAg as target antigens have been reported yet. Currently, a 
phase I/II clinical trial is conducted using vaccination of peptides in patients 
transplanted in a HA-1 and/or HA-2 mismatched setting (136). 
However, the applicability of both vaccination and adoptive transfer of T 
lymphocytes is hampered due to the small panel of identified hematopoietic-
restricted-mHAg and their low overall applicability, which is calculated from 
the mHAg and HLA phenotype frequencies. Consequently, a low number of 
patients can be treated with these mHAg-based immunotherapeutic modalities. 
In the future, expansion of the panel of hematopoietic-restricted mHAg with 
favourable characteristics is a prerequisite to increase the number of patients 
eligible for immunotherapy. 
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Scope of this thesis 
 
HLA-identical allogeneic SCT is a successful treatment modality of 
hematopoietic malignancies. Unfortunately, a significant number of patients do 
not respond and eventually suffer from relapse of the disease. For these patients 
it is necessary to develop adjuvant cellular immunotherapeutic approaches to 
eliminate residual tumor cells by inducing specific anti-tumor T cell reactivity. 
A major requirement to achieve this goal is the molecular charaterization of 
antigens selectively expressed by hematopoietic tumor cells. This thesis 
describes the identification and characterization of leukemia-associated mHAg, 
which provide novel potential targets for anti-tumor immunotherapy.  
Chapter 2 describes the development of a genomic typing assay to determine 
the HB-1 allele and genotype frequencies. Furthermore, it was investigated 
whether mHAg HB-1 can induce bi-directional CTL responses. Chapter 3 
describes the potency of mHAg HB-1 to induce CD4+ and CD8+ T cell 
responses in the autologous setting. In addition, the molecular nature of two 
novel MHC class II-restricted epitopes, recognized by anti-HB-1 helper T cells, 
is elucidated.  
Chapter 4 describes the optimalisation of two commonly used molecular 
mHAg identification strategies, namely the cDNA expression cloning and 
genetic linkage analysis, to facilitate the molecular identification of 
hematopoietic-restricted mHAg. In chapter 5 we present the molecular 
identification of the novel leukemia-associated mHAg LRH-1 using the refined 
genetic linkage approach in combination with gene expression profiling. 
Furthermore, we studied the mechanism responsible for the mHAg 
immunogenicity, expression of the LRH-1-encoding P2X5 gene and the 
correlation between CTL emergence and remission induction.  
Finally, in chapter 6 the expression of the HB-1 and P2X5 genes is studied in 
malignant lymphoid-restricted cell lines and primary cells using real-time 
quantitative RT-PCR. Furthermore, we investigated LRH-1-specific CTL 
recognition and cytotoxicity against hematopoietic tumor cell lines. 
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Summary  
 
Human minor histocompatibility antigens (mHAgs) are target antigens of the 
graft-versus-leukemia response observed after allogeneic HLA-identical stem 
cell transplantation. We previously defined the molecular nature of the B cell 
lineage-specific mHAg HB-1. The CTL epitope was identified as the decamer 
peptide EEKRGSLHVW presented in the context of HLA-B44. The HB-1 
antigen is encoded by a locus of yet unknown function on chromosome 5q32. A 
single nucleotide polymorphism within this locus results in an amino acid 
change from histidine (H) to tyrosine (Y) at position P8 within the CTL epitope. 
Based on genomic information, we have developed a PCR-RFLP assay to 
perform HB-1 typing at the DNA level. We determined that the allelic frequency 
for the H and Y variant is 0.79 and 0.21, respectively. From these data, we 
calculated that the expected recipient disparity between HLA-B44-matched 
sibling pairs for HB-1H is 2.8%, whereas recipient disparity for HB-1Y is 
expected to be 12.4%. Therefore, we addressed whether the HB-1Y peptide is 
reciprocally immunogenic. We revealed that both peptide variants bind equally 
efficient to HLA-B44 molecules and that the H/Y substitution has no influence 
on formation of epitope precursor peptides by 20 S proteasome-mediated 
degradation. More directly, CTL recognizing the naturally presented HB-1Y 
peptide could be generated from a HB-1H homozygous donor using peptide-
pulsed dendritic cells. Using a set of synthetic structurally related peptide 
variants, we found that the H/Y substitution has a major impact on TCR 
recognition by CTLs specific for either of the HB-1 allelic homologues. HB-1 is 
the first human mHAg described that induces bi-directional allogeneic CTL 
responses that may contribute to a specific graft-versus-leukemia response 
following allogeneic stem cell transplantation. 
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Introduction 
 
Disparities in minor histocompatibility antigens (mHAgs) between HLA-
matched donor/recipient pairs can lead to vigorous T cell responses involved in 
graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) reactivity 
after allogeneic stem cell transplantation (SCT) (1). mHAgs are peptides derived 
from polymorphic cellular proteins presented at the cell surface by MHC 
molecules (2, 3). More than 50 different mHAg loci have been defined among 
inbred strains of mice (4). However, the number of mHAgs in humans is 
unknown and knowledge about the structure, genetics and tissue expression of 
their encoding genes is scarce. Identification of human mHAgs has been 
achieved using specific T cells isolated from SCT recipients (5–14). By this way 
a number of male-specific HY mHAgs (5–10) and four autosomal mHAgs, 
known as HA-1, HA-2, HB-1 and HA-8 have been identified (11–14). Human 
mHAgs characterized so far have shown to be unidirectional due to differential 
MHC binding or antigen processing (12, 14, 15). Reciprocal CTL responses 
have been found for mouse mHAg (16–19).  
We previously reported that a mismatch for HB-1 could induce donor-derived 
CTLs reactive against B lineage acute lymphoblastic leukemia (ALL) cells after 
HLA-matched SCT (20). By cDNA library screening, using HB-1-specific 
CTLs as reagent, the antigen was identified as peptide EEKRGSLHVW 
presented in the context of HLAB44 molecules (i.e. HB-1H.B44 epitope) (13). 
The HB-1-coding cDNA exists in two allelic variants, designated as HB-1H and 
HB-1Y. A single nucleotide polymorphism (SNP) results in an amino acid 
exchange from histidine (H) to tyrosine (Y) at position P8 of the HB-1H.B44 
epitope. Interestingly, expression of HB-1 is restricted to cells of the B lymphoid 
lineage including tumor cells of B lineage ALL patients (13). Therefore, 
disparity for HB-1 might be involved in selective GVL reactivity against B 
lymphoid malignancies after SCT.  
In this study, we characterized the genomic structure of mHAg HB-1 that 
allowed us to develop a typing method at the genomic level. Using this method, 
we determined the allele and genotype distribution for the H and Y variant. 
From these data, we calculated that the expected recipient disparity for HB-1H 
between HLA-B44-matched sibling pairs is around 2.8%. The reciprocal 
recipient disparity for HB-1Y is significantly higher which is 12.4%. Therefore, 
we investigated whether HB-1 induces bi-directional CTL responses. We 
demonstrate that the HB-1Y allelic variant is equally immunogenic. 
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Materials and methods 
 
Cell culture 
Cell lines were cultured in IMDM (Gibco BRL, Gaithersburg, MD) containing 
10% FCS. EBV-LCL were generated by transformation with B95–8 EBV 
supernatant, and cultured in IMDM/10% FCS. The cell line Raji was transfected 
with pCR3.B*4402 or pCR3.B*4403 by electroporation. Raji.B44 transfectants 
were selected with 1.5 mg/ml G418 (Gibco BRL) and cloned by limiting 
dilution. One clone of Raji.B*4402 and Raji.B*4403 were subsequently 
cotransfected with either pcDNA3-zeo.HB-1H or pcDNA3-zeo.HB-1Y, selected 
with 0.5 mg/ml zeocin (Invitrogen, San Diego, CA) and cloned by limiting 
dilution. CTL MP1, generated from common-ALL patient MP (HLA-B*4403+) 
after HLA-identical SCT, was grown in IMDM/10% human serum (HS), 
irradiated EBV-LCL of patient MP (2.5×105/ml), irradiated allogeneic PBMCs 
(5×105/ml), 100 IU/ml IL-2 (Eurocetus, Amsterdam, The Netherlands), and 1 
μg/ml PHA (Boehringer, Mannheim, Germany). CTL MP1 recognizes the HB-
1H.B44 epitope, EEKRGSLHVW, in association with either HLA-B*4403 or 
HLA-B*4402 (13, 20). 
 
Genotyping of HB-1 mHAg polymorphism 
DNA was isolated using the Puregene method (Gentra Systems). HB-1 DNA 
amplification was performed by PCR using 0.5 μM HB1–5B forward primer 
(5’-GAGAAGTTGTAAGCTCAAGTCTCAGC-3’), 0.5 μM HB1–3B reverse 
primer (5’-CAAACCTCAACAGCAGTGTCAAAG-3’), 0.25 mM dNTP and 
2.5 U Taq Gold polymerase (Perkin Elmer). A fragment of 153 bp was obtained 
by 35 cycles of the following PCR protocol: 1 min at 95°C, 1 min at 60°C, and 1 
min at 72°C. Ten microliters of the amplification product was digested with 10 
U NlaIII for 2 h at 37°C and analyzed on a 2% agarose gel. The HB-1H allele 
produced 95- and 58-bp bands, whereas the HB-1Y allele produced a single 
153-bp band. 
 
Peptide synthesis 
Peptides were synthesized by solid-phase strategies on an automated multiple 
peptide synthesizer (Abimed AMS 422). Peptides were purified by reversed 
phase-HPLC and lyophilized. Finally, peptides were dissolved in DMSO, 
diluted in IMDM to a peptide concentration of 1 mM and stored at –20°C before 
use. 
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HLA-B44 peptide-binding assay 
We designed an HLA-B44 peptide-binding assay using 721.221.B*4403 cells 
similar to the assay described by Van der Burg et al. (21). Briefly, naturally 
bound peptides were eluted by exposing 721.221.B*4403 cells for 90 s to ice-
cold citric acid buffer with pH 3.1 (1:1 mixture of 0.263 M citric acid and 0.123 
M Na2HPO4). Cells were immediately buffered with ice-cold IMDM/2% FCS, 
washed, and resuspended at a concentration of 0.5×106/ml in IMDM/2% FCS 
containing 1.5 μg/ml β2-microglobulin (Sigma). Subsequently, the stripped cells 
were incubated at 5×104/well in a V-bottom 96-well plate with 1.25 μM of a 
fluorescein (Fl)-labeled HLA-B44-binding reference peptide and a titrated 
concentration of competitor test peptide. The sequence of the Fl-labeled was 
EENLLDFVRF (EBNA3c 281–290) wherein we substituted the aspartic acid 
(D) with a cysteine (C) to tag a Fl group to the peptide: EENLLC(Fl)FVRF. 
After 24 h incubation at 4°C, cells were washed three times with PBS/1% BSA, 
fixed with 0.5% paraformaldehyde, and analyzed on an Epics XL flow 
cytometer (Beckman Coulter, Fullerton, CA). The percentage inhibition of Fl-
labeled reference peptide binding was calculated using the following formula: % 
inhibition = [1–(mean fluorescence intensity (MFI)reference and competitor peptide –  
MFIno reference peptide)/(MFIreference peptide – MFI no reference peptide)]×100. 
 
Proteasome digestion assay 
The 20 S proteasomes were purified from EBV-LCL as described elsewhere 
(22). HB-1 peptides (22-mer, 20 μg) were incubated with 1 μg of purified 
proteasomes in 300 μl digestion buffer at 37°C for 8 and 18 h. Trifluoroacetic 
acid (30 μl) was added to stop the digestion. Peptide digestions were analyzed 
by electrospray ionization mass spectrometry as described previously (23, 24). 
Briefly, digestion solutions were diluted five times in water-methanol-acetic 
acid (95:5:1, v/v/v) and 1 μl was trapped on the precolumn (MCA-300–05-C8; 
LC Packings). The precolumn was washed for 3 min to remove the buffers 
present in the digests. Subsequently, the trapped analytes were eluted with a 
steep gradient going from 70% B to 90% B in 10 min, with a flow of 250 nl/min 
[A, water-methanol-acetic acid (95:5:1, v/v/v); B, water-methanol-acetic acid 
(10:90:1, v/v/v)]. Mass spectra were recorded from mass 50–2,000 Da every 
second with a resolution of 5,000 full width/half maximum (FWHM). The 
intensity of the peaks in the mass spectra was used to estimate the relative 
amounts of peptides generated after proteasome digestion. The relative amounts 
of the peptides are given as a percentage of the total amount of peptide digested 
by the proteasome at the indicated time. Fragments with intensities less than 
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three times the noise peak in a spectrum were ignored in the determination of 
sequences of peptides generated after proteasome digestion. 
 
In vitro CTL response induction 
Dendritic cells (DCs) used as stimulator cells were generated from thawed 
PBMCs of an HLA-B44+ donor. Briefly, PBMCs (5×106/ml) were resuspended 
in IMDM/2% HS and incubated for 2 h at 37°C in 75-cm2 tissue culture flasks. 
Nonadherent cells were removed and adherent cells were subsequent cultured in 
IMDM/5% HS supplemented with 800 U/ml GM-CSF (Schering-Plough, 
Amstelveen, The Netherlands) and 1,000 U/ml IL-4 (Schering-Plough). After 6 
days, cells were washed and cultured for 3 days in IMDM/5% HS supplemented 
with 800 U/ml GM-CSF, 1,000 U/ml IL-4 and 1 μg/ml recombinant trimeric 
CD40L (kindly provided by Immunex Corporation). On day 9, DC were 
harvested and pulsed with 50 μM HB-1Y.B44 peptide for 4 h at room 
temperature in the presence of 3 μg/ml human β2-microglobulin (Sigma). 
Subsequently, peptide-pulsed DCs were irradiated (30 Gy), washed, and 
resuspended at 2×105 cells/ml in IMDM/10% HS. CD8+ T cells were isolated by 
positive selection using CD8 mAb-coupled magnetic beads (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Primary stimulation was performed in 24-well 
plates. CD8+ T cells (106/well) were cocultured with autologous peptide-pulsed 
mature DCs (2×105/well) and autologous irradiated PBMCs as feeder cells 
(105/well) in 2 ml IMDM/10% HS supplemented with 1,000 U/ml IL-6 (Sandoz, 
Basel, Switzerland) and 10 ng/ml IL-12 (Hoffman-La Roche, Nutley, NJ). At 
day 7 and 14, CTL were harvested, washed and restimulated with peptide-pulsed 
DCs at an effector/stimulator ratio of 10:1 in the presence of 100 U/ml IL-2 and 
5 ng/ml IL-7 (Genzyme, Cambridge, MA). From day 21 on, CTLs were 
maintained by weekly stimulation with irradiated adherent PBMCs or EBV-LCL 
pulsed with 10 μM peptide in IMDM/10% HS containing 100 U/ml IL-2 and 5 
ng/ml IL-7. 
 
Antibodies and immunofluorescence analysis 
The following mAbs were used for immunofluorescence analysis: TS2/18 
(CD2), SPV-T3b (CD3), M310 (CD4), DK25 (CD8), CRI304.3 (TCRBV6S1), 
IG125 (TCRBV21S3), MAB104 (CD80), HB15A (CD83), HA5.2B7 (CD86), 
W6/32 (HLA-class I), Q5/13 (HLA-DR/DP), and SPV-L3 (HLA-DQ). 
Immunofluorescence analysis was performed by direct or indirect labeling. 
FITC-conjugated goat F(ab’)2 anti-mouse IgG and IgM (Tago Immunologicals, 
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Camarillo, CA) was used for secondary staining. Cells were analyzed on an 
Epics XL flow cytometer (Beckman Coulter). 
 
Chromium-release assay 
Chromium-release assays were performed to assess cytolytic activity of CTL. 
Briefly, 106 target cells were incubated with 100 μCi 51Cr (Amersham, 
Buckinghamshire, GB) for 1 h at 37°C. Labeled target cells were mixed in V-
bottom microtiter plates (103/well) with various numbers of effector cells in a 
total volume of 150 μl IMDM with 10% FCS. In peptide recognition assays, 
target cells were preincubated with various concentrations of peptide for 30 min 
at room temperature in a volume of 100 μl prior to the addition of effector cells. 
After 4 h of incubation at 37°C, 100 μl supernatant was collected and 
radioactivity was measured by a gamma counter. The mean percentage specific 
lysis of triplicate wells was calculated using the following formula: % specific 
lysis = [(experimental release – spontaneous release)/(maximal release – 
spontaneous release)]×100. 
 
IFN-γ secretion assay 
IFN-γ-producing CTLs were detected by the IFN-γ secretion assay (Miltenyi 
Biotec). Briefly, 0.5×106 CTLs were incubated in a 24-well plate with 0.5×106 
irradiated Raji.B*4402 cells in a total volume of 2 ml IMDM/10% HS. Peptides 
were added to a final concentration of 10 μM. After 16 h of incubation at 37°C, 
cells were harvested, washed with PBS/0.5% FCS/5 mM EDTA and labeled at a 
concentration of 108 cells/ml with 50 μg/ml Ab–Ab conjugates directed against 
CD45 and IFN-γ for 10 min on ice. Subsequently, cells were diluted with 
IMDM/10% FCS at 1×105 cells/ml and allowed to secrete for 45 min at 37°C. 
After the cytokine-capturing period, cells were collected, resuspended at a 
concentration of 108 cells/ml in PBS/0.5% FCS/5 mM EDTA and stained with 5 
μg/ml PE-conjugated anti-IFN-γ mAb and FITC-conjugated anti-CD8 mAb for 
20 min at 4°C. Cells were analyzed on an Epics XL flow cytometer (Beckman 
Coulter). 
 
Results 
 
Genomic structure of the HB-1 coding sequence 
Typing for mHAg HB-1 can be performed by functional assays using CTL MP1. 
However, to determine HB-1 disparity by typing at the genomic level, we 
unravelled the genomic structure surrounding the SNP. In the Human Genome 
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Project the HB-1 coding sequence has been mapped to contig NT-006489 of ~1 
Mb on chromosome 5q32, which we confirmed by FISH analysis. To define 
exon-intron boundaries, we compared consensus sequences between the 
previously cloned HB-1 cDNA fragment (AF103884) and contig NT-006489. 
This analysis revealed that the HB-1H antigenic peptide is encoded by two 
exons (provisionally named A and B) which are separated by an intron of ~8.2 
kb (Figure 1). A splice donor site could be identified thirteen nucleotides after 
the first HB-1 peptide coding triplet and a splice acceptor site could be identified 
just before the second peptide coding region (Figure 2). The C/T SNP is located 
at position 9 in exon B. These data reveal that the first four residues, EEKR, of 
the HB-1 peptide sequence are encoded by exon A and the remaining six 
residues including the polymorphic histidine residue, GSLHVW, are derived 
from exon B. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Scheme of the mHAg HB-1-encoding locus mapped to chromosome 5q32. The 
organization of the HB-1 locus was established by comparing sequences from the HB-1 384 
bp transcript (AF103884) and genomic contig NT-006489. Position of the C/T SNP in exon B 
is shown by the vertical arrow. Primers 5B and 3B depicted by horizontal arrows are used for 
HB-1 genotyping. 
 
Genomic typing for the HB-1 H and Y polymorphism 
Knowledge of the genomic organization surrounding the HB-1 SNP allowed us 
to design a PCR-RFLP method for genomic typing. PCR primers (represented 
by horizontal arrows in Figure 1) were chosen to amplify a DNA fragment 
containing a part of the intronic sequence and a part of the allele-specific 
sequence of exon B. Amplification with these primers resulted in a 153-bp 
fragment and subsequent NlaIII restriction analysis rendered an easily 
interpretable H/Y allele assignation. To determine the population frequency of 
the HB-1 alleles and genotypes, we typed a large number of unrelated 
individuals. In total, we have typed 162 individuals of which 32 were Dutch and 
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130 Spanish (Table 1). The genotype distribution in the Spanish cohort was not 
statistically different from the genotype distribution in the Dutch cohort (Chi-
square test, p=0.20). The overall genotype frequency was 63% HH, 33% HY 
and 4% YY, and the H and Y alleles were present at frequencies of 0.79 and 
0.21, respectively (Table 1). Between siblings, the frequency of recipient 
disparity for mHAg can be calculated from the formula p×q3 + 0.75×p2×q2, 
where p and q represent allele frequencies (25). The predicted recipient disparity 
for HB-1H is 2.8% (p=0.79 and q=0.21), whereas recipient disparity for HB-1Y 
is expected to be 12.4% (p=0.21 and q=0.79). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Genomic sequence encoding mHAg HB-1. The exon-intron boundaries of the two 
exons involved are shown. Splice donor and acceptor sites are underlined. The intronic 
sequence shown in lowercase letters is derived from genomic contig NT-006489. The 
uppercase letters represent cDNA sequence derived from the previously published HB-1 
transcript (13; AF103884). As depicted, the locus consists of two alleles, HB-1H and HB-1Y, 
encoding proteins with a H/Y substitution. Genotyping can be performed by PCR followed by 
NlaIII digestion as described in Materials and methods. 
 
Table 1. HB-1 allele and genotype frequencies. 
  
  Spanish Dutch Total 
  (n=132) (n=30) (n=162) 
  
 Allele 
 H 77% 87% 79% 
 Y 23% 13% 21% 
 Genotype 
 HH 60% 77% 63% 
 HY 36% 20% 33% 
 YY 4% 3% 4% 
  
Chapter 2 
 
 50 
Differential recognition of the HB-1H peptide by CTL MP1 
Immunogenicity of mHAgs is due to differential antigen processing and 
presentation or due to TCR discrimination of the variant peptides. The HB-1H 
peptide is recognized by CTL MP1, whereas the HB-1Y peptide is not, even 
when exogenously added to HLA-B44+ target cells (Figure 3A). This suggests 
that P8 is a dominant residue for CTL recognition. To address this, we 
investigated which amino acids of the HB-1H.B44 epitope are engaged in HLA 
binding and/or TCR interactions. Variant peptides were synthesized in which the 
native amino acids were replaced by an alanine (A) residue. Not surprisingly, 
substitutions at HLA-B44 anchor positions 2 and 10 diminished CTL 
recognition (Figure 3B). Furthermore, substitutions at position 3, 4, 5, 6, 7 and 8 
completely abolished CTL recognition. These data show that the polymorphic 
amino acid at position P8 is one of the key determinants within the HB-1H.B44 
epitope for recognition by CTL MP1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Specific reactivity of HB-1H.B44 specific CTL MP1. (A) Specific lysis against 
Raji.B*4403 cells pulsed with 5 μM HB-1H (EEKRGSLHVW) or HB-1Y (EEKRGSLYVW) 
peptide and Raji.B*4403 transfected with HB-1H or HB-1Y cDNA. (B) CTL recognition of 
Raji.B*4403 cells pulsed with A-substituted HB-1H peptide analogues. Closed and open bars 
represent effector cell activation at a peptide concentration of 3 and 1 μM, respectively. The 
E/T cell ratio was 10:1. The arrow indicates the polymorphic P8 position. 
 
Effect of HB-1 polymorphism on MHC class I binding 
To determine whether the HB-1Y peptide is reciprocally antigenic, we first 
assessed whether the H/Y substitution influences peptide binding to HLA-B44 
molecules. Known anchors for optimal binding to HLA-B44 are a glutamic acid 
(E) at P2 and a Y, phenylalanine (F) or tryptophan (W) at P10. The H/Y 
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polymorphism is at P8, suggesting that binding is probably not influenced. To 
determine whether both peptides bind to HLA-B44 molecules, we measured 
their relative binding affinity using a competition-based peptide-binding assay 
(Figure 4). Peptide EEKRGSLHVW and EEKRGSLYVW inhibited binding of 
a Fl-labeled EBNA3c.B44 peptide by 50% (IC50 value) at 8.5 μM and 4.0 μM, 
respectively. These data demonstrate that both HB-1 peptides bind efficiently to 
HLA-B44 molecules and, therefore, the H/Y amino acid change does not result 
in differential peptide binding to HLA-B44. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Binding capacity of the HB-1H (EEKRGSLHVW) and HB-1Y (EEKRGSLYVW) 
peptide to HLA-B44 molecules. Peptides were tested in a competition-based peptide-binding 
assay as described in Materials and methods. Reference peptide was EENLLC(Fl)FVRF; a C-
derivative of the EBNA3c antigenic peptide presented by HLA-B44. The native HLA-B44- 
binding peptide EENLLDFVRF and the HLA-A2.1-binding peptide FLPSDFFPSV derived 
from the hepatitis B virus nucleocapsid protein were used as positive and negative control, 
respectively. 
 
Effect of HB-1 polymorphism on proteasome cleavage 
To address whether antigen processing allows antigenicity of the HB-1Y 
peptide, we investigated whether the H/Y substitution changes proteasome-
mediated cleavage of epitope precursor peptides. Therefore, we performed in 
vitro proteasome digestions with 22-mer synthetic peptides containing either the 
HB-1H or HB-1Y peptide sequence flanked by its natural amino acids (Table 2). 
Proteasome-mediated cleavage generally determines the exact C-terminal 
residue of the CTL epitope, whereas the N terminus is usually elongated 
requiring trimming by amino peptidases (23, 26, 27). The 20 S proteasome-
mediated proteolysis of both peptides yielded a heterogeneous mixture of 
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peptides. Digestion of the HB-1H peptide resulted in the generation of three 
epitope-containing fragments: i.e. the 15-mer QPECREEKRGSLHVW, the 11-
mer REEKRGSLHVW, and the 9-mer EKRGSLHVW. The proteasome 
precisely determines the C-terminal W of the HB-1H epitope. The minimal 10-
mer epitope, EEKRGSLHVW, could not be found in this digest. The most likely 
relevant epitope precursor peptide is the 11-mer fragment, which requires N-
terminal trimming to generate the minimal epitope. However, this fragment can 
also be recognized as efficiently as the minimal epitope without further 
trimming (Figure 5). CTL MP1 also recognizes the 9-mer peptide fragment 
when loaded on Raji.B*4403 cells, but a high peptide concentration is required 
for lysis (Figure 5). The 20 S proteasome-mediated digestion of the HB-1Y 
peptide resulted in formation of the following fragments: the 15-mer 
QPECREEKRGSLYVW, the 11-mer REEKRGSLYVW, and the 5-mer 
SLYVW. Again the proteasome properly cleaves after the C-terminal W. 
Furthermore, the Y amino acid does not introduce an extra cleavage site 
indicating that the H/Y substitution within mHAg HB-1 does not lead to 
differential processing by the proteasome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Determination of the minimal HB-1H.B44 epitope. Raji.B*4403 cells were pulsed 
with indicated peptides at various concentrations before adding CTL MP1 at an E/T ratio of 
10:1. 
 
The HB-1Y peptide forms an immunogenic CTL epitope 
To prove that mHAg HB-1 is reciprocally immunogenic, we attempted to 
generate CTLs with specificity for the HB-1Y peptide. Therefore, CD8+ T cells 
isolated from a HB-1H homozygous donor were stimulated with HB-1Y.B44 
peptide-pulsed mature DC. After three rounds of stimulation, peptide specificity 
of the initiated T cell culture was tested. The generated T cell culture (CTL KU) 
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produced 905 pg/ml IFN-γ upon stimulation with HB-1Y peptide-pulsed 
Raji.B*4402 cells, whereas upon stimulation with unpulsed or HB-1H peptide-
pulsed Raji.B*4402 cells IFN-γ production was 3 and 31 pg/ml, respectively. 
After repeated stimulation with peptide-pulsed autologous EBV-LCL, >95% of 
CTL KU were positive for TCRBV21S3 (data not shown). As shown in Figure 
6A and B, CTL KU recognized Raji.B*4402 cells pulsed with the HB-1Y 
peptide more efficiently than pulsed with the HB-1H peptide. Moreover, CTL 
KU also recognized the naturally processed and presented HB-1Y.B44 peptide 
on the cell surface of Raji.B*4402 cells stably transfected with the HB-1Y allele 
(Raji.B*4402.HB-1Y). These results are in line with our findings that the HB-
1Y peptide is not destructed by proteasomal cleavage and binds to HLA-B44 
molecules. In contrast to CTL MP1 which recognizes only the HB-1H peptide 
(Figure 3A), the anti-HB-1Y CTL KU cross-reacts with the HB-1H antigen 
when naturally processed on Raji.B*4402.HB-1H cells (Figure 6A). This 
difference in specificity may be due the lower avidity of the in vitro-induced 
anti-HB-1Y CTLs that has been induced using a high concentration of synthetic 
peptide. Nevertheless, our data clearly demonstrate that disparity for mHAg HB-
1 can result in bi-directional CTL epitope formation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Specific reactivity of HB-1Y.B44 peptide-induced CTL KU. (A) Specific lysis 
against Raji.B*4402 cells pulsed with 5 μM HB-1H (EEKRGSLHVW) or HB-1Y 
(EEKRGSLYVW) peptide and Raji.B*4402 stably transfected with HB-1H or HB-1Y cDNA. 
(B) Production of IFN-γ by CTL KU upon stimulation with peptide-pulsed or HB-1Y-
transfected Raji.B*4402 cells. 
 
Effect of HB-1 polymorphism on TCR discrimination 
The TCR of the HB-1H-specific CTL MP1 includes the TCRBV6S1 β-chain, 
whereas the TCR of the HB-1Y-specific CTL KU is composed of the 
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TCRBV21S3 β-chain. To investigate whether differential recognition of the HB-
1H and HB-1Y epitope is the result of TCR discrimination, we have compared 
TCR specificity of both CTLs using a set of synthetic structurally related epitope 
variants (Figure 7A and B). Substitution of the polymorphic residue with an A 
abrogates lysis of both CTL. Interestingly, the HB-1H-specific CTL MP1 also 
recognizes the R analogue, which closely resembles the H residue, whereas the 
F analogue, which is more structurally related to the Y residue, is not 
recognized. Vice versa, the HB-1Y-specific CTL KU recognizes the F analogue 
and not the R analogue. These data indicate that the H/Y antigenic disparity 
results from differences in TCR interactions probably due to conformational 
changes of the polymorphic epitopes in the context of HLA-B44. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. TCR specificity of HB-1H.B44-specific CTL MP1 (A) and HB-1Y.B44-specific 
CTL KU (B). Cytolytic activity was determined against the appropriate Raji.B44 transfectant 
sensitized with either the native polymorphic HB-1 peptides or structurally related peptide 
analogues. Closed and open bars represent target cell sensitization at a peptide concentration 
of 3 and 1 μM, respectively. The E/T cell ratio was 10:1. 
 
Discussion 
 
The HB-1-encoding gene of yet unknown function is located on chromosome 
5q32. HB-1 consists of at least two allelic variants, HB-1H and HB-1Y, which 
encode the HLA-B44-restricted peptides EEKRGSLHVW and 
EEKRGSLYVW, respectively. These peptides are generated from two different 
exons separated by an intronic region of ~8.2 kb. Based on this genomic 
information, we have developed a method to perform HB-1 typing at the DNA 
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level. Using this assay, we determined that the allelic frequency for the H and Y 
polymorphism is 0.79 and 0.21, respectively. From these frequencies we 
calculated that the expected recipient disparity for HB-1H is 2.8%, whereas 
recipient disparity for HB-1Y is expected to be 12.4%. So anti-tumor 
alloresponses in B lineage ALL patients after SCT are more likely to occur in 
the HB-1Y direction than in the HB-1H direction.  
Disparity for mHAgs between SCT recipients and donors results from genetic 
polymorphisms that either affect MHC presentation, antigen processing or TCR 
recognition of self-peptides (3). For instance, immunogenicity of mHAg HA-1 is 
a clear example where the amino acid change has effect on peptide binding so 
that the negative allelic peptide is not presented at the cell surface by HLA-
A*0201 molecules (12). In contrast, Brickner et al. (14) reported that disparity 
for mHAg HA-8 results from altered antigen processing rather than from 
differences in interaction with HLA. They showed that the negative allelic 
peptide of HA-8 is poorly transported into the ER by TAP molecules. Another 
possibility is that allelic variant peptides of mHAgs are cleaved differentially by 
the proteasome resulting in either creation or loss of a cleavage site. Beekman et 
al. (23) showed that single amino acid substitutions in variant viral sequences 
can lead to premature destruction of the CTL epitope by proteasome-mediated 
digestion. Here, we describe that disparity for mHAg HB-1 is neither the result 
from altered peptide binding to MHC nor from differential antigen processing, 
but results from differences in TCR recognition. Other examples where both 
allelic variant peptides bind with similar affinity to the relevant HLA molecule 
are the SMCY-derived mHAgs HY.B7 and HY.A2 (5, 6), the UTY-derived 
HY.B60 mHAg (9) and the DFFRY-derived HY.A1 mHAg (7). Like these 
mHAgs, HB-1 stimulates T cells with the appropriate TCR specificity that 
discriminates mHAg+ from mHAg- target cells. It has been shown that such 
discriminative T cell recognition can be further affected by post-translational 
modification of the polymorphic residue (6, 7). However, a reciprocal CTL 
response against different allelic peptides of human mHAgs has not been 
formally demonstrated. We found that the HB-1Y variant peptide is also able to 
stimulate CTLs recognizing the naturally processed and presented peptide on 
HB-1Y expressing target cells. These results indicate that allelic discrimination 
of HB-1 epitopes results from different conformations adopted in the same HLA 
molecule leading to differential T cell triggering. Interestingly, HB-1 is the first 
described human mHAg inducing bi-directional CTL responses. 
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Table 2. In vitro proteasome-mediated digestion of 22-mer HB-1H and HB-1Y polypeptides 
containing the HLA-B44-restricted epitope. 
 
  
 Intensity (% digestion)A 
     
 
HB-1 Allele Digestion fragment  8 h 18 h 
  
 
HB-1H QPECREEKRGSLHVWKSELVEV 
 
 QPECREEKRGSLHVW 3.3 3.3 
     REEKRGSLHVW 3.3 4.9 
       EKRGSLHVW 2.5 4.4 
           SLHVWKSEL 5.1 8.8 
             HVWKSEL 0.8 1.9 
 QPECREEKRGSLHVWKSELVEV 36.4 -  
  PECREEKRGSLHVWKSELVEV 3.2 3.4 
     REEKRGSLHVWKSELVEV 9.7 9.3  
          GSLHVWKSELVEV 1.5 1.8  
           SLHVWKSELVEV 7.5 9.7  
             HVWKSELVEV 4.0 6.4  
              VWKSELVEV 5.2 10.7  
               WKSELVEV 1.7 2.6  
                KSELVEV 6.6 11.7  
                  ELVEV 9.2 21.1  
  
HB-1Y QPECREEKRGSLYVWKSELVEV 
 
 QPECREEKRGSLYVW 3.4 2.0 
     REEKRGSLYVW 8.8 8.5 
           SLYVW - 3.7 
           SLYVWKS 1.3 3.9 
            LYVWKS 1.2 2.1 
        KRGSLYVWKSEL 1.9 1.3 
           SLYVWKSEL 2.9 4.0 
 QPECREEKRGSLYVWKSELVEV 17.1 - 
     REEKRGSLYVWKSELVEV 27.1 - 
               WKSELVEV 1.5 2.4 
                KSELVEV 7.6 9.4  
                 SELVEV 3.1 2.5  
                  ELVEV 24.1 60.2  
  
A20S proteasomes isolated from an EBV-LCL were incubated with 22-mer H and Y peptides 
at 37oC for 8 and 18 h. Digestion mixtures were analyzed by mass spectrometry as described 
in Materials and methods. Intensity is given as percentage of the total amount of intensity of 
the digestion fragments depicted.  
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The development of methods to type donor/recipient pairs for mHAgs makes 
it possible to establish whether recipient disparity for molecular-defined mHAgs 
is associated with GVHD and GVL responses. It has been documented that 
recipient disparity for HA-1 and HA-8 is associated with acute GVHD (28-30). 
Because HA-8 is expressed ubiquitously, HA-8-specific donor CTL responses 
will be directed against both cells of hematopoietic as well as non-hematopoietic 
origin. But linkage of HA-1 incompatibility with GVHD was surprising, since 
HA-1 is selectively expressed in hematopoietic cells. However, HA-1 is highly 
expressed in DCs and it has been shown that host-derived DCs play a crucial 
role in the initiation of GVHD (24). Thus, inflammatory responses mediated by 
HA-1-specific CTLs against recipient DCs in tissues might cause cytokine-
mediated damage or attracts other donor CTLs that recognize mHAgs on non-
hematopoietic cells of the host. In contrast, HB-1 is selectively expressed on 
immature B lymphoblasts including B lineage ALL cells and is not 
endogenously expressed by DC. Therefore, HB-1 probably induces a selective 
GVL response without collateral damage of normal tissues. Whether 
incompatibility for hematopoietic cell-restricted mHAgs, such as HA-1, HA-2 
and HB-1, is associated with a reduced risk of relapse is so far unknown. 
The real impact of mHAgs in GVL responses may be answered in approaches 
using hematopoietic cell-restricted mHAgs as targets for immunotherapy (31). 
HB-1 is differentially expressed in cells of the B lymphoid lineage including 
tumor cells of all B lineage ALL subtypes (pro-B-ALL, common-B-ALL, pre-B-
ALL and B-ALL). Such highly restricted tissue expression renders HB-1 an 
ideal target for anti-tumor immunotherapy. HB-1H- and HB-1Y-specific T cells 
could be generated ex vivo and used for adoptive immunotherapy post-
transplant. Studies in mice showed that the adoptive transfer of mHAg-specific 
CTLs has the ability to eradicate leukemic cells (32). Recipient disparity for 
HB-1H (~2.8% in the HLA-B44+ population) and for HB-1Y (~12.4% in the 
HLA-B44+ population) is low which limits the potential therapeutic value of 
HB-1 mHAg-specific T cells. We have preliminary results that the HB-1 amino 
acid sequence harbors another potential mHAg (SLH/YVWKSEL) that binds 
with intermediate affinity to HLA-A2.1 molecules as determined in a 
competition-based peptide-binding assay (data not shown). Furthermore, peptide 
fragments containing this sequences with the C-terminal L residue are generated 
by 20 S proteasome-mediated digestion (Table 2). Currently, we are 
investigating whether these HLA-A2.1-restricted polymorphic peptides are able 
to stimulate CTL responses. Molecular characterization of additional 
hematopoietic cell-restricted mHAgs will be required for treatment of 
Chapter 2 
 
 58 
substantial numbers of leukaemia patients by adoptive immunotherapy with 
mHAg-specific CTLs. 
 
Acknowledgements 
 
We thank G. F. M. Merkx for FISH analysis of the HB-1 gene and Dr. J. W. 
Drijfhout for generously providing the fluorescent-labeled HLA-B44-restricted 
EBNA3c peptide. This work was supported by grants from the Dutch Cancer 
Society (KUN 97–1508) and the Fondo de Investigacion Sanitaria, Ministry of 
Health, Spain (00/0363). 
 
References 
 
1. Goulmy, E. 1997. Human minor histocompatibility antigens: new concepts for marrow 
transplantation and adoptive immunotherapy. Immunol. Rev., 157: 125–140. 
2. Wallny, H.J., and Rammensee, H.G. 1990. Identification of classical minor 
histocompatibility antigen as cell-derived peptide. Nature, 343: 275–278. 
3. Simpson, E., and Roopenian, D.C. 1997. Minor histocompatibility antigens. Curr. Opin. 
Immunol., 9: 655–661. 
4. Doolittle, D.P., Davisson, M.T., Guidi, J.N., and Green, M.C. Catalog of mutant genes 
and polymorphic loci. In Lyon, M.F., Rastan, S. and Brown, S.D.M. (Eds.). 1996. 
Genetic variants and strains of the laboratory mouse. Oxford University Press, NJ, pp 
17–854. 
5. Wang, W., Meadows, L.R., den Haan, J.M.M., Sherman, N.E., Chen, Y., Blokland, E., 
Shabanowitz, J., Agulnik, A.I., Hendrickson, R.C., Bishop, C.E., Hunt, D.F., Goulmy, 
E., and Engelhard, V.H. 1995. Human H-Y: a male-specific histocompatibility antigen 
derived from the SMCY protein. Science, 269: 1588–1590. 
6. Meadows, L.R., Wang, W., den Haan, J.M.M., Blokland, E., Reinhardus, C., Drijfhout, 
J.W., Shabanowitz, J., Pierce, R., Agulnik, A.I., Bishop, C.E., Hunt, D.F., Goulmy, E., 
and Engelhard, V.H. 1997. The HLA-A*0201-restricted H-Y antigen contains a 
posttranslationally modified cysteine that significantly affects T cell recognition. 
Immunity, 6: 273–281. 
7. Pierce, R.A., Field, E.D., den Haan, J.M.M., Caldwell, J.A., White, F.M., Marto, J.A., 
Wang, W., Frost, L.M., Blokland, E., Reinhardus, C., Shabanowitz, J., Hunt, D.F., 
Goulmy, E., and Engelhard, V.H. 1999. Cutting edge: the HLA-A*0101-restricted HY 
minor histocompatibility antigen originates from DFFRY and contains a cysteinylated 
cysteine residue as identified by a novel mass spectrometric technique. J. Immunol., 
163: 6360–6364.  
8. Warren, E.H., Gavin, M.A., Simpson, E., Chandler, P., Page, D.C., Disteche, C., 
Stankey, K.A., Greenberg, P.D., and Ridell, S.R. 2000. The human UTY gene encodes a 
novel HLA-B8-restricted HY antigen. J. Immunol., 164: 2807–2814. 
9. Vogt, M.H., Goulmy, E., Kloosterboer, F.M., Blokland, E., de Paus, R.A., Willemze, 
R., and Falkenburg, J.H. 2000. UTY gene codes for an HLA-B60-restricted human 
male-specific minor histocompatibility antigen involved in stem cell graft rejection: 
characterization of the critical polymorphic amino acid residues for T cell recognition. 
Blood, 96: 3126–3132. 
10. Vogt, M.H., de Paus, R.A., Voogt, P.J., Willemze, R., and Falkenburg, J.H. 2000. 
DFFRY codes for a new human male-specific minor transplantation antigen involved in 
bone marrow graft rejection. Blood, 95: 1100–1105. 
Reciprocal CTL responses against minor antigen HB-1 
 
 59
11. Den Haan, J.M.M., Sherman, N.E., Blokland, E., Huczko, E., Koning, F., Drijfhout, 
J.W., Skipper, J., Shabanowitz, J., Hunt, D.F., Engelhard, V.H., and Goulmy, E. 1995. 
Identification of a graft versus host disease-associated human minor histocompatibility 
antigen. Science, 268: 1476–1480. 
12. Den Haan, J.M.M., Meadows, L.M., Wang, W., Pool, J., Blokland, E., Bishop, T.L., 
Reinhardus, C., Shabanowitz, J., Offringa, R., Hunt, D.F., Engelhard, V.H., and 
Goulmy, E. 1998. The minor histocompatibility antigen HA-1: a diallelic gene with a 
single amino acid polymorphism. Science, 279: 1054–1057. 
13. Dolstra, H., Fredrix, H., Maas, F., Coulie, P.G., Brasseur, F., Mensink, E., Adema, G.J., 
de Witte, T.M., Figdor, C.G., and van de Wiel-van Kemenade, E. 1999. A human minor 
histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J. Exp. 
Med., 189: 301–308. 
14. Brickner, A.G., Warren, E.H., Caldwell, J.A., Akatsuka, Y., Golovina, T.N., Zarling, 
A.L., Shabanowitz, J., Eisenlohr, L.C., Hunt, D.F., Engelhard, V.H., and Riddell, S. R. 
2001. The immunogenicity of a new human minor histocompatibility antigen results 
from differential antigen processing. J. Exp. Med., 193: 195–205. 
15. Pierce, R.A., Field, E.D., Mutis, T., Golovina, T.N., Von Kap-Herr, C., Wilke, M., Pool, 
J., Shabanowitz, J., Pettenati, M.J., Eisenlohr, L.C., Hunt, D.F., Goulmy, E., and 
Engelhard, V.H. 2001. The HA-2 minor histocompatibility antigen is derived from a 
diallelic gene encoding a novel human class I myosin protein. J. Immunol., 167: 3223–
3230. 
16. Zuberi, A.R., Christianson, G.J., Mendoza, L.M., Shastri, N., and Roopenian, D.C. 
1998. Positional cloning and molecular characterization of an immunodominant 
cytotoxic determinant of the mouse H3 minor histocompatibility complex. Immunity, 9: 
687–698. 
17. Mendoza, L.M., Paz, P., Zuberi, A., Christianson, G., Roopenian, D., and Shastri, N. 
1997. Minors held by majors: the H13 minor histocompatibility locus defined as a 
peptide/MHC class I complex. Immunity, 7: 461–472. 
18. Mendoza, L.M., Villaflor, G., Eden, P., Roopenian, D., and Shastri, N. 2001. 
Distinguishing self from nonself: immunogenicity of the murine H47 locus is 
determined by a single amino acid substitution in an unusual peptide. J. Immunol., 166: 
4438–4445. 
19. Ostrov, D.A., Roden, M.M., Shi, W., Palmieri, E., Christianson, G.J., Mendoza, L., 
Villaflor, G., Tilley, D., Shastri, N., Grey, H., Almo, S.C., Roopenian, D., and 
Nathenson, S.G. 2002. How H13 histocompatibility peptides differing by a single 
methyl group and lacking conventional MHC binding anchor motifs determine self-
nonself discrimination. J. Immunol., 168: 283–289. 
20. Dolstra, H., Fredrix, H., Preijers, F., Goulmy, E., Figdor, C.G., de Witte, T.M., and van 
de Wiel-van Kemenade, E. 1997. Recognition of a B cell leukemia-associated minor 
histocompatibility antigen by CTL. J. Immunol., 158: 560–565.  
21. Van der Burg, S.H., Ras, E., Drijhout, J.W., Benckhuijsen, W. E., Bremers, A.J., 
Melief, C.J., and Kast, W.M. 1995. An HLA class I peptide-binding assay based on 
competition for binding to class I molecules on intact human B cells. Identification of 
conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum. Immunol., 44: 
189–198. 
22. Groettrup, M., Ruppert, T., Kuehn, L., Seeger, M., Standera, S., Koszinowski, U., and 
Kloetzel, P.M. 1995. The interferon-gamma-inducible 11 S regulator (PA28) and the 
LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J. 
Biol. Chem., 270: 23808–23815. 
23. Beekman, N.J., van Veelen, P.A., van Hall, T., Neisig, A., Sijts, A., Camps, M., 
Kloetzel, P.M., Neefjes, J.J., Melief, C.J., and Ossendorp, F. 2000. Abrogation of CTL 
epitope processing by single amino acid substitution flanking the C-terminal 
proteasome cleavage site. J. Immunol., 164: 1898–1905. 
Chapter 2 
 
 60 
24. Shlomchik, W.D., Couzens, M.S., Tang, C.B., McNiff, J., Robert, M.E., Liu, J., 
Shlomchik, M.J., and Emerson, S.G. 1999. Prevention of graft versus host disease by 
inactivation of host antigen-presenting cells. Science, 285: 412–415. 
25. Martin, P.J. 1997. How much benefit can be expected from matching for minor antigens 
in allogeneic marrow transplantation? Bone Marrow Transplant., 20: 97–100. 
26. Craiu, A., Akopian, T., Goldberg, A., and Rock, K.L. 1997. Two distinct proteolytic 
processes in the generation of a major histocompatibility complex class I-presented 
peptide. Proc. Natl. Acad. Sci. USA, 94: 10850–10855. 
27. Kessler, J.H., Beekman, N.J., Bres-Vloemans, S.A., Verdijk, P., van Veelen, P.A., 
Kloosterman-Joosten, A.M., Vissers, D.C., ten Bosch, G.J., Kester, M.G., Sijts, A., 
Drijfhout, J.W., Ossendorp, F., Offringa, R., and Melief, C.J. 2001. Efficient 
identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the 
widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. 
Exp. Med., 193: 73–88. 
28. Goulmy, E., Schipper, R., Pool, J., Blokland, E., Falkenburg, J.H., Vossen, J., 
Grathwohl, A., Vogelsang, G.B., van Houwelingen, H.C., and van Rood, J.J. 1996. 
Mismatches of minor histocompatibility antigens between HLA-identical donors and 
recipients and the development of graft-versus-host disease after bone marrow 
transplantation. N. Engl. J. Med., 334: 281–285. 
29. Tseng, L.H., Lin, M.T., Hansen, J.A., Gooley, T., Pei, J., Smith, A.G., Martin, E.G., 
Petersdorf, E.W., and Martin, P.J. 1999. Correlation between disparity for the minor 
histocompatibility antigen HA-1 and the development of acute graft-versus-host disease 
after allogeneic marrow transplantation. Blood, 94: 2911–2914. 
30. Akatsuka, Y., Warren, E.H., and Brickner, A.G. 2000. Effect of disparity in the newly 
identified minor histocompatility antigen SKH13 on the development of graft-versus-
host disease after HLA-identical sibling bone marrow transplantation. Blood, 96: 202a. 
31. Mutis, T., Verdijk, R., Schrama, E., Esendam, B., Brand, A., and Goulmy, E. 1999. 
Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T 
lymphocytes specific for hematopoietic system-restricted minor histocompatibility 
antigens. Blood, 93: 2336–2341. 
32. Fontaine, P., Roy-Proulx, G., Knafo, L., Baron, C., Roy, D.C., and Perrault, C. 2001. 
Adoptive transfer of minor histocompatibility antigen-specific cytotoxic T lymphocytes 
eradicates leukemia cells without causing graft-versus-host disease. Nat. Med., 7: 789–
794. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 3 
 
 
 
 
Generation of autologous cytotoxic and helper T-cell responses against 
the B-cell leukemia–associated antigen HB-1: relevance for precursor 
B-ALL–specific immunotherapy 
 
Björn de Rijke1 
Hanny Fredrix1 
Agnes Zoetbrood1 
Frank Scherpen1 
Henry Witteveen1 
Theo de Witte2 
Elly van de Wiel-van Kemenade1 
Harry Dolstra1 
 
1Central Hematology Laboratory and 2Department of Hematology, University Medical Center 
St Radboud, Nijmegen, The Netherlands. 
 
 
 
 
 
 
 
 
 
 
Blood 2003; 102: 2885-2891.   
 
Chapter 3 
 
 62 
Summary  
 
Tumor relapses in patients with precursor B-cell acute lymphoblastic leukemia 
(B-ALL) occur frequently after primary treatment. Therefore, development of 
additional treatment modalities to eliminate residual tumor cells is needed. 
Active immunotherapy using dendritic cells (DCs) loaded with tumor-associated 
antigens is a promising approach to induce specific T-cell immunity in patients 
with cancer. In previous studies, we described HB-1 as a B-cell lineage-specific 
antigen that is recognized by donor-derived cytotoxic T lymphocytes (CTLs) on 
allogeneic B-ALL tumor cells. Here, we investigated the potential use of the 
HB-1 antigen as an autologous T-cell vaccine target. To determine whether HB-
1–specific CTL precursors are present within the T-cell repertoire, we induced 
expansion of CD8+ T cells using mature monocyte-derived DCs pulsed with the 
previously identified HB-1.B44 antigenic peptide. In 6 of 8 donors, CD8+ CTL 
lines have been generated that exert cytotoxicity against target cells exogenously 
pulsed with peptide or endogenously expressing the HB-1 antigen. From one of 
these HB-1–specific T-cell lines, we isolated a CD8+ CTL that produces 
interferon-γ on stimulation with B-ALL tumor cells. Interestingly, the HB-1 
antigen also induced CD4+ T-helper responses on activation with protein-loaded 
mature monocyte-derived DCs. We identified 2 novel epitopes recognized in the 
context of HLA-DR4 and HLA-DR11 with the use of HB-1–specific CD4+ T-
cell clones generated from different donors. These present data, that HB-1 
induces both helper and cytotoxic T-cell responses, indicate that the HB-1 
antigen is a candidate target to induce T-cell–mediated antitumor immunity in 
patients. 
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Introduction 
 
Precursor B-cell acute lymphoblastic leukemia (B-ALL) is primarily a pediatric 
disease, as about 75% of cases occur in children (1).  Most of these children 
have a good prognosis, and approximately 80% will be cured by chemotherapy 
only. However, 25% of B-ALL cases comprise adults whose prognosis is 
generally worse. They usually require more intensive treatment, including high-
dose chemotherapy followed by autologous or allogeneic stem cell 
transplantation (SCT) (2-4). Although intensive treatment has improved the 
overall response rate, relapse is still a major problem, indicating that not all 
tumor cells are eliminated by current available treatment modalities. Therefore, 
development of new therapeutic approaches for B-ALL remains a challenge. 
One such approach could be active immunotherapy that targets tumor-associated 
antigens (TAAs) to induce or enhance tumor-specific T-cell immunity in a 
setting of residual disease after primary treatment. 
Proteins that are differentially (over) expressed in human tumor cells are 
attractive targets for T-cell–based vaccines. Various melanocyte differentiation 
antigens, such as tyrosinase (5), Pmel17/gp100 (6), Melan-A/Mart-1 (7), and 
tyrosinase-related protein 1 and 2 (TRP1-2) (8, 9), have been identified as 
targets for melanoma-specific cytotoxic T lymphocytes (CTLs). However, CTL 
responses directed against TAAs specific for leukemia have been identified 
rarely. Proteinase 3, a granule protein that is overexpressed in myeloid leukemia, 
and the Wilms tumor-1 (WT1) protein that is preferentially expressed in acute 
leukemia, have been shown to induce antileukemic CTL reactivity (10-12). In 
previous studies, we have described a polymorphic TAA, named HB-1, which is 
recognized by a donor-derived CTL on allogeneic tumor cells of patients with 
B-ALL and Epstein-Barr virus (EBV)–transformed B cells (13, 14). This 
allogeneic CTL recognizes only the HB-1H variant, but CTL responses toward 
the HB-1Y variant can also be induced (14, 15). The HB-1 coding transcript was 
found differentially expressed in all B-ALL subtypes, and its normal tissue 
expression is restricted to low levels in testis, thymus, and tonsils with B-cell 
hyperplasia (14, H. D. et al., unpublished data, 2002). This finding suggests that 
an HB-1–based vaccine will be tumor restricted with limited toxicities to healthy 
tissues. 
Preclinical studies demonstrate that development of efficient antitumor 
immune responses requires induction of antigen (Ag)–specific CD4+ T-helper 
(Th) cells next to the generation of Ag-specific CD8+ T cells (16-19). Activated 
CD4+ Th cells deliver help to the generation of CTL in 2 ways. First, they 
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express surface ligands such as CD40L that bind to CD40 on dendritic cells 
(DCs), thereby inducing expression of costimulatory molecules and the 
production of interleukin 12 (IL-12). Second, they amplify and sustain CD8+ T-
cell function by the secretion of IL-2. In the effector phase, activated CTLs 
exhibit direct tumor cell killing. CD4+ T cells also participate in the effector 
phase by recruiting and activating cells with tumoricidal activity such as natural 
killer (NK) cells and macrophages or by exerting direct cytotoxicity. Therefore, 
TAA-based vaccines should elicit both CD4+ and CD8+ T-cell responses. 
In this study, we examined immune reactivity toward the HB-1 antigen in the 
autologous setting and evaluated its potency as a therapeutic T-cell vaccine 
target. We generated in vitro autologous T-cell responses toward naturally 
processed epitopes using peripheral blood T lymphocytes of healthy donors. 
Induction of anti–HB-1 CTL responses is feasible by using mature monocyte-
derived DCs pulsed with the previously identified immunogenic HB-1H.B44 
peptide. Moreover, we demonstrate that mature monocyte-derived DCs pulsed 
with the full-length HB-1 protein also induce CD4+ T-cell reactivity. 
 
Materials and methods 
 
Cell culture 
Cell lines were cultured in Iscove modified Dulbecco medium (IMDM; Gibco 
BRL, Paisley, United Kingdom) supplemented with 10% fetal calf serum (FCS). 
EBV-transformed lymphoblastoid cell lines (LCLs) were generated from 
peripheral blood B cells by transformation with EBV of the B95-8 cell line and 
further cultured in IMDM/10% FCS. T-cell blasts were generated by stimulating 
peripheral blood mononuclear cells (PBMCs) with 20 μg/mL 
phytohemagglutinin-mucoprotein (PHA-M; Boehringer, Mannheim, Germany) 
in IMDM/10% human serum (HS; PAA Laboratories, Linz, Austria) for 3 days. 
Subsequently, T-cell blasts were washed and further cultured with 100 IU/mL 
IL-2 (Eurocetus, Amsterdam, The Netherlands). Leukemic cells were collected 
from patients with precursor B-ALL at diagnosis. B-ALL cells were 
preincubated with 10 ng/mL tumor necrosis factor α (TNF-α; Endogen, 
Woburn, MA) and 100 U/mL interferon-γ (IFN-γ; Boehringer, Zaandam, The 
Netherlands) for 2 days. The Burkitt lymphoma cell line Raji was transfected 
with either pCR3.B*4402 or pCR3.B*4403 plasmid by electroporation. 
Subsequently, Raji.B44 transfectants were selected with 1.5 mg/mL G418 
(Gibco BRL) and cloned by limiting dilution. Raji.B*4402 and Raji.B*4403 
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clones were subsequently cotransfected with pcDNA3-zeo.HB-1H and selected 
with 0.5 mg/mL zeocin (Invitrogen, San Diego, CA). 
 
Antibodies and immunofluorescence analysis 
The following monoclonal antibodies (mAbs) were used for 
immunofluorescence analysis or for inhibition of T-cell reactivity: UCHT1 
(CD3), MT310 (CD4), DK25 (CD8), MAB104 (CD80), HB15A (CD83), 
HA5.2B7 (CD86), W6/32 (anti–HLA class I), L243 (anti–HLA-DR), B7/21 
(anti–HLA-DP), and Tü22 (anti–HLA-DQ). Anti–HLA class II antibodies 
werekindly provided by Dr G. Pawelec (Department of Internal Medicine, 
University of Tubingen Medical School, Germany). Clonality of generated T-
cell lines was determined by using T-cell antigen receptor beta-chain variable 
(TCR-BV)–specific mAb (Beckman Coulter, Fullerton, CA). 
Immunofluorescence analysis was performed either by direct or indirect 
labeling. Fluorescein isothiocyanate (FITC)–conjugated goat F(ab’)2 antimouse 
immunoglobulin G (IgG) and IgM (Tago Immunologicals, Camarillo, CA) was 
used for secondary staining. Cells were analyzed by an Epics XL flow cytometer 
(Beckman Coulter). 
 
Peptide and protein synthesis 
Peptides were synthesized by solid-phase strategies on an automated multiple 
peptide synthesizer (AbimedAMS 422). Peptides were purified by reversed 
phase high-performance liquid chromatography (HPLC) and lyophilized. 
Finally, peptides were dissolved in 10% dimethylsulfoxide (DMSO; Merck, 
Darmstadt, Germany), diluted in IMDM to a peptide concentration of 1 mM, 
and stored at -20°C before use. HB-1 protein (40 amino acids) was synthesized 
and purified by reversed phase HPLC (Ansynth BV, Roosendaal, The 
Netherlands). HB-1 protein was dissolved to a concentration of 1 mg/mL in 
phosphate-buffered saline (PBS) containing 10% DMSO and stored at -20°C 
before use. 
 
Peripheral blood mononuclear cells of healthy donors 
PBMCs were isolated from leukapheresed blood of healthy donors by density 
gradient centrifugation on Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). Cells 
were collected and washed twice in Hanks balanced salt solution (HBSS; 
BioWitthaker, Verviers, Belgium) and finally resuspended in IMDM/10% FCS 
supplemented with 10% DMSO. Cells were cryopreserved and stored in liquid 
nitrogen until use. 
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Monocyte-conditioned medium 
Monocyte-conditioned medium (MCM) was prepared by stimulating monocytes, 
enriched from buffy coat preparations of healthy donors by density gradient 
centrifugation and counterflow centrifugation, with polyclonal plastic-
immobilized IgG (CLB, Amsterdam, The Netherlands) for 18 hours at 37°C. 
 
Generation of monocyte-derived dendritic cells 
DCs were used as stimulator cells and generated from thawed PBMCs. Briefly, 
PBMCs (5×106/mL) were resuspended in IMDM/5% HS and incubated for 2 
hours at 37°C in 75-cm2 tissue culture flasks. Nonadherent cells were removed, 
and adherent cells were subsequently cultured in IMDM/5% HS supplemented 
with 800 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF; 
Schering-Plough, Amstelveen, The Netherlands) and 500 U/mL IL-4 (Schering-
Plough) for 6 days at 37°C. After 3 days, DCs were harvested and resuspended 
in IMDM/5% HS supplemented with 800 U/mL GM-CSF and 500 U/mL IL-4 at 
1×106/well in 6-well plates. At day 6, cells were washed and further cultured for 
3 days in IMDM/5% HS supplemented with 800 U/mL GM-CSF, 500 U/mL IL-
4, and either 50% MCM, 1 μg/mL recombinant trimeric CD40L (kindly 
provided by Immunex, Seattle, WA), or 20 ng/mL TNF-α (Endogen) plus 10 
μg/mL prostaglandin E2 (PGE2; Pharmacia and Upjohn, Puurs, Belgium). At 
day 9, DCs were harvested and used for T-cell inductions. The generated DC 
populations expressed high levels of major histocompatibility complex (MHC) 
class I and MHC class II, and were more than 80% positive for CD80, CD83, 
and CD86 (data not shown). 
 
In vitro CTL induction with peptide-loaded monocyte-derived DCs 
Monocyte-derived mature DCs were pulsed with 50 μM peptide for 4 hours at 
room temperature in the presence of 3 μg/mL human β2-microglobulin (Sigma). 
Subsequently, peptide-pulsed DCs were irradiated (30 Gy), washed to remove 
free peptide, and resuspended at 2×105 cells/mL in IMDM/10% HS. 
Cryopreserved PBMCs were thawed, and CD8+ T cells were isolated by positive 
selection using CD8 mAb-coupled magnetic beads (Miltenyi Biotec, Bergisch 
Gladbach, Germany). CD8+ T cells (106/well) were cocultured with autologous 
peptide-pulsed DCs (2×105/well), and autologous-irradiated PBMCs as feeder 
cells (105/well) in 2 mL IMDM/10% HS supplemented with 1000 U/mL IL-6 
(Sandoz, Basel, Switzerland) and 10 ng/mL IL-12 (Hoffman-La Roche, Nutley, 
NJ). At day 7 and 14, CTL cultures were harvested, washed, and restimulated 
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with peptide-pulsed DCs at an effector-to-stimulator ratio of 10:1 in the 
presence of 100 IU/mL IL-2 and 5 ng/mL IL-7 (Genzyme, Cambridge, MA). 
From day 21 on, cultures were maintained by weekly stimulation with irradiated 
adherent autologous PBMCs or EBV-LCL pulsed with 10 μM peptide in 
IMDM/10% HS containing 100 U/mL IL-2 and 5 ng/mL IL-7. 
 
In vitro T-helper cell induction with protein-loaded monocyte-derived DCs 
Immature monocyte-derived DCs at day 3 of culture were pulsed with 25 μg/mL 
HB-1 protein. Subsequently, protein-loaded DCs were further cultured and 
matured with 20 ng/mL TNF-α plus 10 μg/mL PGE2. Cryopreserved PBMCs 
were thawed, and CD4+ T cells were isolated by positive selection using CD4 
mAb-coupled magnetic beads (Miltenyi Biotec). CD4+ T cells (106/well) were 
cocultured with autologous protein-loaded DCs (2×105/well) in 24-well plates 
containing 2 mL IMDM/10% HS supplemented with 1000 U/mL IL-6 and 10 
ng/mL IL-12. At days 7 and 14, T-cell cultures were harvested, washed, and 
restimulated with protein-loaded DCs at an effector-to-stimulator ratio of 5:1 in 
the presence of 100 IU/mL IL-2. At day 21, T-cell cultures were tested for 
specific HB-1 reactivity and cloned by limiting dilution. For this procedure, 
autologous EBV-LCLs (2×106) were incubated overnight at 37°C with 25 
μg/mL HB-1 protein. T cells were diluted to a concentration of 1, 3, and 10 
cells/well in a 96-well round-bottom microtiter plate containing 200 μL 
IMDM/10% HS with irradiated (80 Gy) HB-1 protein-loaded EBV-LCLs 
(2×104), irradiated (60 Gy) allogeneic PBMCs (2×104/donor) isolated from 2 
healthy donors, 100 IU/mL IL-2, and 1 μg/mL PHA-M. Established T-cell 
clones were expanded weekly by using autologous EBV-LCLs loaded with HB-
1 protein, irradiated (30 Gy) allogeneic PBMCs from 2 donors (5×105/donor), 
200 IU/mL IL-2, and 1 μg/mL PHA-M in a total volume of 2 mL IMDM/10% 
HS. 
 
Chromium release assay 
Chromium release assays were performed to assess cytolytic activity of CTLs. 
Briefly, 106 target cells were incubated with 100 μCi (3.7 MBq) 51Cr 
(Amersham, Buckinghamshire, United Kingdom) for 1 hour at 37°C. Labeled 
target cells were mixed in V-bottomed microtiter plates (103/well) with various 
numbers of effector cells in a total volume of 150 μL IMDM with 10% FCS. In 
peptide recognition assays, target cells were preincubated with various 
concentrations of peptide for 30 minutes at room temperature in a volume of 100 
μL prior to the addition of effector cells. After 4 hours of incubation at 37°C, 
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100 μL supernatant was collected, and radioactivity was measured by a gamma 
counter. The mean percentage of specific lysis of triplicate wells was calculated 
by using the following formula: percentage of specific lysis =   [(experimental 
release - spontaneous release)/(maximal release - spontaneous release)] × 100. 
 
IFN-γ secretion assay 
IFN-γ–producing CTLs were detected and isolated using the IFN-γ secretion 
assay (Miltenyi Biotec). Briefly, 1×106 CTLs were incubated in a 24-well plate 
with 1×106 irradiated (30 Gy) autologous PBMCs in a total volume of 2 mL 
IMDM/10% HS. Peptides were added to a final concentration of 10 μM. After 
16 hours of incubation at 37°C, cells were harvested, washed with PBS/0.5% 
FCS/5 mM ethylenediaminetetraacetic acid (EDTA), and labeled at a 
concentration of 108 cells/mL with 50 μg/mL Ab-Ab conjugates directed against 
CD45 and IFN-γ for 10 minutes on ice. Subsequently, cells were diluted with 
IMDM/10% FCS at 1×105 cells/mL and allowed to secrete IFN-γ for 45 minutes 
at 37°C. After the cytokine-capturing period, cells were collected, resuspended 
at a concentration of 108 cells/mL in PBS/0.5% FCS/5 mM EDTA, and stained 
with 5 μg/mL phycoerythrin (PE)–conjugated anti–IFN-γ mAb and FITC-
conjugated anti-CD8 mAb for 20 minutes at 4°C. Finally, cells were analyzed 
and isolated by cell sorting using an Epics Elite flow cytometer (Beckman 
Coulter). 
 
T-cell stimulation assay 
Production of IFN-γ by the generated CD8+ and CD4+ T-cell lines was 
determined as described (14). Briefly, 3,000 to 7,000 CD8+ or 5,000 CD4+ T 
cells were added in flat-bottom microwells containing 3 to 5×104 stimulator cells 
in a total volume of 200 μL IMDM/10% FCS and 25 IU/mL IL-2. After 18 
hours of incubation at 37°C, 100 μL supernatant was collected, and its IFN-γ 
concentration was determined by enzyme-linked immunosorbent assay (ELISA; 
Endogen). Peptide recognition assays were performed by using either 
autologous EBV-LCLs or PHA-stimulated T-cell blasts. Target cells (3×104) 
were incubated with various peptide concentrations for 30 minutes at room 
temperature and tested for recognition by CD8+ and CD4+ T cells. 
 
 
 
 
 
Autologous T-cell responses against HB-1 antigen 
 
 69
Results 
 
Mature monocyte-derived DCs induce expansion of autologous CD8+ CTLs 
against HB-1 
To determine whether CTL precursors recognizing the HB-1H.B44 antigenic 
peptide exist within the T-cell repertoire of HB-1H–positive individuals, we 
stimulated CD8+ T cells isolated from healthy donors 3 times with autologous 
peptide-loaded mature DCs. Specificity of the initiated T-cell cultures was tested 
by chromium release assays. Six of 8 in vitro–induced CTL lines significantly 
lysed peptide-pulsed Raji cells transfected with either HLA-B*4402 or HLA-
B*4403 according to the donor HLA-B44 subtype (Table 1). Cytolytic activity 
of 3 HB-1H–specific CTL lines (CTL donor lines 1, 2, and 6) against unpulsed 
and peptide-pulsed autologous target cells is shown in Figure 1. All 3 CTL lines 
significantly lysed HB-1H–pulsed autologous PHA-stimulated T-cell blasts, 
whereas HB-1Y–pulsed T-cell blasts were not recognized. Furthermore, all 3 
CTL lines recognized autologous EBV-transformed B cells endogenously 
expressing the HB-1H allele (Figure 1). Nonspecific lysis of K562 cells was not 
observed. These results clearly demonstrate that anti–HB-1H CTLs can be 
generated in vitro using peptide-loaded mature DCs and exert specific cytolytic 
activity. This finding implicates that their precursors have not been deleted from 
the T-cell repertoire of HLA-B44–positive individuals positive for the HB-1H 
allele. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Specific reactivity of 3 HB-1H.B44 peptide-induced autologous CD8+ CTL lines. 
Cytolytic activity was tested in chromium release assays against autologous PHA-stimulated 
T-cell blasts either pulsed with 5 μM HB-1H.B44 or HB-1Y.B44 peptide, and autologous 
EBV-transformed B-cell lines that endogenously express HB-1H. K562 was used to 
determine aspecific lysis. 
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Table 1. HLA-B44-restricted and HB-1H peptide-specific cytotoxicity of in vitro-induced T 
cell lines. 
  
     % Specific LysisC 
   
                                                       E:T ratio=30:1           E:T ratio=10:1            E:T ratio=3:1 
       
     CTL          B44        HB-1      + HB-1H  - HB-1H    + HB-1H  - HB-1H    + HB-1H  - HB-1H 
donor line  subtypeA  typingB 
  
 1  B*4402    HH              40       4            22             1          11 1 
 2 B*4402 HY 35 1 26 1 17 1 
 3 B*4402 HH 24 8 22 2 13 1 
 4 B*4402 HH 24 10 17 7 15 4 
 5 B*4402 HH 42 2 2 2 2  2
 6 B*4403 HH 35 1 21 1 14 1 
 7 B*4403 HY 22 13 20 3 13 2 
 8 B*4403 HH 2 2 3 2 2 3 
  
AHLA-B44 subtyping was performed by PCR and digestion analysis as described previously 
(13). 
BHB-1 typing was performed by PCR amplification and digestion of PCR products with 
restriction enzyme NlaIII, as described previously (15). 
CCytolytic activity of HB-1H peptide-induced CTL was tested against Raji.B*4402 or 
Raji.B*4403 cells (according to the HLA-B44 subtype of the donor) either untreated or 
loaded with 5 μM HB-1H.B44 peptide. Specific lysis was determined by chromium release 
assays at different effector to target cell ratios. 
 
Autologous CD8+ CTLs recognize the naturally presented HB-1H.B44 
epitope 
Next, we characterized in more detail HB-1–specific autologous CTLs generated 
in vitro and compared reactivity with that of in vivo–induced allogeneic anti–
HB-1H CTL MP1. To isolate HB-1–specific CTLs from bulk cultures, we used 
the IFN-γ secretion assay. CTL donor line 2 contained 20% IFN-γ–producing 
CD8+ T cells (data not shown). These IFN-γ–secreting cells were sorted by flow 
cytometry and were restimulated weekly with autologous peptide-pulsed EBV-
LCLs. TCR repertoire analysis of the resulting culture revealed that more than 
95% were positive for TCRBV2 and CD8 (data not shown). CTL clone donor 2 
recognizes specifically the endogenously processed HB-1H epitope but not the 
HB-1Y epitope, like the allogeneic CTL MP1 (Figure 2A).  
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To characterize the avidity of CTL clone donor 2, we tested for IFN-γ release 
on stimulation with Raji.B*4402 cells pulsed with different peptide 
concentrations, ranging from 0.01 to 10 μM. The in vitro-induced CTL clone 
donor 2 started to recognize Raji. B*4402 cells pulsed with approximately 300 
nM (data not shown). In contrast, the in vivo–induced CTL MP1 started to 
recognize Raji.B*4403 cells pulsed with very low concentrations of peptide 
(approximately 3 nM; data not shown). Autologous EBV-LCLs naturally 
expressing HB-1H clearly stimulated CTL clone donor 2 to release IFN-γ, 
despite the lower avidity compared with CTL MP1 (Figure 2A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Specific reactivity of in vitro–induced anti–HB-1H.B44 CTL clone donor 2 in 
comparison with in vivo–induced CTL MP1. Production of IFN-γ of CTL clone donor 2 and 
MP1 was determined on stimulation with (A) Raji cells transfected with HLA-B44 (B*4402 
or B*4403) plus HB-1H or HB-1Y and EBV-transformed B-cell lines endogenously 
expressing HB-1, and (B) B-ALL cells of HLA-B44–positive patients. HB-1 typing for each 
stimulator cell is shown in parenthesis. HLA-B44 subtype of patients 1, 2, and 3 is B*4402 
and of patient 4 is B*4403. 
 
We have shown previously that the in vivo–induced CTL MP1 mediates 
cytokine release and cytotoxicity against allogeneic B-ALL cells expressing 
HB-1 (13, 14). To determine whether the in vitro–induced HB-1–specific CTL 
clone donor 2 also recognizes B-ALL cells, we have tested tumor cells obtained 
from patients at diagnosis for their ability to induce cytokine production. As 
shown in Figure 2B, significant amounts of IFN-γ are released by CTL clone 
donor 2 when stimulated with allogeneic HLA-B*4402–positive B-ALL tumor 
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cells. Furthermore, B-ALL cells of the B*4403-positive patient 4 and 1 of 3 
B*4402-positive patients were recognized by CTL MP1 (Figure 2B). This 
finding confirms our previous results that CTL MP1 recognizes the HB-1 
peptide much more efficiently in the context of the HLA-B*4403 subtype (data 
not shown).  
Together, these data demonstrate that autologous anti–HB-1 CTLs secrete 
IFN-γ on stimulation with the endogenously processed epitope on HB-1–
expressing cell lines and B-ALL tumor cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Specific reactivity of CD4+ T cells stimulated 3 times with autologous DCs loaded 
with the HB-1 protein. IFN-γ production of the established T-cell lines was tested on 
stimulation with autologous EBV-LCLs either untreated or pulsed with 25 μg/mL HB-1 
protein or Candida albicans protein extract. Error bars represent 1 SD of triplicates. 
 
Autologous CD4+ Th responses against HB-1 can be induced by mature 
monocyte-derived DCs 
To investigate the potential of the HB-1 protein to induce Th responses, we 
stimulated CD4+ T cells isolated from 2 healthy donors (donors 9 and 10) with 
autologous protein-loaded mature monocyte-derived DCs. After 3 rounds of 
stimulation, the induced T-cell lines were tested for HB-1 specificity in cytokine 
release assays. As shown in Figure 3, we obtained 2 T-cell lines that on 
stimulation with autologous EBV-LCLs pulsed with the HB-1 protein produced 
higher levels of IFN-γ than on stimulation with untreated EBV-LCLs or EBV-
LCLs pulsed with C. albicans protein extract. Next, HB-1–specific CD4+ T-cell 
lines were cloned by limiting dilution. Three and 5 CD4+ clones recognizing the 
full-length HB-1 protein were obtained from donor 9 (M1G1, M1A5, and 
M3A4) and donor 10 (R3A8, R10A5, R3D1, R1G10, and R1D1), respectively 
(Figure 4). To determine which part of the HB-1 protein is recognized by these 
T-cell clones, 3 overlapping peptides were generated: designated as HB-14-25, 
HB-111-34, and HB-119-41. T-cell clones M1G1 and M1A5 of donor 9 recognized 
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EBV-LCLs loaded with the peptides HB-111-34 and HB-119-41, whereas clone 
M3A4 recognized only the HB-119-41 peptide (Figure 4). Interestingly, all HB-1–
specific CD4+ clones isolated from donor 10 were specific for the N-terminal 
HB-14-25 peptide. These data clearly demonstrate that CD4+ Th responses can be 
induced against the HB-1 protein by using mature monocyte-derived DCs. We 
isolated several CD4+ Th clones specific for different epitopes within the HB-1 
protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Localization of the Th epitopes recognized by the CD4+ T-cell clones generated 
from the HB-1–specific bulk cultures. Production of IFN-γ by the CD4+ clones was tested on 
stimulation with autologous EBV-LCLs pulsed with the HB-1 protein or HB-1–derived 
peptides. Error bars represent 1 SD of triplicates. 
 
HB-1–specific CD4+ Th clones recognize HLA-DR–restricted epitopes 
Next, we determined the MHC class II restriction molecule for clones M3A4 
and R3A8 recognizing distinct HB-1 epitopes. Recognition of autologous EBV-
LCLs pulsed with the appropriate peptide was inhibited by anti–HLA-DR mAb, 
whereas anti–HLA-DP and -DQ mAbs had no effect (Figure 5). To further 
identify the HLA-DR molecule involved in presentation of the HB-1 epitopes, 
we tested a panel of EBV-LCLs sharing one or more HLA-DR molecules with 
the autologous EBV-LCLs. Clone M3A4 recognized 2 individuals sharing DR4 
and DR53 with the autologous EBV-LCLs (Table 2). However, EBV-LCLs of 4 
individuals positive for DR53 but negative for DR4 were not recognized, 
indicating that the epitope recognized by clone M3A4 is presented by DR4. 
Clone R3A8 recognized EBV-LCLs sharing both DR11 and DR52 with the 
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autologous EBV-LCLs (Table 3). Four individuals sharing only DR52 were not 
recognized, indicating that this epitope is presented by DR11. These data 
demonstrate that the HB-1 antigen contains distinct Th epitopes presented by 
either HLA-DR4 or HLA-DR11. 
 
Table 2. Presentation of the HB-1 epitope to clone M3A4 by HLA-DR4. 
  
 IFN-γ production (pg/ml)A 
   
 EBV-LCLs HLA-DR specificity - peptide + peptide 
  
 Donor 9 DR3+ DR4+ DR52+ DR53+   <      748 
 No. 11 DR3+ DR4- DR52+ DR53- < < 
 No. 12 DR3+ DR4- DR52+ DR53- < < 
 No. 13 DR3+ DR4- DR52- DR53- < < 
 No. 14 DR3- DR4+ DR52- DR53+ < 895 
 No. 15 DR3- DR4+ DR52- DR53+ < 544 
 No. 16 DR3- DR4- DR52+ DR53+ < < 
 No. 17 DR3- DR4- DR52+ DR53- < < 
 No. 18 DR3- DR4- DR52+ DR53- < < 
 No. 19 DR3- DR4- DR52- DR53+ < < 
 No. 20 DR3- DR4- DR52- DR53+ < < 
 No. 21 DR3- DR4- DR52- DR53+ < < 
  
AEBV-LCL were incubated for 18 h with 25 μg/ml HB-119-41 peptide and washed. CD4+ T cell 
clone R3A8 was then incubated for 20 h with 30,000 untreated and peptide-pulsed EBV-LCL. 
IFN-γ released in the supernatant was measured by ELISA. < indicates < 70 pg/ml IFN-γ. 
 
Identification of DR4- and DR11-restricted HB-1 Th epitopes 
To define the minimal HB-1 epitopes recognized by CD4+ clones M3A4 and 
R3A8, a set of overlapping peptides were pulsed at various concentrations on 
autologous EBV-LCLs and tested for recognition. CD4+ clone M3A4 
recognized peptide EDDVYLRHSSSLTYRL (HB-126-41) very efficiently 
(Figure 6A). Truncation of 3 amino acids, 26 to 28 or 39 to 41, resulted in a 
significant decrease in recognition, whereas deletion of one amino acid, 26 or 
41, resulted only in a minor decrease. This finding indicates that the shortest 
peptide well recognized by CD4+ clone M3A4 is the 16-mer HB-126-41 peptide 
that is also predicted to bind efficiently to HLA-DRB1*0401 molecules by the 
epitope binding program SYFPEITHI (http://syfpeithi.bmi-
heidelberg.com/scripts/MHCServer.dll/home.htm; data not shown). Half-
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maximal IFN-γ release was obtained by incubating EBV-LCL stimulator cells 
with approximately 40 nM of this peptide, indicating high avidity of CD4+ clone 
M3A4 for the epitope. This finding is concordant with results obtained for other 
HLA class II-restricted epitopes (20-22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Inhibition of IFN-γ release by anti–HLA class II mAb. HB-1–specific CD4+ clones 
M3A4 and R3A8 were stimulated with autologous EBV-LCLs pulsed with the HB-119-41 
peptide or the HB-14-25 peptide, respectively. Blocking studies were performed by using 
purified anti–HLA-DR (L234), anti–HLA-DP (B7/21), or anti–HLA-DQ (Tü22) mAb (10 
μg/mL) which were present throughout the assay. Error bars represent 1 SD of triplicates 
 
Three peptides spanning the amino acid sequence EQPECREEKRGSLHV 
(HB-13-17) were recognized by CD4+ clone R3A8 (Figure 6B). Truncation of the 
glutamic acid at position 3 resulted in a decrease in recognition, which could be 
improved by the addition of the valine at position 17. Peptide 
EQPECREEKRGSLHV is also predicted to bind to HLADRB1*1101 molecules 
by the epitope-binding program SYFPEITHI (data not shown). These data 
indicate that the HLA-DR11–restricted epitope recognized by CD4+ clone R3A8 
is the 15-mer HB-13-17 peptide. High concentrations of peptide were needed to 
stimulate clone R3A8 to release IFN-γ, indicating low avidity of this CD4+ clone 
for the HB-1.DR11 epitope (Figure 6B).  
 
Discussion 
 
Effective cellular immunotherapy for leukemia needs identification of specific 
tumor antigens that are recognized by the immune system. A potential group of 
antigens are those proteins that are differentially (over) expressed in 
hematopoietic tumor cells. So far, only a few of these leukemia-associated 
antigens (proteinase 3 and WT1) have been shown to induce autologous CTL 
responses (10-12). Previously, we have identified HB-1 as a polymorphic 
leukaemia-associated antigen that is recognized by donor-derived CTLs on 
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allogeneic tumor cells of patients with B-ALL (13, 14) Its B-cell–restricted 
expression pattern strongly suggests that the HB-1 protein could serve as an 
autologous vaccine target to induce antitumor immunity in patients with B-ALL 
after primary treatment. In the autologous setting, HB-1 represents a B-cell–
specific “self-antigen” inducing T-cell tolerance. However, it has been shown 
that toward many tissue-specific differentiation antigens autologous T-cell 
immunity can be induced by using professional antigen-presenting dendritic 
cells by breaking immunologic tolerance (19). Here, we addressed whether 
autologous HB-1–specific T-cell responses can be induced by in vitro 
stimulation with antigen-pulsed monocyte-derived mature DCs. We observed 
that HB-1–specific CTL responses against the previously identified HLA-B44–
restricted peptide EEKRGSLHVW could be generated in 6 of 8 healthy donors. 
This finding indicates that HB-1–specific T-cell precursors have not been 
deleted from the T-cell repertoire of healthy individuals. Apparently, HB-1 is 
immunologically ignored because of its relatively low expression as suggested 
for other differentially expressed tumor antigens (19). 
 
 
Table 3. Presentation of the HB-1 epitope to clone R3A8 by HLA-DR11. 
  
 IFN-γ production (pg/ml)A 
   
 EBV-LCLs HLA-DR specificity - peptide + peptide 
  
 Donor 10 DR11+ DR13+ DR52+ < 92 
 No. 22 DR11+ DR13- DR52+ < 89 
 No. 23 DR11+ DR13- DR52+ < 196 
 No. 24 DR11- DR13+ DR52+ < < 
 No. 25 DR11- DR13- DR52+ < < 
 No. 26 DR11- DR13- DR52+ < < 
 No. 27 DR11- DR13- DR52+ < < 
 No. 28 DR11- DR13- DR52- < < 
 No. 29 DR11- DR13- DR52- < < 
  
AEBV-LCL were incubated for 18 h with 25 μg/ml HB-14-25 peptide and washed. CD4+ T cell 
clone R3A8 was then incubated for 20 h with 30,000 untreated and peptide-pulsed EBV-LCL. 
IFN-γ released in the supernatant was measured by ELISA. < indicates < 40 pg/ml IFN-γ. 
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Figure 6. Identification of the HLA-DR–restricted Th epitopes recognized by CD4+ clones 
M3A4 and R3A8. Autologous EBV-LCLs were pulsed at various concentrations with HB-1–
derived peptides and tested for recognition by the CD4+ T-cell clones M3A4 (A) and R3A8 
(B). 
 
For 3 of the in vitro–induced HB-1–specific CTL lines, we showed specific 
lysis of autologous EBV-transformed B-cell lines naturally expressing and 
presenting the HB-1.B44 epitope as well as peptide-loaded target cells. From 
one of these CD8+ T-cell lines, we isolated CTL clone donor 2 that produces 
IFN-γ on stimulation with Raji cells transfected with the HB-1 cDNA in the 
context of HLA-B*4402. Like the in vivo–induced HB-1–specific CTL MP1, 
CTL clone donor 2 releases significant amounts of IFN-γ when stimulated with 
B-ALL tumor cells obtained from HLA-B44–positive patients. From these 
findings, we can conclude that DCs pulsed with the HLA-B44–restricted HB-1 
peptide induce autologous CTLs with the ability to recognize B-ALL tumor 
cells. 
Because of its capacity to mediate direct killing of tumor cells, much attention 
has been focused on CD8+ T-cell–mediated antitumor immunity. However, 
preclinical data clearly demonstrate that CD4+ Th cells are important in inducing 
effective antitumor responses (16-18). For instance, Ossendorp et al. (17) 
showed that tumor protection against a highly aggressive MHC class II–negative 
T-lymphoma cell line was enhanced when a tumor-specific CTL epitope was 
injected simultaneously with a tumor-specific CD4+ Th epitope. The 
requirement of CD4+ T-cell help during the induction of antitumor CTL 
Chapter 3 
 
 78 
responses was also demonstrated in the human setting (23). It has been shown 
that many TAAs contain CD4+ Th epitopes besides CTL epitopes (24). Here, we 
demonstrate that HB-1 induces CD4+ Th responses. We identified 2 HB-1–
derived Th epitopes presented by different HLA-DR subtypes. Peptide HB-126-41 
(EDDVYLRHSSSLTYRL) was recognized by CD4+ clone M3A4 in the context 
of HLA-DR4. This epitope is not only predicted to bind to HLA-DR4 but also to 
HLA-DR3 and HLA-DR11 as determined by the SYFPEITHI peptide-binding 
program. It is known that Th peptides can be promiscuous in binding to MHC 
class II molecules (25, 26) Therefore, peptide HB-126-41 could serve as a widely 
applicable Th epitope in HB-1–based vaccination. Interestingly, the peptide HB-
13-17 (EQPECREEKRGSLHV), recognized by CD4+ clone R3A8 in the context 
of HLA-DR11, overlaps almost completely the HLA-B44–restricted CTL 
epitope EEKRGSLHVW. In conclusion, our present data show that the 
leukemia-associated HB-1 antigen contains both CD4+ and CD8+ T-cell epitopes 
as described for many other human tumor antigens (24). 
DCs pulsed with short MHC class I–binding synthetic peptides have been 
used for inducing CD8+ T-cell immunity against cancer (27-30). The observed 
immunologic and clinical responses were limited and require further 
development to improve efficacy. Several other formulations of tumor antigens 
can be used to load DCs such as tumor cell lysates, apoptotic bodies, purified 
proteins, or nucleic acids (31). An even more interesting approach is the use of 
long synthetic peptides of 30 to 40 amino acids containing both Th and CTL 
epitopes (32). The advantage of these long peptides may be more efficient 
cellular uptake and processing, resulting in a high-epitope density at the cell 
surface. It has been shown that the physical linkage of MHC class I– and class 
II–restricted epitopes within long peptides potentiates specific CTL responses 
(32-34). DCs pulsed with the 40-aa synthetic HB-1 protein can be recognized by 
both HB-1–reactive CD4+ as well as CD8+ T-cell clones (data not shown). 
Currently, we are analyzing whether this 40-aa long protein induces more 
vigorous CTL responses in vitro. 
In this report, we demonstrate that the B-cell leukaemia-associated antigen 
HB-1 is able to induce both CD4+ Th and CD8+ CTL responses, implicating that 
HB-1 is a suitable target for B-ALL–specific immunotherapy. On the basis of 
the results of our previous and present studies, a clinical pilot study has been 
initiated to use autologous HB-1 protein-pulsed DCs in patients with residual 
disease after primary treatment. A major challenge of such vaccination studies 
will be the correlation between immunologic responses and the disappearance of 
residual tumor cells. 
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Summary  
 
Minor histocompatibility antigens (mHAgs) constitute the target antigens of the 
T cell-mediated graft-versus-host disease and graft-versus-leukemia response 
after HLA-identical allogeneic stem cell transplantation (SCT). Several human 
mHAgs have been identified, but only a few are selectively expressed by 
hematopoietic cells representing potential targets for specific immunotherapy 
after allogeneic SCT. Molecular approaches including cDNA library screening 
and genetic linkage analysis have been successfully applied to identify T cell-
defined mHAgs, but each approach has several shortcomings which may lead to 
mis-identification of the mHAg of interest. We improved both molecular 
strategies to facilitate more robust identification of hematopoietic-restricted 
mHAgs. First, we adapted cDNA library cloning by using 293T cells with stable 
expression of the relevant MHC class I allele, CD80 and CD54. We 
demonstrated that cDNA library screening using this 293T expression system 
results in strong CTL activation, which significantly contributes to improvement 
of the assay sensitivity. Second, we refined genetic linkage analysis using single 
nucleotide polymorphism (SNP) genotyping to narrow down the defined genetic 
region that holds the mHAg-encoding gene. We showed that SNP marker 
analysis provides additional information about the genetic position of the 
antigen-encoding gene. Application of these optimized molecular approaches 
will lead to more rapid and reliable molecular identification of hematopoietic-
restricted mHAgs. 
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Introduction 
 
In HLA-identical allogeneic stem cell transplantation (SCT), T cells specific for 
minor histocompatibility antigens (mHAgs) play a major role in graft rejection, 
graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) reactivity 
(1, 2). These mHAgs are HLA-bound peptides derived from cellular proteins 
that differ in amino acid sequence between donor and recipient due to genetic 
polymorphisms (3). Functional analysis with mHAg-specific cytotoxic T 
lymphocytes (CTLs) showed that mHAgs display either an ubiquitous or tissue-
restricted expression pattern (4). Minor HAgs which are selectively expressed 
by hematopoietic cells or cell lineages are especially relevant to GVL reactivity. 
Only a few hematopoietic mHAgs have been identified until now. Therefore, 
characterization of a larger variety of hematopoietic-restricted mHAgs is of 
great importance in order to broaden their immunotherapeutic potential. 
Furthermore, it allows detailed analysis of the dynamics of mHAg-specific T 
cell responses during GVL and GVHD.  
Various biochemical and molecular approaches have led to the identification 
of human mHAgs. Most frequently, the biochemical approach has been 
employed, in which the polymorphic amino acid sequence is identified by mass-
spectrometry of eluted peptides from the relevant HLA molecules (5-12). 
However, a major drawback of this approach is the need for highly specialized 
equipment. Alternatively, molecular approaches have been succesfully applied 
for the characterization of mHAgs. One approach involves cDNA library 
screening, in which the mHAg-encoding gene is identified by transfecting pools 
of a cDNA library established from antigen-positive cells into a mammalian 
expression system, followed by screening with mHAg-specific CTLs (13, 14). 
Another approach involves genetic linkage analysis using EBV-lymphoblastoid 
cell lines (LCL) established from large Centre d’Etude Polymorphism Humain 
(CEPH) reference families, which are allele-typed for thousands of polymorphic 
genetic markers. Following initial screening of HLA-transfected CEPH EBV-
LCL with mHAg-specific CTLs, genome wide linkage analysis can be utilized 
to map the chromosomal position of the mHAg-encoding gene (15, 16). 
Although these molecular approaches can be executed for the identification of 
human mHAgs, there are several pitfalls which might affect the reliability of 
these strategies. 
In this study, we optimized both molecular approaches to facilitate robust 
identification of novel mHAgs. We improved cDNA library cloning by using a 
293T cell line with stable expression of the relevant MHC class I allele, CD80 
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and CD54. Furthermore, we refined genetic linkage analysis by additional fine-
mapping using single nucleotide polymorphism (SNP) markers. We propose that 
these refinements will facilitate more rapid and reliable molecular identification 
of novel hematopoietic mHAgs by cDNA library screening and genetic linkage 
analysis.  
 
Materials and methods 
 
Cell culture 
Previously, we established two CTL clones recognizing hematopoietic-restricted 
mHAg in the context of MHC class I molecules that are frequently expressed 
within the Caucasian population (Table 1). CD8+ CTL MP1 was isolated from a 
patient with common B cell acute lymphoblastic leukemia (B-ALL) after HLA-
identical allogeneic SCT (17). CTL MP1 (5x106) was cultured in Iscove’s 
modified Dulbecco’s medium (IMDM; Invitrogen) containing 10% human 
serum (HS; PAA laboratories) containing irradiated (80 Gy) recipient EBV-LCL 
(5x106), irradiated (60 Gy) allogeneic PBMCs (5x106) from 2 donors, 100 IU/ml 
IL-2 (Eurocetus) and 1 μg/ml PHA-M (Boerhinger) in a total volume of  15 ml.  
CD8+ CTL RP1 was isolated from a chronic myeloid leukemia (CML) patient 
after post-alloSCT donor lymphocyte infusion (16). CTL RP1 (0.5x106) was 
cultured in 24-well plates with IMDM/10% HS, irradiated (80 Gy) recipient 
EBV-LCL (0.5x106), irradiated (60 Gy) allogeneic PBMC (0.5x106) of two 
donors, 100 IU/ml IL-2 and 1 μg/ml PHA-M in a total volume of 2 ml. CTL 
cultures were used in stimulation assay 7 days after stimulation. Cell lines were 
cultured in IMDM/10% fetal calf serum (FCS). Adherent cell lines (1x106/ml) 
were cultured in 150-cm2 flasks in a total volume of 20 ml and refreshed twice a 
week. 
 
T cell stimulation assay 
Production of IFN-γ by CTLs was determined as described (13). Briefly, 3,000-
5,000 CD8+ T cells were added in flat-bottom microwells containing 3x104 
stimulator cells in a total volume of 200 μl IMDM/10% FCS and 25 IU/ml IL-2. 
After 18 h of incubation at 37°C, 100 μl supernatant was collected and its IFN-γ 
concentration was determined by ELISA (Endogen).  
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Table 1. Characteristics of mHAg-specific CTL clones. 
           
CTL Patient  mHag   MHC       Gene PeptideA Tissue                   Phenotype Refs 
   restriction                                         distributionB                frequencyC               
                               
MP1 B-ALL HB-1   HLA-B44 HB-1 EEKRGSLHVW  Lymphoblastic leukemia 96%           (13, 27) 
RP1   CML  LRH-1  HLA-B7 P2X5 TPNQRQNVC CD34+ progenitor cells, 54%           (16) 
 lymphoid cells 
       
AImmunogenicity of peptides is caused by a change at the amino acids underlined and 
highlighted in bold. 
BBased on CTL studies and real-time quantitative RT-PCR analysis. 
CBased on genotyping assays. 
 
Generation of cDNA constructs 
Expression vectors encoding HLA-B*4403, HLA-B*0702, CD54, CD80 and 
mHAg HB-1 were constructed using standard molecular methods. Briefly, 
CMV-based pCR3 vector (Invitrogen) encoding HLA-B*4403 was digested 
with HindIII and EcoRI and the cDNA fragment was ligated into the CMV-
based pVAX1 vector (Invitrogen) without an SV40 origin of replication. PSR1 
vector encoding HLA-B*0702 cDNA, kindly provided by Dr. T. Mutis 
(Department of Hematology, University of Utrecht), was digested with EcoRI 
and cloned into the pVAX1 vector. SFG vector encoding CD54 molecule, 
kindly provided by Dr. M. Sadelain (Memorial Sloan-Kettering Cancer Center, 
NY, USA), was used to amplify CD54 cDNA by PCR.  The reaction mixture 
contained 0.5 μM forward primer ICAMBAMHI-F 5’-
TTTGGATCCCCATGGCTCCCAGCA-3’, 0.5 μM reverse primer 
ICAMXHOI-R 5’-TTTCTCGAGGGATCCGGGATAGGTTCAGG-3’, 0.25 
mM dNTPs and 1.25 U Taq polymerase (Invitrogen) using the following  
amplification conditions:  35 cycles of 95°C for 1 min, 61°C for 1 min, and 
72°C for 1 min. CD80 cDNA was amplified using cDNA generated from an 
EBV-LCL with specific primers as described previously (18). The following 
PCR conditions were used: 35 cycles of 95°C for 1 min, 55°C for 1 min, and 
72°C for 1 min. Next, CD80 and CD54 fragments were ligated into vector 
pCRII (Invitrogen). Subsequently, pCRII vector was EcoRI digested, fragments 
were isolated by gel extraction (Qiagen), and subcloned into pVAX1 vector. 
SV40-based pSV-Sport1 vector encoding HB-1 mHAg was used to amplify 
HB1H cDNA by PCR and cloned into vector pCR3 using the unidirectional TA 
cloning kit (Invitrogen). Digestion analysis was performed on all constructs to 
determine the insert orientation. 
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Generation of 293T stable transfectants 
Stable transfectants were generated using the lipofection method. Briefly, 293T 
cells (2x106) were seeded in 25-cm2 flasks and incubated overnight at 37°C. 
Lipofection mixture was prepared by incubating 200 μl IMDM containing 18 μl 
Lipofectamine (Invitrogen) with 200 μl IMDM containing 3 μg plasmid DNA 
encoding either HLA-B*4403, HLA-B*0702, CD80 or CD54 for 30 min at 
room-temperature. The mixture was adjusted to 2 ml and added to the washed 
cells. After 6 hours of incubation at 37°C, 2 ml of IMDM/20% FCS was added. 
Transfected cells were sorted after 7 days and cloned by limiting dilution. 
Clonal stable transfectants were analyzed by flow cytometry to validate 
expression of the surface molecules. 
 
Antibodies and immunofluorescence analysis 
Immunofluorescence analysis was performed by direct staining using FITC- or 
PE-conjugated antibodies against CD3 (UCHT1), CD4 (13B8.2), CD8 (B9.11), 
CD80 (MAB104) and HLA-B7 (BB7.1), which were purchased from Beckman 
Coulter. Labeled CD54 (6.5B5) and HLA-B12 (FH0066) antibodies were 
obtained from DAKO and One lambda, respectively. Cells were analyzed by an 
Epics XL flow cytometer (Beckman Coulter). 
 
cDNA library construction  
Library construction using a SV40-based pSV-Sport1 expression vector from 
the Superscript Plasmid System (Invitrogen) and the isolation of the HB-1 
cDNA, was described previously (13). To optimize the expression cloning 
procedure, pools were generated consisting of one HB-1 cDNA bacteria colony 
diluted in various number of irrelevant bacteria colonies. Next, pools were 
resuspended in 5 ml LB medium with 100 μg/ml ampicillin and incubated for 2 
h at 37°C. Plasmid DNA was isolated using Quantum plasmid miniprep kit 
(Bio-rad Laboratories). For the identification of mHAg LRH-1, a cDNA library 
was constructed with the Superscript Plasmid System with Gateway technology 
(Invitrogen) using cDNA generated from a LRH-1-positive EBV-LCL. Briefly, 
total RNA was extracted from EBV-LCL using the guanidine isothiocyanate 
method. Poly(A)+ RNA was isolated using the Oligotex kit (Qiagen) and cDNA 
was synthesized using Powerscript RT (Clontech) and an oligo-dT primer that 
contains a NotI site at its 5’ end. Next, cDNA was ligated to SalI adaptors, 
digested with NotI and ligated into the expression vector pCMV-Sport6. 
ElectroMAX DH10B E. coli cells (Invitrogen) were electroporated with the 
recombinant plasmids using the BioRad gene pulser (Biorad) according to the 
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manufacturers instructions. The constructed cDNA library consisted of ~1.5x106 
transformants. Next, the library was divided into 1,100 pools of approximately 
50 cDNA clones. Each pool was incubated for 2 h at 37°C and plasmid DNA 
was isolated using the 96 R.E.A.L. prep plasmid kit (Qiagen).  
 
cDNA library screening 
293T stable transfectants (0.3x105/ml) were seeded into poly-D-lysine coated 
96-wells flat bottom wells (Becton Dickinson), and incubated overnight at 37°C. 
50 μl IMDM without supplements, containing 400 ng plasmid DNA and 0.75 μl 
Lipofectamine (Invitrogen), was prepared. The mixture was incubated at room 
temperature for 30 min and added gently to the cells. 293T cell lines cells 
without stable expression of MHC class I molecules were cotransfected with 
cDNA encoding HLA-B*4403 and library cDNA at a ratio of 2:1. Transfections 
were performed in duplo. After 4 h of incubation at 37°C, 50 μl IMDM/20% 
FCS was added. After two days, transfected 293T cells were used as targets to 
test their ability to stimulate CTLs. CTL sensitivity was measured by using 
serial dilutions of recipient EBV-LCL into mHAg-negative K562 cells as 
targets. 
 
Genetic linkage analysis 
Mapping of the LRH-1 locus was accomplished in a subset of CEPH reference 
families. Genotypes were retrieved from the CEPH database version 9.0 
(http://www.cephb.fr/cephdb/; 19, 20). Two-point linkage was performed using 
the MLINK subroutine of the FASTLINK (v4.0) program as reported previously 
(15, 20, 21). An autosomal dominant, single gene model was assumed for the 
LRH-1 trait. The population frequency of the encoding allele was estimated at 
0.5 and the penetrance of the LRH-1 phenotype was set at 0.9. Population allele 
frequencies for the genetic markers were used when present in the CEPH 
database; otherwise equal allele frequencies were assumed. Resulting log odds 
ratio (lod) scores were examined for regions of highly significant linkage and 
the identification of the LRH-1 locus was interpreted from the Marshfield 
genetic map (22). 
 
SNP genotyping  
SNP genotyping was performed using SNP-specific Assays-on-Demand 
Genotyping kits (Applied Biosystems) according to the manufacturers 
instructions. Briefly, genomic DNA was isolated from cell lines using the 
QIAamp DNA Blood mini kit (Qiagen).  20 ng of DNA was amplified in a 25 μl 
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reaction mixture containing 12.5 μl 2xTaqMan Universal PCR Master Mix, No 
AmpErase UNG Applied Biosystems) and 1.25 μl 20x SNP Genotyping Assay 
Mix (Applied Biosystems). PCR amplification was performed using an ABI 
Prism 7700 (Applied Biosystems) with the following PCR conditions: enzyme 
activation for 10 min at 95°C, followed by 40 cycles of 92°C for 15 s and 60°C 
for 1 min. After amplification, an endpoint plate read was performed using ABI 
Prism 7700 allelic discrimination software. 
 
Results 
 
Generation of a 293T stable expression system for cDNA library screening  
A proven approach to identify hematopoietic-restricted mHAgs is cDNA library 
screening, which is schematically outlined in Figure 1. Previously, we used this 
approach successfully to identify the molecular nature of mHAg HB-1 (13). In 
this analysis, we screened 1,500 pools of ~100 cDNA clones after transient 
transfection into COS-1 cells for recognition by CTL MP1. After screening the 
library twice, we identified a weakly positive pool from which we finally 
isolated a cDNA of 397 nucleotides encoding the polymorphic peptide 
EEKRGSLHVW recognized by CTL MP1. 
To improve cDNA library cloning for more efficient identification of 
additional mHAgs, we developed an alternative expression system with a strong 
ability to stimulate CTLs. For this, we stably transfected the human kidney 293T 
cell line with the HLA-B*4403 molecule. Subsequently, this 293T-HLA-
B*4403 transfectant was co-transfected with cDNA encoding CD80 and/or 
CD54. Each generated cell line showed appropriate expression of the transfected 
surface molecules as measured by flow cytometry (data not shown). To 
determine whether these stable transfectants significantly improved CTL 
triggering, we transiently transfected the generated target cell lines with HB-1 
cDNA and tested them for CTL MP1 recognition (Figure 2A). Strong CTL 
activation was observed when HB-1H cDNA into a CMV promoter-based vector 
was introduced into 293T/HLA-B*4403 cells, whereas HB-1H cDNA in a SV40 
promoter-based vector was less effective. However, the highest CTL recognition 
was observed using the 293T/HLA-B*4403/CD80/CD54 cell line in 
combination with both SV40-HB1H and CMV-HB1H constructs.  
To determine whether the 293T cell line with stable expression of HLA-
B*4403, CD54 and CD80 significantly improves cDNA expression cloning, we 
analyzed its ability to stimulate HB-1-specific CTL MP1 using a titration 
experiment. Therefore, one bacteria colony containing HB-1H cDNA was 
diluted into bacteria colonies containing irrelevant cDNAs at various ratios. 
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Plasmid DNA isolated from the bacteria pools was transfected into the different 
293T stable transfectants, which were used as targets in a CTL stimulation assay 
(Figure 2B). The combined expression of HLA-B*4403, CD80 and CD54 
resulted in the most efficient CTL recognition. Even up to a dilution ratio of 
1:100 a very strong IFN-γ signal was detectable (Figure 2B). These data clearly 
demonstrate that the 293T/HLA-B*4403/CD80/CD54 target cell line is an 
excellent expression system for efficient cDNA library screening with improved 
sensitivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic overview of the cDNA library cloning approach. A cDNA library was 
constructed from antigen-positive cells and divided into pools of 50-100 bacteria colonies 
were incubated for 2 h at 37oC. Part of the bacteria was stored in glycerol at -80oC and from 
the remaining bacteria plasmid DNA was extracted. In the COS-1 system, these plasmid 
cDNA pools and cDNA encoding the appropriate MHC molecule are co-transfected by 
Lipofectamine into COS-1 cells, whereas in the 293T-HLA system plasmid cDNA pools are 
transfected into 293T cells that already stably express the relevant MHC allele. After 48 h of 
incubation, the transfectants are tested for their ability to stimulate mHAg-specific CTLs and 
the amount of cytokines in the supernatant is measured after 24 h using a cytokine-specific 
ELISA. Eventually, the positive pool can be subcloned from the library backup to identify a 
single bacteria colony containing the antigen-encoding cDNA. 
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Figure 2.  The 293T/HLA-B*4403/CD80/CD54 cell line is an efficient expression system for 
cDNA library screening. (A) 293T cells were transfected with CMV-HLA-B*4403 cDNA 
together with HB-1H cDNA under control of either the SV40 or CMV promoter. Transient 
transfected 293T cells showed ~15% expression of HLA-B44. In contrast, 293T/HLA-
B*4403 and 293T/HLA-B*4403/CD80/CD54 were only transfected with HB-1H cDNA. 
After 48 h of incubation, transfectants were tested for their ability to stimulate HB-1H-
specific CTLs and release of IFN-γ was measured by ELISA. CTL MP1 had a sensitivity of 
detecting HB-1-positive recipient (Rt) EBV-LCL into K562 cells at a ratio of 1:30. (B) One 
HB-1H encoding cDNA bacteria colony was titrated at different ratios into bacteria colonies 
containing irrelevant cDNAs. Plasmid DNA extracted from the bacteria pools was transfected 
into 293T/HLA-B*4403 cell lines with stable expression of CD80 and/or CD54 molecules. 
After 48 h of incubation, transfectants were tested for their ability to stimulate HB-1H-
specific CTLs and the amount of IFN-γ in the supernatant was measured by ELISA. CTL 
sensitivity during the assay was 1:30.  
 
cDNA library screening using the 293T/HLA-B*0702/CD80/CD54 target 
cell line  
To validate our refined 293T stable expression system we used CTL RP1 that 
recognizes a HLA-B7-restricted mHAg, designated LRH-1. This mHAg is 
selectively expressed by CD34+ progenitor cells and lymphoid cells with an 
expression frequency of 54% (Table 1). Therefore, we generated a CMV-based 
cDNA library from an LRH-1-positive EBV-LCL, with an average cDNA 
fragment length of 1.8 kb (data not shown). This library was divided into 1,100 
pools of ~50 cDNA clones and the extracted cDNA was transfected into 
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293T/HLA-B*0702/CD54/CD80 stable cell line in duplicate. The transfected 
target cells were analyzed for recognition using CTL RP1 that has a sensitivity 
of detecting LRH-1-positive EBV-LCL at a ratio of 1:30 into K562 cells (Figure 
3A). Library screening resulted in the identification of three pools #385, #395 
and #470 with duplicate IFN-γ extinction level above the background (Figure 
3B). However, positive recognition of these pools could not be confirmed after 
multiple re-screening (data not shown). Unfortunately, despite the use of our 
refined 293T stable expression system and the use of a high quality cDNA 
library, we were not successful to identify a pool containing the LRH-1-
encoding cDNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Screening of the cDNA library with CTL RP1 using the 293T-HLA system. (A) 
LRH-1-positive EBV-LCL were diluted into K562 cells up to 1:100 and co-cultured with 
CTL RP1 to determine the sensitivity of the CTLs during cDNA library screening. (B) cDNA 
library pools consisting of ~50 bacterial colonies were transfected into 293T/HLA-
B*0702/CD80/CD54 and tested for CTL recognition. The amount of IFN-γ released by CTL 
RP1 was determined by ELISA. The results of duplicate co-cultures of 96 library pools are 
shown. cDNA pools with duplicate IFN-γ levels above the background, are indicated by an 
arrow. The IFN-γ background level is indicated by a dashed line. 
 
Genetic linkage analysis using CTL RP1  
Because we failed to identify mHAg LRH-1 using cDNA library screening, we 
applied genetic linkage analysis as an alternative approach. This approach relies 
on CTL recognition analysis of individual family members from large allele-
Chapter 4 
 
 94 
typed CEPH reference families which is outlined in Figure 4A. To map the 
chromosomal region containing the LRH-1-encoding gene using linkage 
analysis, we initially used 5 CEPH families (i.e. 1331, 1332, 1347, 1362 and 
1413) of which either one or both parents were LRH-1 positive. CTL RP1 
recognition analysis yielded informative LRH-1 segregation patterns in all 5 
families of which a representative example of CEPH family 1413 is shown in 
Figure 4B and C. Next, genome wide linkage analysis showed that a cluster of 
markers on chromosome 17p13.2 was significantly linked (i.e., lod scores > 3.0) 
to the locus encoding LRH-1 (Figure 5). A 7.5 cM critical region of no 
recombination was defined between the flanking markers D17S1845 (7.19 cM) 
and D17S938 (14.69 cM) on the Marshfield genetic map. The maximum lod 
score obtained was 13.81 at θ = 0.001 for marker D17S1810. In the 3.5 Mb 
region deduced from linkage analysis, we identified 72 known RefSeq genes 
using the UCSC Genome Bioinformatics database (http://genome.ucsc.edu/; ref. 
23). Alternative methods for rapid and reliable fine mapping of this critical 
region are needed in order to decrease the number of candidate genes. 
 
Fine-mapping of the LRH-1-encoding region by haplotype analysis  
To narrow down the genetic region that includes the LRH-1 locus, we searched 
for individuals of the analyzed reference families with a recombination between 
marker D17S831 and D17S796 on chromosome 17p13.2. LRH-1-positive 
individual 4889 of family 1332 inherited a recombinant maternal haplotype, 
which implicated that the LRH-1 coding gene lies centromeric to marker 
D17S1845 (Table 2). This finding was confirmed by the recombinant paternal 
haplotype inherited by the LRH-1-negative individual 8564 in family 1362. To 
further decrease the region, we screened additional CEPH families for 
individuals with recombinations in the genetic region carrying the LRH-1 locus. 
This search identified recombinant haplotypes in individual 13182 of CEPH 
family 102 (Table 2). The recombinant paternal haplotype inherited by the LRH-
1-positive individual 13182 in family 102 indicated that the gene encoding 
LRH-1 is located telomeric to marker D17S1876. UCSC Genome database 
analysis revealed that the established region between the markers D17S1845 and 
D17S1876 still harbors 33 known RefSeq genes. 
Next, we fine-mapped this 1.64 Mb region using SNP genotyping of the 3 
recombinant LRH-1-positive individuals. Genotype analysis of individual 1332-
4889 for marker Rs1223918 showed that this marker was derived from the 
maternally inherited haplotype carrying the LRH-1-positive phenotype (Table 
2). Marker Rs1223918 was also uninformative in LRH-1-negative individual 
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1362-8564 (Table 2). In parallel, we performed genotype analysis of the SNP 
markers Rs1052617 and Rs2053256 in LRH-1-positive individual 102-13182 in 
order to decrease the region telomeric of marker D17S1876 (Table 2). 
Unfortunately, both SNP markers were derived from the paternally inherited 
haplotype carrying the LRH-1-positive phenotype. In conclusion, in this study 
additional fine-mapping of all available recombinant CEPH individuals did not 
result in a further decrease of the chromosomal region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Schematic overview of the genetic linkage approach. (A) The genetic mapping 
approach is a linear multi-step strategy which consists of 1) collection and phenotype analysis 
of saturation-mapped CEPH reference families, 2) two-point linkage analysis to identify a 
genomic region with no recombination, 3) fine-mapping of the identified chromosomal region 
of interest, and 4) identification methods of the mHAg-encoding gene. (B) LRH-1 
phenotyping analysis was performed using EBV-LCL of informative CEPH families. For 
example, EBV-LCL of all available family members of CEPH family 1413 were transduced 
with HLA-B*0702 and tested for recognition by CTL RP1. IFN-γ production was determined 
by ELISA. (C) LRH-1 segregation pattern for individuals of the CEPH pedigree 1413. Filled 
circles (females) or squares (males) represent individuals scored as positive for the LRH-1 
phenotype and open circles (females) or squares (males) represent individuals scored as 
negative. Shaded symbols represent individuals from whom no LCL was available. 
 
Two-point linkage analysis of genotyped SNP markers  
To localize the LRH-1-encoding gene more precisely between marker 
D17S1845 and D17S1876, we genotyped 9 SNP markers in the CEPH families 
and performed two-point linkage analysis (Figure 6). This analysis revealed a 
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0.26 Mb region, between the flanking SNP marker Rs551581 (at position 
3489342 bp) and CEPH marker D17S1828 (at position 3757108 bp), with a 
cluster of markers with significant lod scores > 7.0 (Figure 6). A search in the 
UCSC Genome database for known RefSeq genes resulted in the identification 
of 9 genes. These remaining candidate genes were subjected to gene expression 
profile analysis using real-time quantitative RT-PCR, which resulted in the 
identification of P2X5 as the LRH-1-encoding gene (16). Retrospective linkage 
analysis of SNP marker RS3215407 (at position 3541030), which is located in 
the P2X5 coding sequence and controlling expression of the LRH-1 antigenic 
epitope, showed a maximal lod score of 14.46 at θ = 0.001 (Figure 6). Taken 
together, these data showed that linkage analysis of additional SNP markers 
within the identified region of no recombination can provide reliable additional 
information about the localization of the mHAg-encoding gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The LRH-1 locus is closely linked to a cluster of markers on chromosome 17p13.2. 
Genetic map of chromosome 17p13.2 showing relative marker loci oriented with the 
centromere at the bottom of the figure. Lod scores summed for CEPH families 1331, 1332, 
1347, 1362 and 1413 used in the linkage analysis are depicted to the right of each genomic 
marker. CEPH families that are not genotyped for a particular marker and therefore not 
included in the linkage analysis are indicated in parentheses. This figure is reproduced from 
reference 16 with minor modifications. 
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Figure 6. Lod score distribution of genetic markers on chromosome 17.p13.2. Genetic 
markers, informative in ≥ 4 CEPH families, are positioned according to the physical 
chromosomal map in the UCSC Genome database (http://genome.ucsc.edu/; May 2004 
assembly) with the centromere at the right of the figure. Single nucleotide deletion 
polymorphism (Rs3215407) in the P2X5 sequence controls expression of the LRH-1 
antigenic epitope. Marker locations are depicted in parenthesis. Lod scores at θ = 0.001, 
summed for CEPH families 1331, 1332, 1347, 1362, 1413 and 102 are depicted for each 
genomic marker. Mean lod score is indicated by the dashed line. Position of the P2X5 gene is 
depicted by the black bar.  
 
Discussion 
 
Alloreactive CTLs isolated from SCT recipients have been used to characterize 
the molecular nature of mHAgs. The classical biochemical approach to identify 
human mHAgs is by mass-spectrometry of eluted peptides from the relevant 
HLA molecules (5-12). Alternatively, molecular approaches like cDNA library 
cloning and genetic linkage analysis have been successfully applied for the 
identification of mHAgs (13-16). However, these techniques have several 
pitfalls that affect the reliability to identify the mHAg-encoding gene. Here, we 
optimized both cDNA expression cloning and genetic linkage analysis in order 
to speed up the discovery of hematopoietic-restricted mHAgs. 
Successful cDNA library screening depends on the ability of mHAg-specific 
CTLs to produce significant amounts of cytokines upon recognition of a cell line 
transfected with pools of the cDNA library. Full CD8+ T cell activation requires 
efficient TCR engagement with peptide-MHC class I complexes presented on 
the cell surface in combination with co-stimulatory signals mediated by 
CD80/CD28 and CD54/LFA-1 interactions (24-26). However, the concentration 
of specific peptide-MHC complexes on the transiently transfected stimulator 
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cells is often low, and CD54 and CD80 molecules are not expressed on suitable 
cell lines such as COS-1 and 293T. Consequently, cDNA library screening may 
be inefficient especially when the CTL produces low amounts of cytokines. 
Here, we show that strong CTL activation is achieved by using a 293T cell line 
with stable expression of MHC class I, CD54 and CD80 molecules. Titration 
experiments revealed that this 293T-HLA/CD54/CD80 cell line may be an 
excellent expression system for cDNA library screening. Therefore, we used this 
cell line in combination with a high quality CMV-based cDNA library to 
identify a novel HLA-B7-restricted mHAg, designated LRH-1. However, 
screening of 1,100 pools containing ~50 cDNA clones with a high sensitive 
CTL (i.e. detection of LRH-1-positive EBV-LCL into K562 at a ratio of 1:100) 
did not result in the isolation of the LRH-1 encoding cDNA. A plausible 
explanation for this mis-identification may be that LRH-1 epitope is encoded by 
a large gene that has a very low abundance or is absent in the established cDNA 
library. Retrospectively, we observed that the LRH-1 epitope is encoded by 
exon 3 of the 12 exons encoding P2X5 gene (16). P2X5 RNA is 2.2 kb long 
which is slightly above the average insert length of 1.8 kb of the cDNA library 
used for expression cloning. Usage of a subtractive cDNA library in which low 
abundant mRNA transcripts are enriched by removal of high abundant 
housekeeping gene transcripts is an option to circumvent a low number of 
antigen-encoding cDNA. 
Another possibility for the molecular identification of human mHAgs 
involves genetic linkage analysis using EBV-LCL from CEPH families. The 
feasibility of this approach was shown by a retrospective study on the HA-8 
antigen (21). Thereafter, this strategy has successfully been executed for the 
identification of 2 BCL2A1-encoded mHAgs ACC-1 and ACC-2, and the 
P2X5-encoded mHAg LRH-1 (15, 16). Initially, genetic linkage analysis using 
CTL reactivity as a phenotypic marker results in mapping of the chromosomal 
location of the mHAg-encoding gene. Further identification largely depends on 
the accuracy and completeness of information in genetic databases regarding the 
number of known genes and their position in the relevant region, tissue 
distribution data and the presence of non-synonymous SNP in de coding 
sequences. Therefore, additional selection criteria are crucial to identify a small 
set of candidate genes, each of which can then be directly evaluated whether it 
encodes the mHAg of interest. 
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Table 2. Haplotypes of the parental probands and their informative offspring who had a 
recombination between the markers D17S831 and D17S796A. 
      
                                              Family 1332                   Family 1362                Family 102            
Genomic       Position     Father    Mother     Child     Father   Mother   Child    Father   Mother   Child 
markerB        (bp)           (8260)    (8262)      (4889)   (8563)   (8574)   (8564)  (13180)  (13181) (13182) 
  
D17S831      1857150      6   2        8   1        6   1        3   1       6   2       3   2       6   2      7   1       6   7 
D17S1528    1971527      5   2        2   8        5   8        3   3       2   2       3   2       1   2      2   3       1   2 
D17S1845    2651618      8   5        9 10        8 10        5   3       4   3       5   3       4   2      6   1       4   6  
 
Rs1223918D 3061382      1   1        2   1        1   2        1   1       0   0       1   2       2   2      2   1       2   2 
D17S126      3008678      1   1        1   1        1   1        2   1       2   1       1   1       1   1      1   2       1   1 
D17S1152    3249172      4   2        4   4        4   4        1   5       5   3       5   3       0   0      0   0       0   0 
D17S829      3492018      2   2        3   3        2   3        5   4       3   6       4   6       3   4      4   4       3   4 
D17S1298    3613278      1   3        1   3        1   1        2   3       2   2       3   2       1   1      3   1       1   3 
D17S1828    3757108      4   3        1   1        4   1        1   1       4   6       1   6       3   4      3   4       3   3 
Rs1052617   3856153      2   1        2   1        2   2        0   0       0   0       0   0       1   2      2   2       1   2 
Rs2053256   4055397      1   2        2   2        1   2        1   1       0   0       1   2       2   1      1   1       2   1 
 
D17S1876    4291770      1   2        5   4        1   5        8   3       8   6       3   6       4   3      3   3       3   3 
D17S1810    4969631      1   2        3   1        1   3        4   1       1   1       1   1       6   2      1   1       2   1 
D17S1832    5913299      4   4        8   1        4   8        3   3       5   3       3   3       6   7      4   4       7   4 
D17S938      6189992      3   5        3   2        3   3        2   7       5   2       7   2       1   2      3   3       2   3 
D17S796      6192246      2   3        1   4        2   1        1   6       3   4       6   4       7   1      5   5       1   5 
                                                                                                                             
CTL recognitionC:              -         +        +        +        -        -        +       +       + 
  
AThis table is reproduced from reference 16 with minor modifications. The genotypes are 
arranged by haplotype, with the paternally and maternally inherited haplotypes on the left and 
right, respectively. The haplotypes carrying the LRH-1-positive phenotype are indicated with 
filled and open boxes. Their LRH-1-negative counterparts are indicated with shaded boxes. 
Appearance of 0 indicates that the genotype was not available in the CEPH database. 
Recombinant haplotypes of individuals 102-13182, 1332-4889 and 1362-8564 are comprised 
of two different boxes. Recombination events in these individuals point out that the region 
within which the LRH-1 locus resides is defined by the flanking markers D17S1845 and 
D17S1876, indicated by line spaces.  
BGenetic markers available in the CEPH database and genotyped SNP markers are positioned 
according to the physical chromosomal map in the UCSC Genome database 
(http://genome.ucsc.edu/; May 2004 assembly).  
CRecognition of EBV-LCL of each individual by CTL RP1. 
DSNP ID is based on TaqMan SNP genotyping kit ID C__1223918_10. 
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We and others have previously shown that the genetic region controlling the 
mHAg expression can be decreased by comparing the recombinant haplotypes 
of the offspring with the CTL-defined mHAg phenotypes (15, 16, 21). Here, we 
have used mHAg LRH-1 to further refine this haplotype analysis for future 
identification of novel hematopoietic-restricted mHAgs. Genetic linkage 
analysis using 5 CEPH families revealed that the LRH-1 encoding gene is 
located within a large region of 3.5 Mb on chromosome 17p13.2. Next, several 
strategies were tested to narrow down the LRH-1 encoding genetic region. First, 
in addition to the 5 CEPH families used for linkage analysis, we screened other 
CEPH families for offspring with recombination in the genetic region carrying 
the LRH-1-encoding gene. This resulted in the identification of an individual in 
CEPH family 102, which showed a recombination in the affected haplotype 
resulting in major decrease of the genetic region of interest from 3.5 to 1.64 Mb. 
Second, we performed genotyping analysis of SNP markers to fine-map the 
established region of interest in recombinant individuals. Unfortunately, in this 
case additional SNP genotyping of the recombinant individuals did not result in 
a further decrease of the region. However, two-point lod score analysis using the 
SNP makers genotyped in all available informative CEPH reference families 
provided reliable information about the precise location of the LRH-1-encoding 
gene. This analysis resulted in a further decrease from 1.64 to 0.26 Mb of the 
relevant genetic region that contains 9 candidate genes. Finally, gene profiling 
analysis of these candidate genes resulted in the identification of P2X5 as the 
LRH-1-encoding gene (16). 
In conclusion, we improved the cDNA library cloning strategy using a 293T 
cell line with stable expression of MHC class I, CD54 and CD80 molecules as a 
mammalian expression system. Furthermore, we introduced SNP marker 
genotyping to narrow down the genetic region established after genetic linkage 
analysis in order to identify the location of the mHAg-encoding gene of interest. 
Application of these optimized methods will facilitate more rapid and reliable 
molecular identification of novel hematopoietic-restricted mHAgs. 
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Summary 
 
Minor histocompatibility antigens (mHAgs) constitute the targets of the graft-
versus-leukemia response after HLA-identical allogeneic stem cell 
transplantation. Here, we have used genetic linkage analysis to identify a novel 
mHAg, designated lymphoid-restricted histocompatibility antigen–1 (LRH-1), 
which is encoded by the P2X5 gene and elicited an allogeneic CTL response in a 
patient with chronic myeloid leukemia after donor lymphocyte infusion. We 
demonstrate that immunogenicity for LRH-1 is due to differential protein 
expression in recipient and donor cells as a consequence of a homozygous 
frameshift polymorphism in the donor. Tetramer analysis showed that 
emergence of LRH-1–specific CD8+ cytotoxic T cells in peripheral blood and 
bone marrow correlated with complete remission of chronic myeloid leukemia. 
Furthermore, the restricted expression of LRH-1 in hematopoietic cells 
including leukemic CD34+ progenitor cells provides evidence of a role for  
LRH-1–specific CD8+ cytotoxic T cells in selective graft-versus-leukemia 
reactivity in the absence of severe graft-versus-host disease. These findings 
illustrate that the P2X5-encoded mHAg LRH-1 could be an attractive target for 
specific immunotherapy to treat hematological malignancies recurring after 
allogeneic stem cell transplantation. 
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Introduction 
 
HLA-identical allogeneic hematopoietic stem cell transplantation (SCT) is a 
curative therapy for various forms of haematological malignancies (1). It has 
become the treatment of choice for patients with chronic myeloid leukemia 
(CML) and is currently the most effective consolidation treatment for patients 
with acute leukemia (2, 3). The therapeutic efficacy is attributed to the graft-
versus-leukemia (GVL) reaction, an immune response in which donor-derived 
CTLs eliminate malignant cells of the recipient (4, 5). Minor histocompatibility 
antigens (mHAgs) are the target antigens of the GVL response, and expansion of 
mHAg-specific CTLs has been shown to precede clinical remission in relapsed 
CML patients treated with donor lymphocyte infusions (DLIs) (6, 7). However, 
alloreactive CTL responses induced upon DLI generally lack tumor specificity 
and are often accompanied by graft-versus-host disease (GVHD). Selective 
GVL responses in the absence of GVHD may result from mHAgs with 
expression limited to hematopoietic cells such as HA-1 (8), HA-2 (9, 10), and 
BCL2A1 (11) or to lineage-specific hematopoietic cells such as HB-1 (12, 13). 
These hematopoietic cell–restricted antigens represent potential targets for 
specific immunotherapy after allogeneic SCT (14–16).  
mHAgs are HLA-bound peptides derived from cellular proteins that differ in 
amino acid sequence between donor and recipient due to genetic polymorphisms 
(4, 17–19). Thus far, approximately 15 human mHAgs have been identified 
through mass spectrometry of HLA-eluted peptides (8, 9, 20–24), cDNA library 
cloning (13, 25), or genetic linkage analysis (11). Immunogenicity of most of 
the molecularly characterized human mHAgs results from single nucleotide 
polymorphisms (SNPs) in homologous donor and recipient genes causing amino 
acid substitutions within the epitope (8–11, 13, 20–24). In one instance, an 
mHAg encoded by the UGT2B17 gene resulted from differential protein 
expression in donor and recipient cells as a consequence of a homozygous gene 
deletion in the donor (25). 
Here, we report the identification of a novel hematopoietic cell–restricted 
mHAg, designated lymphoid-restricted histocompatibility antigen–1 (LRH-1), 
which elicited an HLA-B7–restricted CTL response in a CML patient treated 
with DLI. Using genetic linkage analysis and gene profiling, we have identified 
P2X5 as the polymorphic gene encoding the LRH-1 antigenic peptide. Our data 
provide what we believe to be the first evidence that mHAg disparity can result 
from differential protein expression due to a homozygous frameshift 
polymorphism. Furthermore, we have analyzed the kinetics of the LRH-1–
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specific CTL response in the CML patient and show that emergence of        
LRH-1/B7 tetramer+ T cells is associated with GVL reactivity following DLI. 
Finally, our observation that LRH-1 is selectively expressed within the 
hematopoietic system including leukemic CD34+ progenitor cells offers a novel 
target antigen for the development of immunotherapy for the treatment of 
relapsed leukemia. 
 
Materials and methods 
 
Cell isolation and culture 
CD8+ CTL clone RP1 was isolated from PBMCs obtained 3 months after DLI-2 
by weekly stimulation with CML cells obtained at hematological relapse in 
Iscove’s modified Dulbecco’s medium (IMDM) (Invitrogen Corp.) 
supplemented with 10% human serum (HS) (PAA Laboratories). Relapse CML 
cells that were used as stimulator cells contained 5% CD34+ blasts, 3% CD19+  
B cells, 29% CD3+ T cells, and 60% CD13+CD33+ myeloid cells. Myeloid cells 
were completely of recipient origin, and lymphocytes were mixed chimeric. 
After initial stimulation, CTL RP1 (0.5×106) was cultured in IMDM/10% HS 
containing irradiated (80 Gy) recipient EBV-LCLs (0.5×106), irradiated (60 Gy) 
allogeneic PBMCs (0.5×106) from 2 donors, 100 IU/ml IL-2 (Eurocetus), and 1 
μg/ml PHA-M (Boerhinger) in a total volume of 2 ml. The HLA-B7–
alloreactive CTL KOR18 was kindly provided by E. Goulmy (Leiden University 
Medical Center). CTL KOR18 (2×106) was cultured in IMDM/10% HS 
containing irradiated HLA-B7–positive EBV-LCLs (5×106), irradiated 
allogeneic PBMCs (5×106) from 2 donors, 100 IU/ml IL-2, and 1 μg/ml PHA-M 
in a total volume of 15 ml. CTL cultures were used in cytotoxicity and 
stimulation assays either 7 days after stimulation or 1 day after thawing a frozen 
aliquot. All cell lines and primary cells were cultured in IMDM/10% FCS. EBV-
LCLs from the CEPH families were provided by P. Martin (Fred Hutchinson 
Cancer Research Center, Seattle, Washington, USA) or purchased from the 
Coriell Institute for Medical Research. B cells, T cells, and monocytes were 
isolated from PBMCs using anti-CD19, anti-CD3, and anti-CD14 
immunomagnetic beads (Miltenyi Biotec), respectively. B cell blasts were 
generated by culturing CD19+ B cells in IMDM/10% HS with 1 μg/ml CD40L 
(gift from Immunex Corp.) and 100 U/ml IL-4 (Schering-Plough) for 5 days. T 
cell blasts were generated by stimulating CD3+ T cells in IMDM/10% HS with 
20 μg/ml PHA-M for 3 days. Thereafter, PHA-activated T cells were washed 
and further cultured with 100 IU/ml IL-2 for 2 additional days. Immature DCs 
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were generated by culturing CD14+ monocytes in IMDM/5% HS with 800 U/ml 
GM-CSF (Schering-Plough) and 500 U/ml IL-4 for 6 days. Immature DCs were 
maturated by culturing for 3 additional days in IMDM/5% HS with 800 U/ml 
GM-CSF, 500 U/ml IL-4, 20 ng/ml TNF-α (Endogen), and 10 μg/ml Prostin E2 
(Pfizer). Fibroblasts were isolated from BM aspirates of healthy stem cell 
donors. BM was resuspended in 20 ml IMDM/20% FCS and incubated 
overnight in 75-cm2 tissue culture flasks. The nonadherent fraction was 
removed, and fibroblasts were further cultured in IMDM/20% FCS to passage 3 
before analysis. 
 
Chromium release assay 
Chromium release assays were performed to assess cytolytic activity of CTLs as 
described previously (12). Fibroblasts were pretreated with 10 ng/ml TNF-α and 
100 U/ml IFN-γ (Boehringer) for 2 days before 51Cr labelling. The following 
Abs were used for inhibition of CTL reactivity: SPV-T3b (anti-CD3), W6/32 
(anti–HLA class I), B1.23.2 (anti–HLA-B/C), and SPVL-3 (anti–HLA-DQ). 
 
Retroviral transduction of HLA-B*0702 in cell lines and CTL stimulation 
assay 
HLA-B*0702 cDNA (provided by E. Goulmy) was subcloned in the LZRS-
IRES-EGFP vector. The resulting LZRS-HLA-B*0702-IRES-EGFP vector was 
used to generate a stable producer cell line. Retroviral transduction was 
performed using non–tissue culture–treated 35-mm2 dishes (BD) coated with 10 
μg/ml RetroNectin (Takara Bio Inc.). Target cells (106) were resuspended in 2 
ml virus supernatant and transferred to RetroNectin-coated dishes. After 24 
hours of incubation, cells were collected and incubated with fresh virus 
supernatant. Finally, transduced cells were cultured for 5 additional days before 
use in CTL stimulation assays as described previously (13). Release of IFN-γ 
was determined by ELISA (Endogen; Pierce Biotechnology Inc.). 
 
Genetic linkage analysis 
Mapping of the LRH-1 locus was accomplished in a subset of CEPH reference 
families. Genotypes were retrieved from the CEPH database, version 9.0 
(http://www.cephb.fr/cephdb/; refs. 26, 27). Two-point linkage was performed 
using the MLINK subroutine of the FASTLINK (version 4.0) program 
(http://www.cs.rice.edu/~schaffer/fastlink.html) as reported previously (11, 27, 
28). An autosomal dominant, single gene model was assumed for the LRH-1 
trait. The population frequency of the encoding allele was estimated at 0.5 and 
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the penetrance of the LRH-1 phenotype was set at 0.9. Population allele 
frequencies for the genetic markers were used when present in the CEPH 
database; otherwise equal allele frequencies were assumed. Resulting lod scores 
were examined for regions of highly significant linkage, and the identification of 
the LRH-1 locus was interpreted from the Marshfield genetic map (29). 
 
Real-time PCR analysis of candidate genes 
Total RNA was isolated by the TRIzol method (Invitrogen Corp.) and treated 
with DNase. First-strand cDNA was prepared using oligo-dT primer and 
Powerscript RT (BD Biosciences—Clontech). Gene-specific primer sets were 
designed at the 3’ end of each candidate gene. One microliter of cDNA was 
amplified in a 50-μl reaction mixture containing 1.25 U AmpliTaq Gold 
(Applied Biosystems), 300 nM of each primer, 250 μM of each dNTP, 5 mM 
MgCl2, and 1×SYBR green PCR buffer (Applied Biosystems). The 
porphobilinogen deaminase (Pbgd) gene was used to normalize expression of 
each candidate gene. The following primers and TaqMan probe were used for 
Pbgd real-time PCR: Pbgd-F 5’-GGCAATGCGGCTGCAA-3’, Pbgd-R 5’-
GGGTACCCACGCGAATCAC-3’,and Pbgd-probe 5’-(VIC)-CTCATCTTTG-
GGCTGTTTTCTTCCGCC-(TAMRA)-3’. Pbgd-PCR was performed as 
described above using 300 nM TaqMan probe. PCR amplification was 
performed using an ABI Prism 7700 (Applied Biosystems) with the following 
PCR conditions: enzyme activation for 10 minutes at 95°C, followed by 45 
cycles of 95°C for 15 seconds and 60°C for 1 minute. The cycle threshold (Ct) 
was determined by software analysis (Sequence Detection System, version 
1.9.1; Applied Biosystems). The expression of candidate genes was calculated 
using EBV-LCLs of the recipient as calibrator with the following formula: [2–
(ΔΔCt)] × 100 (30). 
 
Construction of full-length and truncated P2X5 plasmids  
Constructs containing the full-length or a truncated form of the P2X5 transcript 
variants were generated by PCR. cDNA was prepared from a homozygous  
LRH-1–positive and LRH-1–negative EBV-LCLs and amplified using specific 
primers. The following primers were used: P2X5-FLF 5’-CATGGGGCA-
GGCGGG-3’ and P2X5-FLR 5’-AACGTAAGCAGAGGCAATTCACGT-3’. A 
truncated form containing exons 1–5 of P2X5 transcript variant 1 was generated 
with the P2X5-FLF forward primer and reverse primer P2X5-TRR 5’-
GGGGAAACGGATGTGGTTCT-3’. PCR products were purified using the 
QIAGEN gel extraction kit and cloned into vector pCR3 (Invitrogen Corp.) 
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using the unidirectional TA cloning kit (Invitrogen Corp.). Plasmids (400 ng) 
were used for transfection into 3.5×104 293T-HLA-B*0702 cells plated in poly-
d-lysine–coated 96-well flat-bottom wells (BD) using Lipofectamine (Invitrogen 
Corp.). Transfected cells were cultured for 2 additional days and used in CTL 
stimulation assays. 
 
Epitope prediction and reconstitution assay 
HLA-B7–binding peptides were predicted using BIMAS software 
(http://bimas.dcrt.nih.gov/molbio/hla_bind/; ref. 31). Peptides were synthesized 
by solid-phase strategies on an automated multiple peptide synthesizer (AMS 
422; ABIMED). Peptides were purified by reverse-phase HPLC and lyophilized. 
Finally, peptides were dissolved in DMSO, diluted in IMDM to a concentration 
of 1 mM, and stored at –20°C before use. In peptide recognition assays, target 
cells were preincubated with various concentrations of peptide for 30 minutes in 
a volume of 100 μl prior to the addition of CTLs. 
 
Tetramer staining  
PE-labeled LRH-1/HLA-B7 tetramers using peptide TPNQRQNVC were 
produced as described previously (32). LRH-1 tetramers were validated by 
staining against CTL RP1. For staining, PBMC or CTL cell lines were incubated 
with 20 μg/ml LRH-1 tetramer for 30 minutes at room temperature. After 
washing with PBS/0.5% BSA, cells were labeled with the appropriate 
concentration anti-CD8 (LT8-FITC; ProImmune), anti-CD3 (UCHT1-Cy7; 
Beckman Coulter), anti-CD45 (J33-ECD; Beckman Coulter), and 1 μg/ml 7-
amino-actinomycin D (7AAD) at room temperature for 15 minutes. After 
washing, cells were resuspended in PBS/0.5% BSA and analyzed using the 
Coulter FC500 flow cytometer (Beckman Coulter). 
 
Bcr-Abl PCR analysis  
Bcr-Abl PCR analysis was performed on an ABI Prism 7700 system (Applied 
Biosystems) as described previously (33). In brief, total RNA from cells was 
extracted using TRIzol (Invitrogen Corp.). Reverse transcription was performed 
on 1 μg of total RNA using random hexamers and Mo-MuLV RT (Invitrogen 
Corp). Expression of the Pbgd gene was used to normalize Bcr-Abl expression. 
This normalized Bcr-Abl expression in patient samples was related to a standard 
curve obtained from K562 cells diluted into normal BM cells. 
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Real-time quantitative PCR analysis of P2X5 gene  
PBMCs were isolated from normal donors using Ficoll-Paque (Amersham 
Biosciences) and used for isolation of different cell subsets. PBMCs were 
labelled with the appropriate concentration of FITC-, PE-, and/or Cy5-
conjugated Abs. Labeled cells were sorted into CD19+ B cells, CD3+ T cells, 
CD3-CD16/56+ NK cells, and CD14+ monocytes using the Coulter EPICS Elite 
flow cytometer (Beckman Coulter). Normal and leukemic CD34+CD38- and 
CD34+CD38+ cells were sorted from cell suspensions after labeling with CD34-
FITC and CD38-PE Abs (BD). Immature DCs, mature DCs, and fibroblasts 
were cultured as described above. Keratinocytes were provided by S. Ebeling 
(University Medical Center Utrecht, Utrecht, The Netherlands). PTECs, 
HUVECs, and melanocytes were provided by E. Spierings (Leiden University 
Medical Center). Total RNA from each of these cell types was isolated using the 
Zymo RNA isolation kit II (Zymo Research Corp.). RNA of normal tissues was 
obtained from the RNA Master Panel II (BD Biosciences — Clontech). First-
strand cDNA was prepared from total RNA using oligo-dT, random hexamers, 
and Mo-MuLV RT (Invitrogen Corp.). In parallel to P2X5 expression, we used 
CD45 expression to detect the presence of hematopoietic cells in normal tissues. 
The Pbgd housekeeping gene was used to normalize P2X5 and CD45 
expression. One microliter of cDNA was amplified in a 50-μl reaction mixture 
containing 1.25 U AmpliTaq Gold (Applied Biosystems), 300 nM gene-specific 
forward and reverse primer, 150–300 mM gene-specific TaqMan probe (150 nM 
for P2X5, 200 nM for CD45, and 300 nM for Pbgd), 250 μM of each dNTP, 5 
mM MgCl2, and 1×TaqMan PCR buffer (Applied Biosystems). The following 
gene-specific primers and TaqMan probes were used: P2X5: P2X5-F 5’-
TCCTGGCGTACCTGGTCGT-3’, P2X5-R 5’CTTCATTCTCAGCACAGAC-
GTTC-3’, and P2X5-probe 5’-(TET)-TGGGTGTTCCTGATAAAGAAGGG- 
TTACCA-(TAMRA)-3’; and CD45: CD45-F 5’-TTAGAAATGAGTCGCAT- 
AAGAATTGC-3’, CD45-R 5’-CTCCAGGATAGTCTCCATTGTGAAA-3’, 
and CD45-probe 5’-(TET)-ATTTCCGTGTAAAAGATC-(TAMRA)-3’. PCR 
conditions were as follows: enzyme activation for 10 minutes at 95°C, followed 
by 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. P2X5 and CD45 
mRNA expression was quantified by determining calibration functions using 
JVM-2 as reference cell line. The level of P2X5 and CD45 expression of test 
samples was calculated relative to the P2X5 and CD45 expression in the JVM-2 
cell line. P2X5 mRNA expression levels of different cell types were compared 
using ANOVA and Duncan post-hoc comparison. P < 0.05 was considered 
significant. 
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Results 
 
Case description  
In 1996, we transplanted a marrow graft into a 35-year-old woman (UPN389) 
with Philadelphia chromosome–positive (Ph+) CML from her HLA-identical 
brother (A24, A29, B7, B44, Cw7, Cw16) after receiving informed consent. 
Partial T cell depletion was performed using counterflow centrifugation, and 
0.8×106 CD3+ cells/kg body weight were given within the graft (34). The patient 
suffered from acute GVHD grade III (skin and liver), which was successfully 
treated with the addition of corticosteroids. At 6 months after SCT, FISH 
analysis of a BM aspirate showed 7.5% Ph+ cells. Cyclosporin A (CsA) and 
corticosteroids were gradually withdrawn within 2 months without reactivation 
of GVHD. However, 1 month after cessation of immunosuppressive treatment, 
Ph+ cells increased to 85% in the BM. Furthermore, these cells had additional 
chromosomal abnormalities with del(13) and t(4;11), and the patient had 
progressed to accelerated phase. The patient was given lymphocytes from the 
original BM donor (DLI-1; 0.1×108 CD3+ cells/kg body weight) but did not 
respond. After a second and higher dose of DLI (DLI-2; 0.7×108 CD3+ cells/kg 
body weight), the patient developed GVHD of the skin and pancytopenia. For 
GVHD of the skin, she was treated with CsA and mycophenolate mofetil for 
different intervals. Six months after DLI-2, BM cells were of donor origin. Since 
the patient had become and remained pancytopenic, she was given a T cell–
depleted marrow booster from her donor. Nine months after DLI-2 and 2 months 
after the stem cell booster, the patient was in complete cytogenetic and 
molecular remission. 
 
CTL RP1 recognizes an HLA-B7–restricted mHAg expressed on 
hematopoietic cells  
To isolate mHAg-specific CD8+ T cells involved in the GVL response in CML 
patient UPN389, we stimulated PBMCs obtained 3 months after DLI-2 with 
CML cells obtained at haematological relapse. After multiple stimulations, TCR 
repertoire analysis revealed that more than 90% of CD8+ T cells expressed a 
clonal TCR-BV21.3 chain (data not shown). This CD8+ CTL clone, termed RP1, 
mediated specific lysis against the EBV–lymphoblastoid cell line (EBV-LCL) of 
the recipient, but not against donor EBV-LCL and NK-sensitive K562 cells 
(Figure 1A). Specific lysis of recipient EBV-LCL was substantially inhibited by 
anti–HLA class I and anti–HLA-B/C Abs, but not by Ab against anti–HLA class 
II, indicating recognition of an HLA class I–restricted mHAg (data not shown). 
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Testing of EBV-LCLs from unrelated individuals sharing expression of HLA-
B7 with the recipient and EBV-LCL from an HLA class I–mismatched 
individual that were transduced with HLA-B*0702 revealed that CTL RP1 
recognizes an mHAg presented by HLA-B7 (Figure 1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Specific reactivity of HLA-B*0702–restricted CTL RP1 against hematopoietic 
cells. (A) Specific cytotoxicity was tested in 51Cr release assays against EBV-LCLs of the 
recipient (Rt) and donor (Do). NK-sensitive K562 cells were used to determine nonspecific 
lysis. Effector to target (E/T) ratios are indicated. (B) Production of IFN-γ by CTL RP1 
stimulated with recipient EBV-LCLs, EBV-LCLs of 2 unrelated individuals (nos. 1 and 2) 
sharing HLA-B7 with the recipient, and an EBV-LCL of an HLA class I–mismatched 
individual (no. 3) that was transduced with HLA-B*0702. Data are displayed as mean IFN-γ 
release ± SD of triplicate wells. (C) Specific cytotoxicity against hematopoietic cells of 
lymphoid origin (EBV-LCLs, PHA-stimulated T cells, and CD40L-stimulated B cells) and 
BM-derived fibroblasts incubated with 10 ng/ml TNF-α and 100 U/ml IFN-γ for 2 days 
before 51Cr labeling. The E/T ratio was 1:1. (D) IFN-γ production by CTL RP1 upon 
stimulation with hematopoietic cells of myeloid origin (monocytes, immature DCs [iDC] and 
mature DCs [mDC]). 
 
Next we investigated whether the mHAg recognized by CTL RP1 was 
selectively expressed by hematopoietic cells. CTL RP1 significantly lysed cells 
of lymphoid origin such as EBV-LCLs, CD40-activated B cells, and 
phytohemagglutinin-stimulated (PHA-stimulated) T cells, whereas monocytes 
and monocyte-derived DCs were not recognized (Figure 1, C and D). 
Furthermore, no cytotoxicity of CTL RP1 was observed against TNF-α– and 
IFN-γ–pretreated BM-derived fibroblasts (Figure 1C). By contrast, all target cell 
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types were significantly recognized by the allo–HLA-B7–specific CTL KOR18, 
indicating their susceptibility to CTL-mediated recognition (data not shown). 
Together these data indicate that CTL RP1 recognizes an HLA-B7–restricted 
mHAg that is expressed by hematopoietic cells of the lymphoid lineage. Based 
on this CTL recognition pattern, we provisionally designated this novel mHAg 
as LRH-1. 
 
The gene encoding LRH-1 is mapped to a 1.64-Mb region on chromosome 
17p13.2  
We performed genetic linkage analysis to map the chromosomal region 
containing the LRH-1–encoding gene. EBV-LCLs from parental individuals of 
13 Centre d’Etude du Polymorphism Humain (CEPH) families (provided by P. 
Martin, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA) 
were transduced with HLA-B*0702 and tested for CTL RP1 recognition. Six 
CEPH families (i.e., 1331, 1332, 1347, 1362, 1413, and 102), of which either 
one or both parents were positive, were selected for further study. CTL RP1 
recognition of HLA-B*0702–transduced EBV-LCLs from all individuals of 
these families yielded informative LRH-1 segregation patterns for genome-wide 
linkage analysis (Figure 2A). All HLA-B*0702–transduced EBV-LCLs were 
significantly recognized by the allo–HLA-B7–specific CTL KOR18, indicating 
that the HLA-restriction molecule was properly expressed (data not shown). A 
cluster of markers on chromosome 17p13.2 was significantly linked (i.e., log 
odds ratio [lod] scores > 3.0) to the locus encoding LRH-1 (Figure 2B). The 
maximum lod score obtained was 13.77 at θ = 0.001 for marker D17S1810. A 
7.5-cM critical region of no recombination was defined between the flanking 
markers D17S1845 (7.19 cM) and D17S938 (14.69 cM) on the Marshfield 
genetic map. This region corresponds to a distance of 3.5 Mb according to the 
UCSC Genome Bioinformatics database (http://genome.ucsc.edu/; ref. 35). 
To narrow down the genetic region that includes the LRH-1 locus, we 
performed haplotype analysis using markers between D17S831 and D17S796. 
This analysis identified informative recombinant haplotypes in individual 13182 
of family 102, individual 4889 of family 1332, and individual 8564 of family 
1362 (Table 1). The recombinant paternal haplotype inherited by individual 
13182 in family 102 indicated that the gene encoding LRH-1 is located 
telomeric to marker D17S1876. In an analogous fashion, the recombinant 
maternal haplotype inherited by individual 4889 in family 1332 and the 
recombinant paternal haplotype inherited by individual 8564 in family 1362 
implied that the LRH-1–coding gene lies centromeric to marker D17S1845. 
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Taken together, these data indicated that the gene encoding LRH-1 is located 
between marker D17S1845 and D17S1876, a region of 1.64 Mb on chromosome 
17p13.2. 
 
Table 1. Haplotypes of the parental probands and their informative offspring who had a 
recombination between the markers D17S831 and D17S796A. 
     
                                              Family 102                     Family 1332                Family 1362                          
Genomic       Position     Father    Mother     Child     Father   Mother   Child    Father   Mother   Child 
markerA        (bp)          (13180)   (13181)   (13182)   (8260)   (8262)   (4889)   (8563)   (8574)   (8564) 
  
D17S831      2116991      6   2        7   1        6   7        6   2       8   1       6   1       3   1      6   2       3   2 
D17S1528    2231368      1   2        2   3        1   2        5   2       2   8       5   8       3   3      2   2       3   2 
D17S1845    2911459      4   2        6   1        4   6        8   5       9 10       8 10       5   3      4   3       5   3 
 
D17S126      3268519      1   1        1   2        1   1        1   1       1   1       1   1       2   1      2   1       1   1 
D17S1152    3509013      0   0        0   0        0   0        4   2       4   4       4   4       1   5      5   3       5   3 
D17S829      3751859      3   4        4   4        3   4        2   2       3   3       2   3       5   4      3   6       4   6 
D17S1298    3873140      1   1        3   1        1   3        1   3       1   3       1   1       2   3      2   2       3   2 
D17S1828    4016949      3   4        3   4        3   3        4   3       1   1       4   1       1   1      4   6       1   6 
 
D17S1876    4551611      4   3        3   3        3   3        1   2       5   4       1   5       8   3      8   6       3   6 
D17S1810    5229472      6   2        1   1        2   1        1   2       3   1       1   3       4   1      1   1       1   1 
D17S1832    6173140      6   7        4   4        7   4        4   4       8   1       4   8       3   3      5   3       3   3 
D17S938      6449833      1   2        3   3        2   3        3   5       3   2       3   3       2   7      5   2       7   2 
D17S796      6452087      7   1        5   5        1   5        2   3       1   4       2   1       1   6      3   4       6   4 
  
CTL recognitionC:             +        +        +         -        +       +        +       -        - 
  
AThe genotypes are arranged by haplotype with the paternally and maternally inherited 
haplotypes on the left and right, respectively. The haplotypes carrying the LRH-1-positive 
phenotype are indicated with filled and open boxes. Their LRH-1-negative counterparts are 
indicated with shaded boxes. Appearance of 0 indicates that the genotype was not available in 
the CEPH database. Recombinant haplotypes of individuals 102-13182, 1332-4889 and 1362-
8564 are comprised of two different boxes. Recombination events in these individuals point 
out that the region within which the LRH-1 locus resides is defined by the flanking markers 
D17S1845 and D17S1876, indicated by line spaces.  
BGenetic markers available in the CEPH database are positioned according to the physical 
chromosomal map in the UCSC genome database (http://genome.ucsc.edu/; July 2003 freeze).  
CRecognition of EBV-LCL of each individual by CTL RP1. 
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Figure 2. The LRH-1 locus is closely linked to a cluster of markers on chromosome 17p13.2. 
(A) LRH-1 segregation pattern for individuals of the CEPH pedigrees 1331, 1332, 1347, 
1413, 1362, and 102. EBV-LCLs of all available family members were transduced with HLA-
B*0702 and tested for recognition by CTL RP1. Filled circles (females) or squares (males) 
represent individuals scored as positive for the LRH-1 phenotype, and open circles (females) 
or squares (males) represent individuals scored as negative. Shaded symbols represent 
individuals from whom no EBV-LCLs were available. (B) Genetic map of chromosome 
17p13.2 showing relative marker loci oriented with the centromere at the bottom of the figure. 
Lod scores summed for all available families used in the linkage analysis are shown to the 
right of each genomic marker. CEPH families that are not genotyped for a particular marker 
and therefore not included in the linkage analysis are indicated in parentheses. 
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Identification of P2X5 as the gene encoding LRH-1  
In the region deduced from linkage analysis, we identified 30 known genes 
using the NCBI (http://www.ncbi.nlm.nih.gov/) and UCSC Genome 
Bioinformatics databases. Eleven of these genes represented members of the 
olfactory receptor gene family and were excluded from further analysis. For the 
remaining 19 candidate genes, we developed real-time quantitative PCR and 
determined the expression level of each candidate gene in LRH-1–positive 
(EBV-LCL and Raji) and LRH-1–negative cell types (monocytes and 
fibroblasts). Expression profiles of CTNS, P2X5, and ATP2A3 were most 
closely associated with the pattern of recognition by CTL RP1 (Table 2). 
However, the expression level of CTNS and ATP2A3 was only 2- to 3-fold 
lower in monocytes compared with EBV-LCL, whereas P2X5 mRNA was 
expressed at a 20-fold-lower level. Furthermore, P2X5 mRNA was not detected 
in fibroblasts. These data suggested that the P2X5 gene was the most likely 
candidate gene to encode LRH-1.  
To confirm these results, we constructed expression plasmids encoding the 
P2X5 isoforms 1 and 2 using cDNA isolated from the homozygous LRH-1–
positive CEPH individual 1331-8234. P2X5 isoform 2 lacks exon 3 (i.e., 24 aas) 
and 1 codon in exon 7. CTL RP1 efficiently recognized 293T-HLA-B*0702 
cells transfected with P2X5 isoform 1, whereas isoform 2 was not recognized 
(Figure 3A). Both P2X5 isoforms cloned from the homozygous LRH-1–negative 
donor EBV-LCLs did not stimulate IFN-γ release by CTL RP1 (Figure 3A). 
Furthermore, 293T-HLA-B*0702 cells transfected with a deletion construct 
encoding exons 1–5 of P2X5 isoform 1 from CEPH individual 1331-8234 were 
efficiently recognized by CTL RP1 (Figure 3A). Collectively, these data 
demonstrate that the LRH-1 antigenic epitope is derived from the 24-aa 
sequence encoded by exon 3 of P2X5 isoform 1. 
 
A single nucleotide deletion polymorphism in the P2X5 gene determines 
CTL recognition 
We searched the human genome database for previously identified 
polymorphisms in exon 3 of P2X5 and found a cytosine deletion polymorphism 
in the region encoding aas 110 and 111 of P2X5 isoform 1 (Figure 3B). To 
determine whether this polymorphism could be involved in recognition by CTL 
RP1, we sequenced and compared the P2X5 exon 3 sequence (72 bp in length) 
from the homozygous LRH-1–negative donor EBV-LCL and the homozygous 
LRH-1–positive EBV-LCL of CEPH individual 1331–8234. Interestingly, 1 
cytosine nucleotide in the donor P2X5 exon 3 sequence was indeed deleted 
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between bp 329 and 333 of the open reading frame, resulting in a frameshift at 
aa position 112 and a putative truncated P2X5 protein of 146 aas (Figure 3B). 
These results demonstrate that a single nucleotide deletion polymorphism in the 
P2X5 sequence controls expression of the LRH-1 antigenic epitope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Identification of P2X5 as the gene encoding the HLA-B*0702–restricted epitope 
LRH-1. (A) IFN-γ production by CTL RP1 upon stimulation with EBV-LCL from the 
homozygous LRH-1–positive individual 1331-8234 and 293T-HLA-B*0702 cells transfected 
with full-length constructs of P2X5 transcript variants 1 and 2, and deletion constructs of 
P2X5 transcript variant 1 encoding the first 5 exons (Var 1 Δ5) either generated from EBV-
LCL of the homozygous LRH-1–positive individual 1331–8234 or the homozygous LRH-1–
negative stem cell donor. (B) Schematic representation of the P2X5 gene on chromosome 
17p13.2. The nucleotide and deduced aa sequences of exons 3 and 4 of both the LRH-1–
positive and –negative allele present in recipient and donor, respectively, are shown. Disparity 
between the recipient and donor P2X5 protein sequence is due to a frameshift induced by a 
cytosine deletion polymorphism in the nucleotide sequence of exon 3 (5C versus 4C). This 
results in a disparate aa sequence of 9 residues in the recipient direction (shaded box) and 35 
residues in the donor direction (open box). The aa sequence of the antigenic epitope that is 
recognized by the HLA-B*0702–restricted CTL RP1 is underlined. (C) LRH-1 epitope 
reconstitution with synthetic peptides corresponding to the P2X5 exon 3 sequence of the 
recipient. Donor EBV-LCL was pulsed with various peptide concentrations and tested for 
recognition by CTL RP1. IFN-γ production was determined by ELISA. 
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Table 2. Expression profile of candidate genes located between marker D17S1845 and 
D17S1876 on chromosome 17p13.2. 
  
  Normalized relative gene expressionC  
  GenesA Transcript variantB  Raji Monocytes Fibroblast  
        
NYD-SP20 1 1.58 40.64 11.43 
ASPA 1 4.21 26.63 12.95 
TRPV3 1 8.14 4.79 7.54 
TRPV1 1-4 2.51 2.16 1.11 
CARKL 1 0.50 1.74 0.20 
CTNS 1 0.72 0.37 0.21 
TIP-1 1 1.54 3.43 6.66 
MGC2963 1 2.68 3.46 0.70 
P2X5 1-2 2.75 0.05 <0.01 
ITGAE 1 29.45 13.27 2.02 
GSG2 1 4.10 19.09 4.13 
HSA277841 1 3.17 9.55 6.73 
CAMKK1 1-2 0.67 4.58 0.49 
 3 9.48 38.05 3.51 
P2X1 1 0.07 8.66 0.23 
ATP2A3 1-7 0.73 0.47 0.05 
ZZEF1 1 7.84 85.63 2.50 
MGC32124 1 0.91 0.79 0.82 
ANKFY1 1 0.94 1.17 0.38 
 2 4.79 1.91 0.90 
UBE2G1 1-2 3.12 8.66 3.62 
  
CTL recognitionD + - - 
  
AGenes retrieved from the NCBI database (http://ncbi.nlm.nih.gov/; Build 34) and the UCSC 
database (http://genome.ucsc.edu/; July 2003 freeze). Olfactory receptor genes are not listed. 
BRNA transcript variants detected with one set of PCR primers. 
CGene expression profile determined by real-time quantitative PCR using the SYBR green 
method. The housekeeping gene Pbgd was used for normalization. The relative expression in 
each cell type was calculated relative to the expression level measured in recipient EBV-LCL 
using the ∆∆Ct method (30). 
DRecognition of cell type by CTL RP1. 
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Identification of the HLA-B7–restricted LRH-1 antigenic epitope  
As a result of the deletion polymorphism in exon 3, the P2X5 isoform 1 of the 
recipient contains a disparate NQRQNVCAE sequence compared with that of 
the donor (Figure 3B). To identify the antigenic epitope, we analyzed this 
disparate sequence flanked at both sides by 9 naturally occurring aas for HLA-
B7–binding peptides using BIMAS prediction software. This resulted in the 
identification of the nonamer peptide TPNQRQNVC and the decamer peptide 
TPNQRQNVCA, which both have a predicted BIMAS binding score of 2.0. We 
synthesized these peptides and tested their ability to stimulate IFN-γ release by 
CTL RP1 upon loading on donor EBV-LCL at various concentrations. Both 
peptides were efficiently recognized by CTL RP1 (Figure 3C). However, half-
maximal IFN-γ release for the 9-mer peptide was obtained at pulsing EBV-LCL 
with approximately 150 nM, whereas the 10-mer peptide showed half-maximal 
IFN-γ release at a concentration of approximately 350 nM, suggesting higher 
avidity of CTL RP1 for the 9-mer epitope. Furthermore, HLA-B7 tetramers 
constructed with the 9-mer peptide efficiently stained CTL RP1, whereas HLA-
B7 tetramers constructed with the 10-mer peptide were negative (data not 
shown). To further define the minimal epitope, we tested truncated versions of 
the 9-mer peptide. A peptide with a deletion of the Thr aa residue at the NH2 
terminus failed to sensitize donor EBV-LCLs even at very high peptide 
concentrations, indicating that the Thr is the N-terminal end of the naturally 
processed peptide. Deletion of the Cys aa residue at the COOH terminus also 
resulted in a significant decrease in recognition (Figure 3C). Taken together, 
these data indicated that the 9-mer TPNQRQNVC peptide is the naturally 
presented epitope at the cell surface by HLA-B7 molecules that is recognized by 
CTL RP1. 
 
Expansion of LRH-1–specific CD8+ T cells after DLI precedes remission of 
leukemia  
To detect LRH-1–specific CD8+ T cells in vivo, we constructed an HLA-B7 
tetramer using the 9-mer peptide TPNQRQNVC. Before DLI, tetramer+ cells 
could not be detected (≤0.01%) in the peripheral blood of CML patient UPN389 
(data not shown), whereas LRH-1–specific CD8+ T cells were clearly detectable 
after DLI-2 (Figure 4). The PBMC sample that was used for isolation of CTL 
RP1 contained 0.27% of tetramer+ cells among CD8+ T cells. This percentage 
increased rapidly in the peripheral blood to a peak level of 1.6% at 6 months 
after cessation of CsA treatment (Figure 4). At that time, 1.4% LRH-1–specific 
CD8+ T cells could also be detected in the BM (data not shown). These in vivo–
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expanded LRH-1–specific CD8+ T cells displayed the CD45RA+CCR7-CD27- 
cytotoxic effector phenotype, indicative of an ongoing GVL reaction (data not 
shown). The number of circulating tetramer+ cells declined to 0.25% at 12 
months but persisted at a low frequency (0.05–0.10%) (Figure 4). Specific 
detection of LRH-1–specific CTLs by the tetramers was verified after in vitro 
stimulation of PBMC samples with peptide-pulsed donor EBV-LCLs. After 2 
rounds of stimulation, tetramer+ CD8+ T cells markedly increased up to 6.8% for 
month 3, 13.9% for month 6, 4.2% for month 12, and 2.0% for month 38 (Figure 
4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Detection of LRH-1–specific CD8+ T cells in peripheral blood of CML patient 
UPN389 after DLI. PBMCs collected 3, 6, 12, and 38 months after DLI-2 were stained with 
LRH-1/HLA-B7 tetramer, anti-CD8, anti-CD45, anti-CD3, and 7-amino-actinomycin D 
(7AAD). Subsequently, cell populations were analyzed by flow cytometry. Cells were gated 
on CD45+CD3+7AAD- lymphocytes, and the percentages of tetramer-binding cells among 
CD8+ T cells are given. The remaining PBMCs were stimulated twice with LRH-1 peptide–
pulsed (10 µM) EBV-LCL of the donor and assayed on day 14 for LRH-1 tetramer-binding 
CD8+ T cells. 
 
Correlation of the emergence of LRH-1–specific CTLs with clinical outcome 
of DLI-2 revealed that the peak of tetramer+ cells was followed immediately by 
pancytopenia and a dramatic decrease in Bcr-Abl in the peripheral blood without 
an increase of GVHD (Figure 5, A and B). Thereafter, the patient remained in 
complete cytogenetic remission for more than 2 years despite readministration 
of CsA to treat chronic skin GVHD. However, 4 years after DLI-2, PCR for 
Bcr-Abl had become substantially positive (Figure 5B). The patient was given 
DLI-3 at a relatively low dose of 1×106 CD3+ cells/kg body weight in order to 
avoid severe GVHD. The patient did not develop GVHD, and her tumor 
transformed into CML in accelerated phase with almost all BM cells from 
recipient origin and with del(13) and t(4;11) as found during the first relapse. 
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She was treated with imatinib mesylate (Glivec), and despite DLI-4 (0.1×108 
CD3+ cells/kg body weight) and DLI-5 (0.6×108 CD3+ cells/kg body weight), 
she entered myeloid blastic phase and died without GVHD. During this second 
relapse and concomitant treatment, LRH-1–specific CD8+ T cells were present 
but did not expand (Figure 5, A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Longitudinal follow-up of LRH-1–specific CD8+ T cells in peripheral blood from 
CML patient UPN389 in relation to clinical outcome. (A) The percentage of LRH-1 tetramer-
positive cells among CD8+ T cells (right y axis) are compared with the wbc count × 106 per 
ml peripheral blood (left y axis). (B) The percentages of LRH-1 tetramer-positive cells among 
CD8+ T cells (right y axis) are compared with the relative units of Bcr-Abl in peripheral blood 
(left y axis). The lower level of detection of Bcr-Abl PCR is 4×10-6, depicted by the dotted 
line. Administration of DLIs 1–5 and stem cell (SC) boost are indicated by open and filled 
arrows, respectively. Treatment intervals with imatinib mesylate (Glivec) and CsA are shown 
by open and filled bars, respectively. 
 
Selective expression of the P2X5 gene in leukemic and normal CD34+ 
progenitor cells, lymphoid cells, and lymphoid tissue.  
To more comprehensively define which cell types and tissues could be targeted 
by LRH-1–specific CTLs, we developed a real-time quantitative PCR that 
detects P2X5 transcripts encoding the LRH-1 epitope. The mean P2X5 RNA 
expression level compared with the reference cell line was 2.68 in EBV-LCLs, 
0.28 in monocytes, and 0.10 in fibroblasts (Figure 6A). Based on our results that 
LRH-1–specific CTL recognizes EBV-LCLs but not monocytes and fibroblasts, 
we arbitrarily set the cutoff level at 0.4 to discriminate between LRH-1–positive 
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and –negative cell types. CD34+CD38- and CD34+CD38+ cells isolated from 
myeloid leukemias, including CML in blast crisis and acute myeloid leukemia 
(AML), showed significant P2X5 RNA expression levels, as well as CD34+ 
progenitor subsets isolated from normal BM and G-CSF–mobilized blood 
(Figure 6A). Interestingly, leukemic CD34+CD38- cells appear to have a 
significantly higher P2X5 RNA level compared with normal CD34+CD38- cells 
(P = 0.02; ANOVA; Figure 6A). CD34+CD38- cells obtained at first relapse 
from CML patient UPN389 had a relatively low P2X5 RNA expression of 0.61, 
whereas CD34+CD38+ cells had a higher expression level of 2.67. A slightly 
lower P2X5 expression level of 1.31 was found in CD34+CD38+ cells obtained 
at second relapse (data not shown). We were unable to isolate enough CD34+ 
CD38- cells (<5% of the total CD34+ population) from the second relapse 
sample. These data suggest that leukemic CD34+ progenitor subsets could be 
potentially targeted in vivo by LRH-1–specific CTLs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. P2X5 gene expression is restricted to leukemic and normal CD34+ progenitor cells 
as well as lymphoid cells. (A) P2X5 expression determined by real-time quantitative PCR in 
CD34+ subpopulations isolated from leukemia patients (CML blast crises, n = 4 and acute 
myeloid leukemia, n = 10) and healthy stem cell donors (normal BM, n = 4 and G-CSF–
mobilized peripheral blood, n = 5). Leukemic CD34+ subsets isolated from CML patient 
UPN389 at first relapse are indicated by the arrows. (B) P2X5 expression determined by real-
time quantitative RT-PCR in freshly isolated cells or primary cell cultures of hematopoietic 
and nonhematopoietic origin. Expression is shown relative to the P2X5 expression measured 
in the reference cell line JVM-2, which is susceptible to lysis by the LRH-1–specific CTL 
RP1. The housekeeping Pbgd gene was used for normalization. Cell types with P2X5 
expression less than 0.4 were not recognized by CTL RP1, indicating that these cell types can 
be considered as LRH-1 negative. This arbitrary threshold is indicated with a dashed line. The 
mean expression level for each cell population is shown by the thick line. 
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Freshly isolated as well as cultured cells of the lymphoid lineage including B 
cells, EBV-LCLs, T cells, PHA–T cell blasts, and NK cells showed significant 
levels of P2X5 RNA expression (Figure 6B). In contrast, mature cells of the 
myeloid lineage including monocytes and DCs and nonhematopoietic cells 
including fibroblasts, keratinocytes, melanocytes, human umbilical vein 
endothelial cells (HUVECs), and proximal tubular epithelial cells (PTECs) had a 
very low level of or completely lacked P2X5 transcription. Analysis of P2X5 
expression in normal tissues showed high (>1.0) transcription levels in lymphoid 
tissues such as spleen, tonsils, thymus, and BM (Table 3). No significant (<0.4) 
P2X5 expression could be detected in most adult normal tissues, except for low 
levels in neuronal and muscle tissue. Fetal brain showed a relatively high P2X5 
expression level (2.80), whereas expression levels in the adult brain (0.43) and 
cerebellum (0.70) were much lower. Importantly, no P2X5 expression was 
detected in the GVHD target organs skin, liver, colon, and small intestine (Table 
3). These data demonstrate that P2X5 is selectively expressed in leukemic and 
normal CD34+ progenitor cells and hematopoietic cells of the lymphoid lineage. 
 
Discussion 
 
mHAgs play a pivotal role in inducing T cell responses mediating GVL 
reactivity after HLA-identical allogeneic SCT (4, 5). Molecular definition of 
mHAg peptides is crucial for the development of immunotherapeutic protocols 
to either selectively boost the GVL reaction or to inhibit GVHD. In this study, 
we have identified a novel hematopoietic cell–restricted mHAg, designated 
LRH-1, which is presented by HLA-B*0702 and encoded by the P2X5 
purinergic receptor gene. CTLs specific for LRH-1 (RP1 clone) were isolated 
from a CML patient that was successfully treated with high-dose DLI for relapse 
in accelerated phase after allogeneic SCT. Here, we show a direct association 
between in vivo expansion of LRH-1–specific CTLs and the disappearance of 
Bcr-Abl–positive CML tumor cells following DLI. These findings indicate a 
causative role for LRH-1 in GVL reactivity. Although the patient achieved a 
complete cytogenetic remission after high-dose DLI, low levels of Bcr-Abl 
transcripts remained detectable (Figure 5). Therefore, it remains to be 
investigated whether targeting of LRH-1 in patients with CML might be able to 
eradicate the most undifferentiated leukemic stem cells. GVHD was not 
increased by the emergence of LRH-1–specific CTLs despite interruption of 
CsA treatment. However, it is difficult to conclude that LRH-1–specific CTLs 
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had no role in GVHD, since the patient required readministration of CsA for the 
treatment of chronic skin GVHD. 
 
Table 3. P2X5 and CD45 gene expression in normal tissues. 
___________________________________________________________________________  
 Normal tissue P2X5 CD45 Ratio 
 expression expression (P2X5/CD45) 
___________________________________________________________________________  
 Adrenal gland 0.03 0.21 0.1 
 Bone marrow 1.58 5.25 0.3 
 Brain 0.43 0.02 21.5 
 Cerebellum 0.70 0.07 10.0 
 Colon 0.12 0.10 1.2 
 Fetal brain 2.80 0.06 46.7 
 Fetal liver 0.14 0.14 1.0 
 Heart 0.49 0.28 1.8 
 Kidney 0.02 0.06 0.3 
 Liver 0.01 0.15 <0.1 
 Lung 0.48 2.51 0.2 
 Placenta 0.04 0.99 <0.1 
 Prostate 0.19 1.70 0.1 
 Salivary gland 0.37 0.13 2.8 
 Skeletal muscle  0.56 0.01 56.0 
 Skin 0.01 0.80 <0.1 
 Small intestine 0.16 0.46 0.3 
 Spinal cord 0.35 0.67 0.5 
 Spleen 21.86 11.06 2.0 
 Stomach 0.34 1.47 0.2 
 Testis 0.11 0.09 1.2 
 Thymus 6.43 18.04 0.4 
 Thyroid gland 0.33 0.56 0.6 
 Tonsils 21.00 18.58 1.1 
 Trachea 0.76 0.78 1.0 
___________________________________________________________________________  
Normalized mRNA expression of P2X5 transcript variant 1 and CD45 was determined by 
real-time quantitative PCR and expressed relative to the expression level in the JVM-2 cell 
line. 
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The level of expression of mHAgs may determine whether it is involved in 
GVL and/or GVHD (5). Previous studies by RNA dot blot analysis showed that 
P2X5 is selectively expressed in brain and lymphoid tissues (36). Here, we have 
used sensitive real-time quantitative PCR to determine relative expression levels 
of the P2X5 splice variant 1 encoding mHAg LRH-1. Our results confirm that 
P2X5 is highly expressed in various cell types of lymphoid origin and lymphoid 
tissues. Interestingly, we observed that the P2X5 gene is significantly expressed 
in leukemic CD34+ subpopulations from most CML as well as AML patients. 
We were unable, however, to demonstrate in vitro CTL RP1 recognition of 
CD34+ cells of the CML patient from whom the LRH-1–specific CTL was 
isolated (data not shown). This may be explained by the relatively low P2X5 
expression level (0.61) in the leukemic CD34+CD38- progenitor subset of this 
CML patient, which represented approximately 50% of the total CD34+ 
population (data not shown). But, P2X5 expression in vivo could be higher, 
resulting in increased sensitivity to CTL recognition. The efficiency of killing of 
leukemic CD34+ progenitor cell subsets by LRH-1–specific CTLs is currently 
under investigation using sensitive in vitro progenitor cell cytotoxicity assays 
and could be studied in vivo in the NOD/SCID leukemia model (14, 37). 
Importantly, P2X5 is not expressed in prominent GVHD tissues such as skin, 
liver, colon, and small intestine. Furthermore, mature cells of myeloid origin and 
various nonhematopoietic cell types were negative for P2X5. In nonlymphoid 
tissues, we detected only high P2X5 expression levels in fetal brain, whereas in 
adult tissues, we observed low expression in brain, cerebellum, and skeletal 
muscle, which could not be explained by the presence of hematopoietic cells 
(Table 3). This low level of P2X5 expression could be caused by a small subset 
of cells present in these tissues (38, 39). But based on the fact that both brain 
and skeletal muscle are tissues that are not very likely to be infiltrated with 
lymphocytes without significant inflammation (40), it seemed unlikely that 
LRH-1–specific CTLs damage these cells in vivo. This is supported by our 
finding that emergence of LRH-1–specific CTLs was not accompanied by 
significant toxicity to these organs. 
Most previously described human mHAgs result from disparities in protein 
sequences between donor and recipient due to nonsynonymous SNPs in their 
encoding genes. The resulting aa substitutions may affect either peptide 
processing by the proteasome (10), transporter associated with antigen 
processing translocation of the peptide into the ER (23), binding of the peptide 
to MHC (8), or recognition of the MHC-peptide complex by mHAg-specific T 
cells (20, 22, 41). In the case of an mHAg encoded by the UGT2B17 gene, 
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disparity resulted from differential protein expression due to a homozygous gene 
deletion in the donor, although the genetic basis for this gene deletion remains to 
be elucidated (25). Here, we demonstrate for the first time to our knowledge that 
mHAgs can arise from frameshift polymorphisms that are disparate between 
recipients and their HLA-identical transplant donors.  
P2X5 is a member of the P2X purinergic receptor family consisting of at least 
7 proteins, P2X1 to P2X7, which are capable of forming ATP-gated cation 
channels by homo- or heteromultimerization (42). Transcription of the human 
P2X5 gene results in expression of 2 major isoforms as a result of differential 
splicing (36). Splice variant 1 encodes a long isoform consisting of 422 aas, 
whereas translation of splice variant 2 results in a shorter isoform lacking exon 3 
(397 aas). Our results indicate that a donor-specific, homozygous frameshift 
polymorphism in exon 3 of splice variant 1 leads to the formation of a truncated 
aberrant version of the long P2X5 isoform. Hence, donor-derived T lymphocytes 
are not tolerant of the wild-type exon 3 of the recipient. The high genotype 
frequency (i.e., 46%; unpublished observations) of healthy individuals that are 
homozygous for the cytosine deletion in exon 3 indicates that deficiency for the 
long P2X5 isoform is common without any significant phenotypic 
characteristics. The short P2X5 isoform as well as redundancy among P2X 
family members may compensate for the deficiency of the long P2X5 isoform. 
Hematopoietic cell–restricted mHAgs are suitable targets for the application 
of immunotherapy to prevent or to treat recurrences of hematopoietic 
malignancies after allogeneic SCT. Based on its hematopoietic-specific 
expression, the P2X5-encoded mHAg LRH-1 could be an attractive candidate. 
P2X5 is highly expressed in a broad range of lymphoid malignancies including 
T and B cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, 
various types of B cell lymphoma, and multiple myeloma (unpublished 
observations). Furthermore, CD34+CD38- and CD34+CD38+ myeloid leukemic 
progenitor cells were found to have enriched levels of P2X5 transcripts 
compared with mature nonleukemic monocytes (P < 0.05; ANOVA; Figure 6A), 
suggesting that LRH-1–specific CTLs may preferentially target immature 
myeloid leukemia cells. Therefore, vaccination with the LRH-1 peptide would 
be an attractive approach for induction of GVL reactivity. Recently we 
developed a genotyping assay for the LRH-1 mHAg, and of the 45 HLA-B7–
positive SCT donors and recipients analyzed so far, 6 patients (~13%) positive 
for LRH-1 mHAg received a transplant from an LRH-1–negative donor 
(unpublished observations). These patients would be eligible for LRH-1 
peptide–based vaccination. Studies are underway to determine whether LRH-1–
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specific CD8+ T cells can be detected or induced ex vivo in these LRH-1 
disparate transplant recipients. 
In conclusion, we describe a novel hematopoietic cell–restricted mHAg, 
designated LRH-1, that can function as a GVL-specific antigen for 
hematological malignancies. The significance of mHAg LRH-1 for cellular 
immunotherapy of relapsed leukemia is demonstrated by the direct correlation 
between expansion of LRH-1–specific CTLs and disappearance of CML, and 
the expression of its encoding gene in leukemic CD34+ progenitor cells. In 
addition, we describe a novel mechanism responsible for antigenicity of mHAg 
LRH-1. Our data demonstrate for the first time to our knowledge that 
differential protein expression as a consequence of a homozygous frameshift 
polymorphism is the basis for mHAg disparity. This novel mechanism may 
apply to other mHAgs involved in alloresponses after HLA-identical allogeneic 
SCT. 
 
Acknowledgements 
 
We thank Hanny Fredrix, Arie Pennings (†), and Gertie Vierwinden for 
technical assistance. We thank Ingrid Overes for CD45 PCR analysis and Shahla 
Abdollahi for help in LRH-1 phenotyping of LCLs. We thank Els Goulmy and 
Eric Spierings for providing the HLA-B*0702 cDNA, HLA-B7–alloreactive 
CTL KOR18, and RNA from nonmalignant cell types. We acknowledge our 
Molecular Diagnostics unit for performing Bcr-Abl PCR analysis. We thank 
Saskia Ebeling for providing RNA from keratinocytes. We thank Elke de Grouw 
for providing RNA of CD34+ progenitor subsets. We acknowledge Joop Jansen 
and Gosse Adema for critically reading the manuscript. We thank Fred 
Falkenburg (Department of Hematology, Leiden University Medical Center) for 
advice and discussion. This work was supported by grants from the Dutch 
Cancer Society (KUN 2000-2294), the Bekales Foundation, the W.M. Keck 
Foundation, and the George S. and Delores Doré Eccles Foundation. 
 
References 
 
1. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., 
Rimm, A.A., Ringden, O., Rozman, C., Speck, B., Truitt, R.L., Zwaan, F.E., and Bortin, 
M.M. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 
75: 555–562. 
2. Radich, J.P., Olavarria, E., and Apperley, J.F. 2004. Allogeneic hematopoietic stem cell 
transplantation for chronic myeloid leukemia. Hematol. Oncol. Clin. North Am., 18: 
685–702. 
Chapter 5 
 
 128
3. Suciu, S., Mandelli, F., de Witte, T., Zittoun, R., Gallo, E., Labar, B., De Rosa, G., 
Belhabri, A., Giustolisi, R., Delarue, R., Liso, V., Mirto, S., Leone, G., Bourhis, J.H., 
Fioritoni, G., Jehn, U., Amadori, S., Fazi, P., Hagemeijer, A., and Willemze, R. 2003. 
Allogeneic compared with autologous stem cell transplantation in the treatment of 
patients younger than 46 years with acute myeloid leukemia (AML) in first complete 
remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. 
Blood, 102: 1232–1240. 
4. Goulmy, E. 1997. Human minor histocompatibility antigens: new concepts for marrow 
transplantation and adoptive immunotherapy. Immunol. Rev., 157: 125–140. 
5. Bleakley, M., and Riddell, S.R. 2004. Molecules and mechanisms of the graft-versus-
leukaemia effect. Nat. Rev. Cancer, 4: 371–380. 
6. Marijt, W.A., Heemskerk, M.H., Kloosterboer, F.M., Goulmy, E., Kester, M.G., van der 
Hoorn, M.A., van Luxemburg-Heys, S.A., Hoogeboom, M., Mutis, T., Drijfhout, J.W., 
van Rood, J.J., Willemze, R., and Falkenburg, J.H. 2003. Hematopoiesis-restricted 
minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete 
remissions of relapsed leukemia. Proc. Natl. Acad. Sci. USA, 100: 2742–2747. 
7. Kircher, B., Stevanovic, S., Urbanek, M., Mitterschiffthaler, A., Rammensee, H.G., 
Grunewald, K., Gastl, G., and Nachbaur, D. 2002. Induction of HA-1 specific cytotoxic 
T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br. J. 
Haematol., 17: 935–939. 
8. den Haan, J.M., Meadows, L.M., Wang, W., Pool, J., Blokland, E., Bishop, T.L., 
Reinhardus, C., Shabanowitz, J., Offringa, R., Hunt, D.F., Engelhard, V.H., and 
Goulmy, E. 1998. The minor histocompatibility antigen HA-1: a diallelic gene with a 
single amino acid polymorphism. Science, 279: 1054–1057. 
9. den Haan, J.M., Sherman, N.E., Blokland, E., Huczko, E., Koning, F., Drijfhout, J.W., 
Skipper, J., Shabanowitz, J., Hunt, D.F., Engelhard, V.H., and Goulmy, E. 1995. 
Identification of a graft versus host disease-associated human minor histocompatibility 
antigen. Science, 268: 1476–1480. 
10. Pierce, R.A., Field, E.D., Mutis, T., Golovina, T.N., Von Kap-Herr, C., Wilke, M., Pool, 
J., Shabanowitz, J., Pettenati, M.J., Eisenlohr, L.C., Hunt, D.F., Goulmy, E., and 
Engelhard, V.H. 2001. The HA-2 minor histocompatibility antigen is derived from a 
diallelic gene encoding a novel human class I myosin protein. J. Immunol., 167: 3223–
3230. 
11. Akatsuka, Y., Nishida, T., Kondo, E., Miyazaki, M., Taji, H., Iida, H., Tsujimura, K., 
Yazaki, M., Naoe, T., Morishima, Y., Kodera, Y., Kuzushima, K., and Takahashi, T.  
2003. Identification of a polymorphic gene, BCL2A1, encoding two novel 
hematopoietic lineage-specific minor histocompatibility antigens. J. Exp. Med., 11: 
1489–1500. 
12. Dolstra, H., Fredrix, H., Preijers, F., Goulmy, E., Figdor, C.G., de Witte, T.M., and van 
de Wiel-van Kemenade, E. 1997. Recognition of a B cell leukemia-associated minor 
histocompatibility antigen by CTL. J. Immunol., 158: 560–565. 
13. Dolstra, H., Fredrix, H., Maas, F., Coulie, P.G., Brasseur, F., Mensink, E., Adema, G.J., 
de Witte, T.M., Figdor, C.G., and van de Wiel-van Kemenade E.  1999. Human minor 
histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J. Exp. 
Med., 189: 301–308. 
14. Bonnet, D., Warren, E.H., Greenberg, P.D., Dick, J.E., and Riddell, S.R. 1999. CD8(+) 
minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate 
human acute myeloid leukemia stem cells. Proc. Natl. Acad. Sci. USA, 96: 8639–8644. 
15. Mutis, T., Verdijk, R., Schrama, E., Esendam, B., Brand, A., and Goulmy, E. 1999. 
Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T 
lymphocytes specific for hematopoietic system-restricted minor histocompatibility 
antigens. Blood, 93: 2336–2341. 
mHAg LRH-1-specific CTL responses are associated with GVL 
 
 129
16. de Rijke, B., Fredrix, H., Zoetbrood, A., Scherpen, F., Witteveen, H., de Witte, T., van 
de Wiel-Van Kemenade, E., and Dolstra, H. 2003. Generation of autologous cytotoxic 
and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: 
relevance for precursor B-ALL-specific immunotherapy. Blood, 102: 2885–2891. 
17. Wallny, H.J., and Rammensee, H.G. 1990. Identification of classical minor 
histocompatibility antigen as cell-derived peptide. Nature, 343: 275–278. 
18. Simpson, E., and Roopenian, D. 1997. Minor histocompatibility antigens. Curr. Opin. 
Immunol., 9: 655–661. 
19. Venter, J.C., et al. 2001. The sequence of the human genome. Science, 291:1304–1351. 
20. Wang, W., Meadows, L.R., den Haan, J.M.M., Sherman, N.E., Chen, Y., Blokland, E., 
Shabanowitz, J., Agulnik, A.I., Hendrickson, R.C., Bishop, C.E., Hunt, D.F., Goulmy, 
E., and Engelhard, V.H. 1995. Human H-Y: a male-specific histocompatibility antigen 
derived from the SMCY protein. Science, 269: 1588–1590. 
21. Meadows, L.R., Wang, W., den Haan, J.M.M., Blokland, E., Reinhardus, C., Drijfhout, 
J.W., Shabanowitz, J., Pierce, R., Agulnik, A.I., Bishop, C.E., Hunt, D.F., Goulmy, E., 
and Engelhard, V.H. 1997. The HLA-A*0201-restricted H-Y antigen contains a 
posttranslationally modified cysteine that significantly affects T cell recognition. 
Immunity, 6: 273–281. 
22. Pierce, R.A., Field, E.D., den Haan, J.M.M., Caldwell, J.A., White, F.M., Marto, J.A., 
Wang, W., Frost, L.M., Blokland, E., Reinhardus, C., Shabanowitz, J., Hunt, D.F., 
Goulmy, E., and Engelhard, V.H. 1999. Cutting edge: the HLAA*0101-restricted HY 
minor histocompatibility antigen originates from DFFRY and contains a cysteinylated 
cysteine residue as identified by a novel mass spectrometric technique. J. Immunol., 
163: 6360–6364. 
23. Brickner, A.G., Warren, E.H., Caldwell, J.A., Akatsuka, Y., Golovina, T.N., Zarling, 
A.L., Shabanowitz, J., Eisenlohr, L.C., Hunt, D.F., Engelhard, V.H., and Riddell, S. R. 
2001. The immunogenicity of a new human minor histocompatibility antigen results 
from differential antigen processing. J. Exp. Med., 193: 195–206. 
24. Spierings, E., Brickner, A.G., Caldwell, J.A., Zegveld, S., Tatsis, N., Blokland, E., Pool, 
J., Pierce, R.A., Mollah, S., Shabanowitz, J., Eisenlohr, L.C., van Veelen, P., 
Ossendorp, F., Hunt, D.F., Goulmy, E., and Engelhard, V.H. 2003. The minor 
histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage 
of the lymphoid blast crisis (Lbc) oncoprotein. Blood, 102: 621–629. 
25. Murata, M., Warren, E.H., and Riddell, S.R. 2003. A human minor histocompatibility 
antigen resulting from differential expression due to a gene deletion. J. Exp. Med., 197: 
1279–1289. 
26. Dausset, J., Cann, H., Cohen, D., Lathrop, M., Lalouel, J.M., and White, R. 1990. 
Centre d’etude du polymorphisme humain (CEPH): collaborative genetic mapping of 
the human genome. Genomics, 6: 575–577. 
27. Murray, J.C., Buetow, K.H., Weber, J.L., Ludwigsen, S., Scherpbier-Heddema, T., 
Manion, F., Quillen, J., Sheffield, V.C., Sunden, S., Duyk, G.M., Weissenbach, J., 
Gyapay, G., Dib, C., Morrissette, J., Lathrop, G.M., Vignal, A., White, R., Matsunami, 
N., Gerken, S., Melis, R., Albertsen, H., Plaetke, R., Odelberg, S., Ward, D., Dausset, J., 
Cohen, D., and Cann, H. 1994. A comprehensive human linkage map with centimorgan 
density. Science, 265: 2049–2054. 
28. Warren, E.H., Otterud, B.E., Linterman, R.W., Brickner, A.G., Engelhard, V.H., 
Leppert, M.F., Martin, P.J., and Riddell, S.R. 2002. Feasibility of using genetic linkage 
analysis to identify the genes encoding T cell-defined minor histocompatibility antigens. 
Tissue Antigens, 59: 293–303. 
29. Broman, K.W., Murray, J.C., Sheffield, V.C., White, R.L., and Weber, J.L. 1998. 
Comprehensive human genetic maps: individual and sex-specific variation in 
recombination. Am. J. Hum. Genet., 63: 861–689. 
Chapter 5 
 
 130
30. Meijerink, J., Mandigers, C., van de Locht, L., Tonnissen, E., Goodsaid, F., and 
Raemaekers, J. 2001. A novel method to compensate for different amplification 
efficiencies between patient DNA samples in quantitative realtime PCR. J. Mol. Diagn., 
3: 55–61. 
31. Parker, K.C., Bednarek, M.A., and Coligan, J.E. 1994. Scheme for ranking potential 
HLA-A2 binding peptides based on independent binding of individual peptide side-
chains. J. Immunol., 152: 163–175. 
32. Burrows, S.R., Kienzle, N., Winterhalter, A., Bharadwaj, M., Altman, J.D., and Brooks, 
A. 2000. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. 
J. Immunol., 165: 6229–6234. 
33. Mensink, E., van de Locht, A., Schattenberg, A., Linders, E., Schaap, N., Geurts van 
Kessel, A., and de Witte, T. 1998. Quantitation of minimal residual disease in 
Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time 
quantitative RT-PCR. Br. J. Haematol., 102: 768–774. 
34. Schattenberg, A., Preijers, F., Mensink, E., Bar, B., Schaap, N., Geurts van Kessel, A., 
van der Maazen, R., and de Witte, T. 1997. Survival in first or second remission after 
lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in 
first chronic phase. Bone Marrow Transplant., 19: 1205–1212. 
35. Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M., and 
Haussler, D. 2002. The human genome browser at UCSC. Genome Res. 12: 996–1006. 
36. Le, K.T., Paquet, M., Nouel, D., Babinski, K., and Seguela, P. 1997. Primary structure 
and expression of a naturally truncated human P2X ATP receptor subunit from brain 
and immune system. FEBS Lett., 418: 195–199. 
37. Jedema, I., van der Werff, N.M., Barge, R.M., Willemze, R., and Falkenburg, J.H. 2004. 
New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of 
leukemic precursor cells within a heterogeneous target cell population. Blood, 103: 
2677–2682. 
38. Collo, G., North, R.A., Kawashima, E., Merlo-Pich, E., Neidhart, S., Surprenant, A., 
and Buell, G. 1996. Cloning of P2X5 and P2X6 receptors and the distribution and 
properties of an extended family of ATP-gated ion channels. J. Neurosci., 16: 2495–
2507. 
39. Ryten, M., Dunn, P.M., Neary, J.T., and Burnstock, G. 2002. ATP regulates the 
differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on 
satellite cells. J. Cell Biol., 158: 345–355. 
40. Merrill, J.E., and Benveniste, E.N. 1996. Cytokines in inflammatory brain lesions: 
helpful and harmful. Trends Neurosci., 19: 331–338. 
41. Dolstra, H., de Rijke, B., Fredrix, H., Balas, A., Maas, F., Scherpen, F., Aviles, M.J., 
Vicario, J.L., Beekman, N.J., Ossendorp, F., de Witte, T.M., and van de Wiel-van 
Kemenade, E. 2002. Bi-directional allelic recognition of the human minor 
histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur. J. Immunol., 32: 
2748–2758. 
42. Khakh, B.S., Burnstock, G., Kennedy, C., King, B.F., North, R.A., Seguela, P., Voigt, 
M., and Humphrey, P.P. 2001. International union of pharmacology. XXIV. Current 
status of the nomenclature and properties of P2X receptors and their subunits. 
Pharmacol. Rev., 53: 107–118. 
 
 
 
  
Chapter 6 
 
 
 
 
Role for minor histocompatibility antigens HB-1 and LRH-1 in the 
graft-versus-tumor response against lymphoid malignancies  
 
Björn de Rijke1* 
Ingrid Overes1*  
Agnes van Horssen-Zoetbrood1 
Hanny Fredrix1 
Aniek de Graaf1  
Joop Jansen1  
Han van Krieken2 
Theo de Witte3  
Harry Dolstra1 
 
1Central Hematology Laboratory, 2Department of Pathology and 3Department of Hematology, 
Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands. 
 
*The authors equally contributed to this study. 
 
 
 
 
 
 
 
Manuscript in preparation. 
 
Chapter 6 
 
 132
Summary 
 
Minor histocompatibility antigens (mHAgs) selectively expressed by 
hematopoietic cells or cell lineages are attractive targets for specific 
immunotherapy after allogeneic stem cell transplantation (SCT). In previous 
studies, we described HB-1 and LRH-1 as lymphoid-lineage restricted mHAgs 
capable of eliciting an allogeneic cytotoxic T lymphocyte (CTL) response after 
SCT. Here, we examined by real-time quantitative RT-PCR mRNA expression 
of HB-1 and LRH-1 in patient samples and cell lines from numerous lymphoid 
malignancies. We observed that HB-1 mRNA is predominantly expressed in B- 
and T-cell acute lymphoblastic leukemia and a subset of follicular and diffuse 
large-B cell non-Hodgkin’s lymphomas. In contrast, mRNA of LRH-1 is highly 
expressed in malignant cells from all stages of lymphoid development. 
Furthermore, LRH-1-specific CTLs efficiently recognize and lyse LRH-1-
postive lymphoid tumor cell lines. These findings indicate a role for HB-1 and 
LRH-1 as target for cellular immunotherapy in a broad range of lymphoid 
malignancies.  
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Introduction 
 
Allogeneic hematopoietic stem cell transplantation (SCT) and donor lymphocyte 
infusion (DLI) are effective treatments for hematological malignancies (1). The 
therapeutic efficacy is attributed to the graft-versus-tumor (GVT) response, an 
immune reaction during which donor-derived cytotoxic T lymphocytes (CTLs) 
eliminate malignant cells of the recipient (2, 3). Unfortunately, the beneficial 
GVT reactivity is often accompanied by graft-versus-host-disease (GVHD), 
which results in CTL-mediated destruction of normal tissues. Minor 
histocompatibility antigens (mHAgs) are the major target antigens of these 
immune responses, and expansion of mHAg-specific CTL has been shown to 
coincide with tumor remission following DLI (4, 5). Selective GVT responses in 
the absence of GVHD may result from mHAgs with expression limited to 
hematopoietic cells or hematopoietic cell lineages, including their malignant 
counterparts (2, 3). These hematopoietic-restricted mHAgs are, therefore, 
suitable targets for specific immunotherapy after allogeneic SCT. 
We reported on the molecular characterization of two mHAgs, HB-1 and 
LRH-1, which display lymphoid-restricted tissue distribution and relevant 
expression on leukemic cells and their progenitors (5-7). The human leukocyte 
antigen (HLA)-B44-restricted mHAg HB-1 is specifically expressed in 
CD34+CD19+ B lineage precursor cells, tumor cells of all B-cell acute 
lymphoblastic leukemia (B-ALL) subtypes and B cells transformed with the 
Epstein-Bar virus (EBV) (7). In contrast, the HLA-B7-restricted mHAg LRH-1 
is more broadly expressed within the lymphoid system. Expression of the   
LRH-1 encoding P2X5 gene was demonstrated in normal T, B and NK 
lymphocytes as well as CD34+ progenitor cells (5). Functional analysis with 
HB-1- and LRH-1-specific CTL showed efficient lysis of cells of lymphoid 
origin, whereas no CTL recognition was observed when mature myeloid cells 
and non-hematopoietic cells were used as targets cells (5-8). Importantly, both 
HB-1 and LRH-1 mRNA is not detectable in prominent GVHD target tissues 
such as skin, liver and gut (5, 7). These findings illustrate that HB-1 and LRH-1 
may represent attractive targets for specific immunotherapy after allogeneic 
SCT for lymphoid malignancies. 
Here, we studied the expression of HB-1 and LRH-1 in lymphoid leukemias, 
different subtypes of non-Hodgkin’s lymphoma (NHL) and multiple myeloma 
(MM) as potential target antigens for specific immunotherapy. We found that 
HB-1 is exclusively expressed in B- and T-ALL and a subset of follicular and 
diffuse large-B cell lymphomas. In contrast, LRH-1 is expressed in both 
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immature and mature lymphoid malignancies. Furthermore, we demonstrated 
that lymphoid tumor cell lines are significantly recognized and lysed by LRH-1-
specific CTL. These findings illustrate that LRH-1-specific immunotherapy may 
be applicable for a broad range of lymphoid malignancies. 
 
Materials and methods 
 
Patient and donor material 
Primary tumor samples were used for real-time quantitative RT-PCR analysis: 
B-ALL (n = 20), T-ALL (n = 11), B-cell chronic lymphocytic leukemia (B-CLL, 
n = 26), follicular lymphoma (FL, n = 13), diffuse large B-cell lymphoma 
(DLBCL, n = 12), Burkitt’s lymphoma (BL, n = 10), mantle cell lymphoma 
(MCL, n = 10), marginal zone lymphoma (MZL, n = 5), splenic marginal zone 
lymphoma (SMZL, n = 7) and MM (n = 8). Primary B-ALL, T-ALL and B-CLL 
cells were obtained from bone marrow or peripheral blood mononuclear cells 
(PBMC) of patients at diagnosis. Frozen cells from CLL patients were kindly 
provided by Dr. J.W. Gratama (Department of Internal Oncology, Erasmus 
Medical Centre, Rotterdam, The Netherlands). The amount of tumor cells in the 
ALL and CLL samples was >90% as determined by flowcytometric analysis. 
The different NHL samples were obtained from cryopreserved tumor tissue. The 
FL samples contained at least 80% tumor cells. The BL and MCL samples 
contained at least 90% tumor cells. The DLBCL, MZL and SMZL samples 
contained 50-60% tumor cells. Diagnosis and percentage of tumor cells of the 
NHL samples was confirmed by histological examination and supplementary 
immunohisto-chemical staining (data not shown). CD38 brightly positive 
plasma cells with a purity of >95% were sorted from bone marrow cells of MM 
patients using the Coulter Epics Elite flow cytometer (Beckman Coulter). B 
lymphocytes, T lymphocytes and fibroblasts were isolated from peripheral blood 
or bone marrow of healthy donors and cultured as previously described (5). All 
patient and donor material was obtained after informed consent. 
 
Cell culture 
LRH-1-specific CD8+ CTL clone RP1 was isolated from a chronic myeloid 
leukemia (CML) patient who was successfully treated with DLI after allogeneic 
SCT (5). CTL RP1 recognizes the 9-mer epitope TPNQRQNVC in the context 
of HLA-B*0702. CTL RP1 (0.5×106) was cultured in Iscove’s modified 
Dulbecco’s medium (IMDM) (Invitrogen, Paisley, UK) supplemented with 10% 
human serum (HS) (PAA laboratories, Linz, Austria) containing irradiated (80 
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Gy) recipient EBV-transformed lymphoblastoid cell line (LCL) (0.5×106), 
irradiated (60 Gy) allogeneic PBMCs (0.5×106) from two donors, 100 IU/ml IL-
2 (Eurocetus, Amsterdam, The Netherlands) and 1 μg/ml PHA-M (Boerhinger, 
Mannheim, Germany) in a total volume of 2 ml. The HLA-B7-alloreactive CD8 
CTL+ clone KOR18 was kindly provided by Dr. E. Goulmy (Dept. of 
Immunohematology, LUMC, The Netherlands). CTL KOR18 (2×106) was 
cultured in IMDM/10% HS containing irradiated HLA-B7 positive EBV-LCL 
(5×106), irradiated allogeneic PBMCs (5×106) from two donors, 100 IU/ml IL-2 
and 1 μg/ml PHA-M in a total volume of 10 ml. CTL cultures were used in 
stimulation assays 7 days after stimulation. Cell lines were cultured in 
IMDM/10% fetal calf serum (FCS). 
 
Retroviral transduction of HLA-B*0702 in cell lines and CTL stimulation 
assay  
HLA-B*0702 cDNA (kindly provided by Dr. E. Goulmy) was subcloned in the 
LZRS-IRES-EGFP vector. The resulting LZRS-HLA-B*0702-IRES-EGFP 
vector was used to generate a stable producer cell line. Retroviral transduction 
was performed using non-tissue culture-treated 35-mm2 dishes (Becton 
Dickinson) coated with 10 μg/ml RetroNectin (Takara Biomedicals). Target 
cells (106) were resuspended in 2 ml virus supernatant and transferred to 
RetroNectin-coated dishes. After 24 h of incubation, cells were collected and 
incubated with fresh virus supernatant. Finally, transduced cells were cultured 
for at least 5 additional days before use in CTL stimulation assays as described 
previously (6). Briefly, CTL (5×103) were cultured in 96-wells flat-bottom 
plates in the presence of target cells (3×104) and 25 U/ml IL-2 in a total volume 
of 200 μl. Cells were incubated for 24 hours at 37°C. Release of IFN-γ was 
determined by ELISA (Endogen).  
 
Real-time quantitative RT-PCR analysis of HB-1 and P2X5 gene  
Total RNA was isolated from cell samples using Trizol (Invitrogen) or the Zymo 
RNA isolation kit II (Zymo Research Corp.). First strand cDNA was prepared 
from 2 μg total RNA using oligo-dT, random hexamers and Mo-MuLV reverse 
transciptase (Invitrogen). The porphobilinogen deaminase (Pbgd) housekeeping 
gene was used to normalize HB-1 and P2X5 expression. One μl of cDNA was 
amplified in a 50 μl reaction mixture containing 1.25 U AmpliTaq Gold 
(Applied Biosystems), 300 nM gene-specific forward and reverse primer, 150-
300 nM gene-specific Taqman probe (300 nM for HB1, 150 nM for P2X5, and 
300 nM for Pbgd), 250 μM of each dNTP, 5 mM MgCl2 and 1x Taqman PCR 
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buffer (Applied Biosystems). The following gene-specific primers and Taqman 
probes were used: HB-1; HB-1-F 5’-CACCACAGTGGAGAAACCAGAACT-
G-3’, HB-1-R 5’-CGACTTCCAAACATGCAGAGAA-3’ and HB-1-probe 5’-
(TET)-AAAAAGAAGAGACGTAAGACCGACGAGGA-TAMRA)-3’, P2X5; 
P2X5-F 5’-TCCTGGCGTACCTGGTCGT-3’, P2X5-R 5’-CTTCATTCTCAG-
CACAGACGTTC-3’ and P2X5-probe 5’-(TET)-TGGGTGTTCCTGATAAA-
GAAGGGTTACCA-(TAMRA)-3’, and Pbgd; PBGD-F 5’-GGCAATGCGGC-
TGCAA-3’, PBGD-R 5’-GGGTACCCACGCGAATCAC-3’ and PBGD-probe 
5’-(VIC)-CTCATCTTTGGGCTGTTTTCTTCCGCC-(TAMRA)-3’. PCR am- 
plification was performed using an ABI Prism 7700 (Applied Biosystems) with 
the following PCR conditions: enzyme activation for 10 min at 95°C, followed 
by 45 cycles of 95°C for 15 s and 60°C for 1 min. HB-1 and P2X5 mRNA 
expression was quantified by determining calibration functions using KM3 and 
JVM-2 as reference cell lines, respectively. The level of HB-1 and P2X5 
expression of test samples was calculated relative to the HB-1 and P2X5 
expression in the KM3 and JVM-2 cell lines. 
 
P2X5 genotyping 
Genomic DNA was isolated from cell lines using the QIAamp DNA Blood mini 
kit (Qiagen). Nine μg of DNA was amplified in a 50 μl reaction mixture 
containing 1.25 U AmpliTaq Gold (Applied Biosystems), 300 nM  P2X5-
specific forward and reverse primer (Biolegio), 200 nM of each allele-specific 
Taqman probe, 250 μM of each dNTP, 5 mM MgCl2 and 1x Taqman PCR 
buffer (Applied Biosystems). The following gene-specific primers and Taqman 
probes were used: P2X5; P2X5-EXON3-F 5’-CCAAATCAAACCTCAGCAC-
AGAC-3’, P2X5-EXON3-R 5’-CTCAGTGCCTCTCTGGTTCCTTA-3’, P2X5 
5C allele-specific probe 5’-(FAM)-ATTGTGACCCCCAACCA-(TAMRA)-3’ 
and P2X5 4C allele-specific probe 5’-(VIC)-TGTGACCCCAACCAG-
(TAMRA)-3’. PCR amplification was performed using an ABI Prism 7700 
(Applied Biosystems) with the following PCR conditions: enzyme activation for 
10 min at 95°C, followed by 45 cycles of 92°C for 15 s and 62°C for 1 min. 
After amplification, an end-plate read was performed using ABI Prism 7700 
allelic discrimination software. 
 
Carboxy-fluorescein diacetate succinimidyl ester (CFSE)-based cytotoxicity 
assay  
CFSE-based cytotoxicity assays were performed as described by Jedema et al. 
(9) with minor adaptations. Briefly, target cells were washed with phosphate-
LRH-1-specific CTL targets lymphoid malignancies  
 
 137
buffered saline and resuspended at 20×106 cells/ml. Endogenous HLA-B7 
positive cell lines were labeled with 5 μM CFSE (Molecular Probes Europe, 
Leiden, the Netherlands) and HLA-B7 positive EBV-LCL were labeled with 2.5 
μM CFSE for 10 min at 37°C. The reaction was terminated by adding an equal 
volume of FCS, followed by incubation at room temperature for 2 min. CFSE-
labeled targets were washed with IMDM/10% FCS. Alternatively, cell lines 
retrovirally transduced with LZRS-HLA-B*0702-IRES-EGFP were used as 
targets without CFSE labeling. Target cells (1×104) were cultured in 96-wells 
round-bottom plates in the presence of 5×103 CTLs in a total volume of 200 μl 
IMDM/10% FCS plus 25 U/ml IL-2 and incubated for 40 h at 37°C. To 
determine absolute cell numbers prior to co-culture with CTLs a fixed amount of 
Flow-Count Fluorospheres (1×104) (Beckman Coulter) were added to 100 μl of 
target cells and 5×103 beads were acquired by flowcytometry at 525 nM. After 
40 h, cells were labeled with 7-amino-actinomycin D (Sigma) to determine cell 
viability and 1×104 Flow-Count Fluorospheres were added to allow quantitative 
analysis of the cell populations. For each sample 5×103 beads were acquired and 
the absolute numbers of viable target cells were determined. The percentage of 
cell survival in the presence of CTLs compared to medium was calculated using 
the following formula: % survival = {[absolute no. viable CFSE+ or GFP+ target 
cells co-cultured with CTLs (t=x)]/ [absolute no. viable CFSE+ or GFP+ target 
cells cultured in medium (t=x)]}×100%. The percentage of CTL specific lysis 
was calculated as follows: % lysis = {100-[% survival compared to medium]}. 
 
Results 
 
HB-1 and P2X5 mRNA expression in primary tumor cells of lymphoid 
malignancies.  
To define which lymphoid malignancies may be targets for HB-1- and/or LRH-
1-specific CTLs, we analyzed the HB-1 and P2X5 gene expression using real-
time quantitative RT-PCR in a large panel of primary lymphoid tumor samples 
including B-ALL, T-ALL, different subtypes of B-NHL and MM (Figure 1 and 
2). Based on previous results that HB-1-specific CTLs recognize EBV-LCL 
(mean relative HB-1 mRNA expression level of 0.7), but not fibroblasts (mean < 
0.1), we arbitrarily set the mRNA expression cut off level at 0.1 to discriminate 
between HB-1-positive and -negative cell types (6) (Figure 1). As shown 
previously, significant HB-1 mRNA expression was detected in primary B-ALL 
cells (mean = 1.7). Albeit at lower levels, most T-ALL samples (7 of 10) also 
showed significant HB-1 expression (mean = 0.4) as well as some FL (5 of 13) 
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and DLBCL (2 of 12) samples. In contrast, no significant HB-1 mRNA 
transcription levels could be detected in B-CLL, MM and the majority of B-
NHL subtypes (mean < 0.1) (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. HB-1 gene expression in primary tumor samples of lymphoid malignancies. HB-1 
expression determined by real-time quantitative RT-PCR in lymphoid tumor cells. The 
following tumor types were analysed: B-ALL (n = 20), T-ALL (n = 11), B-CLL (n = 26), FL 
(n = 13), DLBCL (n = 12), BL (n = 10), MCL (n = 10), MZL (n = 5), SMZL (n = 7), and MM 
(n = 8). Expression is shown relative to the HB-1 expression measured in reference cell line 
KM3, which is susceptible to lysis by the HB-1-specific CTL MP1. The housekeeping Pbgd 
gene was used for normalization. Tumor cells with HB-1 expression higher than 0.1 were 
considered positive and may be targets for HB-1-specific CTL (6). This arbitrary threshold is 
indicated with a dashed line. The mean expression level for each cell population is shown by 
a line. 
 
In parallel, we analyzed expression of P2X5 mRNA encoding the LRH-1 
epitope using a cut off level of 0.4 to distinguish LRH-1-positive from -negative 
cell types (5, Figure 2). Interestingly, significant P2X5 mRNA expression was 
found in all tested malignant lymphoid cell types. The highest mean P2X5 
expression level was observed in B-CLL samples (mean = 23.0), whereas the 
lowest was found in T-ALL tumor cells (mean = 3.1). 
These findings demonstrate that HB-1 is predominantly expressed in B and 
T-ALL and some B-cell lymphoma samples, whereas LRH-1 is significantly 
expressed in tumor cells from all stages of lymphoid development. 
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Figure 2. P2X5 gene expression in primary tumor samples of lymphoid malignancies. P2X5 
expression determined by real-time quantitative RT-PCR in lymphoid tumor cells. The 
following tumor types were analysed: B-ALL (n = 14), T-ALL (n = 11), B-CLL (n = 20), FL 
(n = 12), DLBCL (n = 11), BL (n = 5), MCL (n = 6), SMZL (n = 5), and MM (n = 6) 
Expression is shown relative to the P2X5 expression measured in the reference cell line JVM-
2 which is susceptible to lysis by the LRH-1-specific CTL RP1. The housekeeping Pbgd gene 
was used for normalization. Tumor cells with P2X5 expression higher than 0.4 were 
considered positive and may be targets for LRH-1-specific CTL (5). This arbitrary threshold 
is indicated with a dashed line. The mean expression level for each cell population is shown 
by a line.  
 
P2X5 expressing malignant lymphoid cell lines are recognized by LRH-1-
specific CTL.  
To investigate potential CTL recognition of lymphoid malignancies, HB-1 and 
P2X5 gene expression levels were measured by real-time quantitative RT-PCR 
in a panel of 18 malignant lymphoid cell lines. Significant HB-1 expression was 
only observed in the B-ALL cell lines KM3 and BV173 (data not shown). In 
contrast, high P2X5 expression was found in a broad range of immature and 
mature lymphoid cell lines (Table 1). Subsequently, P2X5 genotyping analysis 
revealed that several cell lines were either homozygous (C/C) or heterozygous 
(C/-) positive for the LRH-1-encoding allele. Next, tumor cell lines with 
endogenous HLA-B7 expression or retrovirally transduced with HLA-B*0702 
cDNA were tested for stimulation of IFN-γ release by CTL RP1 (Table 1). All 
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HLA-B7-positive lymphoid tumor cell lines were significantly recognized by 
the allo-HLA-B7-specific CTL KOR18, indicating susceptibility of the cell lines 
for appropriate T cell stimulation (range 243-1557 pg/ml IFN-γ; Table 1). The 
majority of the homozygous and heterozygous LRH-1+ tumor cell lines were 
significantly recognized by LRH-1-specific CTL RP1 (>100 pg/ml IFN-γ). 
However, the cell lines HPB-ALL, HS-SULTAN, and RPMI 8226 stimulated 
IFN-γ production by CTL RP1 just slightly above the background (123, 141 and 
107 pg/ml IFN-γ, respectively). Surprisingly, no specific CTL stimulation was 
shown using the cell lines KM3 and RPMI 1788 despite LRH-1 positivity and 
functional recognition by the allo-HLA-B7-specific CTL KOR18 (Table 1). 
These data demonstrate that most LRH-1-postitive tumor cell lines can be 
recognized by LRH-1-specific CTLs, but some tumor cell lines are relatively 
defective in stimulating significant IFN-γ production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Specific cytotoxicity of LRH-1 specific CTL RP1 against lymphoid tumor cell 
lines. Cytolytic reactivity of lymphoid cell lines (n = 18) of several subtypes (B-ALL, T-ALL, 
B-PLL, B-NHL and MM) was tested in a CFSE-based cytotoxicity assay. Black bars 
represent cell lines positive for the LRH-1-encoding allele (C/C or C/- genotype). Grey bars 
represent cell lines negative for the LRH-1-encoding allele (-/-). * indicates cell lines with 
endogenous expression of HLA-B7. 
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P2X5 expressing malignant lymphoid cell lines are efficiently lysed by 
LRH-1-specific CTL.  
To investigate whether malignant lymphoid cell lines are susceptible for lysis by 
LRH-1-specifc CTL RP1, we performed a CFSE-based cytotoxicity assay. All 
HLA-B7-positive tumor cell lines were significantly lysed by the allo-HLA-B7-
specific CTL KOR18 (data not shown). Interestingly, LRH-1-specific CTL RP1 
very effectively lysed all tumor cell lines that were either homozygous (C/C) or 
heterozygous (C/-) positive for the LRH-1-encoding allele (Figure 3). No 
cytotoxicity was observed against cell lines that were homozygous (-/-) negative 
for the LRH-1 encoding allele, confirming the specificity of LRH-1-specific 
CTLs. These data clearly demonstrate that all tested LRH1+ tumor cell lines, 
including KM3 and RPMI 1788, are highly susceptible to direct lysis by LRH-1-
specific CTLs.  
 
Discussion  
 
Human hematopoietic-restricted mHAgs represent suitable targets for the 
application of effective cellular immunotherapy to prevent or treat relapse of 
hematological malignancies after allogeneic SCT. In previous studies, we 
identified the molecular nature of mHAg HB-1 and LRH-1 using cDNA 
expression cloning and genetic linkage analysis, respectively (5, 6). Gene 
expression analysis using real-time quantitative RT-PCR showed that the HB-1 
gene was selectively expressed by all B-ALL subtypes and EBV-transformed B 
cells with only low expression in normal testis (6). In contrast, significant P2X5 
mRNA levels were identified in normal T, B and NK cells, lymphoid tissues and 
in normal and malignant CD34+ progenitor subpopulations. Only limited P2X5 
expression was found in normal adult brain and skeletal muscle. Thus, no HB-1 
and P2X5 expression was detected in prominent GVHD target organs, which 
provides evidence that HB-1- and LRH-1-specific CTLs can play a role in GVT 
reactivity without causing severe GVHD. This role in GVT reactivity is 
corroborated by a longitudinal follow-up of LRH-1-specific CTLs in peripheral 
blood of a CML patient using HLA-B7/LRH-1 tetramers, which demonstrated a 
direct correlation between expansion of LRH-1 specific CTLs and the 
disappearance of LRH-1 positive CML (5). 
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Table 1. P2X5 mRNA expression, genotype and CTL recognition of lymphoid tumor cell 
lines. 
  
Tumor    Cell line  P2X5  P2X5  IFN-γ production (pg/ml)C  
                        expressionA   genotypeB _________________________________  
    CTL RP1  CTL KOR18  
    _____________  ____________  
    - B7  + B7 - B7  + B7 
  
B-ALL KM3 2.2 C/- < < < 1264
 BV173               1.5             -/- < < < 833 
 
T-ALL HSB2 8.6 C/- < 568 < 1531
 HPB-ALL        1.7      C/- < 123 < 1096
 MOLT4             1.7             -/-           <       < < 243
 CEM        1.1   -/- < < < 574 
 
B-PLL JVM-2* 1.0  C/- 1273 1253 1612 1584 
 
B-NHL RAJI 8.0 C/C < 892 < 1557
 HS-SULTAN 6.8 C/C < 141 < 754
 BJAB 3.9  C/C < 291 < 1557
 RPMI 1788      2.0      C/- < < < 989
 U-698-M* 2.5 -/- < < 771 1030
 RAMOS  1.6 -/- < < < 304
 SU-DHL-6 1.3 -/- < < < 311 
 
MM RPMI 8226          1.5               C/C < 107 < 833
 UM9*  1.3 C/- 109 259 1698 1455
 UM1      0.7 C/-       < 281 < 1455
 U266* 0.6 -/- < < 1181 1455 
  
ANormalized P2X5 mRNA expression was determined by real-time quantitative RT-PCR and 
expressed relative to the expression level in the B-cell prolymphocytic leukemia (B-PLL) 
JVM-2 cell line. 
BP2X5 genotyping was performed by PCR amplification of genomic DNA using allele-
specific probes as described in Material and methods. 
CCell lines were retrovirally transduced with HLA-B*0702 and tested for recognition by CTL 
RP1. INF-γ production was measured by ELISA. 
*Cell lines with endogenous expression of HLA-B7. 
< indicates no significant IFN-γ release by CTL (<100 pg/ml). 
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In this study, we investigated which types of lymphoid malignancies may be 
targets for HB-1- and/or LRH-1-specific immunotherapy. Therefore, we 
analyzed a large panel of lymphoid malignancies for HB-1 and P2X5 gene 
expression using real-time quantitative RT-PCR. This analysis revealed that 
significant HB-1 mRNA levels were found in primary B-ALL samples, which 
confirmed previous findings (6). Albeit at lower levels, significant HB-1 
expression was also found in primary T-ALL cells, which contradicts previous 
findings in malignant T-cell lines (6).  
No significant HB-1 gene expression was observed in the majority of the 
tested subtypes of B-NHL, although some FL and DLBCL samples were HB-1 
positive. To address the question whether HB-1 mRNA expression levels 
correlated with a particular FL tumor grade, we classified the analyzed FL 
samples into tumor grades I, II, IIIa and IIIb based on the number of centrocytes 
present in the tumor. This analysis revealed that increase in tumor grade from I 
to IIIa appears to be associated with an increase in HB-1 gene expression, 
although sample numbers per group were too low to draw firm conclusions (data 
not shown). No significant expression was found in FL type IIIb, which is in line 
with the consideration of FL type IIIb as a separate tumor type (10). Some 
DLBCL samples showed moderate HB-1 expression. To correlate HB-1 gene 
expression with different DLBCL subtypes, we subdivided the tested DLBCL 
samples into germinal center B (GCB) originated or non-GCB originated 
DLBCL using a classification system based on expression of CD10, Bcl6 and 
MUM1 (11). Using this classification system, we observed that HB-1 expression 
was only detected in two samples with GCB-like DLBCL (data not shown). 
Further study in an expanded panel of FL and DLBCL samples is necessary to 
investigate the significance of these preliminary observations. 
Real-time quantitative RT-PCR analysis revealed that the LRH-1-encoding 
gene P2X5 is significantly expressed in a broad range of primary lymphoid 
malignancies, including B-ALL, T-ALL, B-CLL, MM and various subtypes of 
B-NHL. Interestingly, LRH-1-specific CTLs were able to significantly lyse 
LRH-1+ lymphoid tumor cell lines in the CFSE-based cytotoxicity assay. 
However, some lymphoid tumor cell lines were defective in stimulating IFN-γ 
production by LRH-1-specific CTLs. This discrepancy can be explained by the 
prescence of dual activation thresholds for cytotoxicity and cytokine production 
in CTLs as a function of antigen concentration at the cell surface of the target 
cell line (12, 13). Our findings clearly indicate that the CFSE-based cytotoxicity 
assay is a very suitable method to determine CTL-mediated recognition of 
malignant target cells.   
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In conclusion, we demonstrated that HB-1 and LRH-1 may function as 
targets in GVT immunity for various lymphoid malignancies. In particular, 
LRH-1 represents a suitable target for the application of cellular 
immunotherapeutic strategies to treat patients with relapsed lymphoid 
malignancies or residual disease after SCT. The overall applicability of LRH-1-
based immunotherapy is estimated around 2.2% based on LRH-1 recipient 
disparity (~13%; unpublished data) and the HLA-B7 phenotype frequency 
(~17% in the Caucasian population; 14). This clearly underscores the potential 
of LRH-1 as T cell target in mHAg-specific immunotherapy.  
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Summary 
 
Nowadays, various forms of hematological malignancies are successfully cured 
by human leukocyte antigen (HLA)-identical allogeneic hematopoietic stem cell 
transplantation (SCT). SCT has become the treatment of choice for patients with 
chronic myeloid leukemia (CML), and can induce durable remissions in patients 
with acute myeloid leukemia, acute lymphoblastic leukemia (ALL), non-
Hodgkin’s lymphoma and multiple myeloma. The therapeutic efficacy is largely 
attributed to an immune-mediated anti-tumor response, collectively referred to 
as the Graft-versus-Tumor (GVT) reactivity, which specifically eliminates 
residual malignant cells of the recipient. Unfortunately, the beneficial GVT 
response is frequently accompanied with Graft-versus-Host-disease (GVHD) 
resulting in severe damage of normal tissues, in particular to skin, liver and gut. 
Both GVHD and GVT are mediated by donor-derived cytotoxic T lymphocytes 
(CTL) recognizing minor histocompatibility antigens (mHAg) on recipient 
target cells. These mHAg arise from cellular proteins that differ between 
recipient and donor due to genetic polymorphisms. Consequently, alloreactive 
donor CTL recognize via their T cell receptors (TCR) recipient-specific mHAg 
as “foreign” HLA-bound peptides. 
Despite the success of HLA-identical allogeneic SCT in the treatment of 
hematopoietic malignancies, a significant number of patients do not respond and 
eventually suffer from relapse of the disease. Therefore, development of novel 
cellular immunotherapeutic approaches is necessary to eliminate residual tumor 
cells in order to prevent or treat relapse. A prerequisite to augment specific anti-
tumor T cell reactivity in the setting of allogeneic SCT is to separate GVT from 
GVHD. This can be achieved by targeting donor-derived CTL to mHAg which 
are exclusively expressed by hematopoietic cells, including hematopoietic tumor 
cells. Therefore, many studies have been initiated to identify novel 
hematopoietic-restricted mHAg by various approaches using mHAg-specific 
CTL as reagents. cDNA library screening, genetic linkage analysis and peptide 
elution combined with high-performance liquid chromatography and mass-
spectrometry have been successfully applied for the characterization of novel 
CTL-defined mHAg.   
In the past decade, a panel of 23 mHAg and their encoding genes has been 
identified and the number is rapidly expanding. Furthermore, additional studies 
provided precise information regarding their genetics, biochemical structure, 
mechanism of immunogenicity and tissue distribution. So far, the majority of the 
identified mHAg exhibits a ubiquitous tissue distribution and, therefore, have 
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been implicated to induce GVT as well as GVHD. Only a few hematopoietic-
restricted mHAg have been characterized which represent attractive targets for 
specific immunotherapy. Previously, we identified a leukemia-associated mHAg 
using cDNA library screening. This 10-mer polymorphic peptide 
EEKRGSLHVW is encoded by the HB-1 gene of yet unknown function on 
chromosome 5q32 and presented in the context of HLA-B44. The HB-1 mHAg 
represents a promising target to induce specific anti-tumor T cell responses due 
to the restricted gene expression in B-ALL and Epstein-Barr virus-transformed 
B cells. Therefore, additional studies were conducted to provide information 
regarding its potency as a T cell target for cellular immunotherapy. 
The immunogenicity of mHAg HB-1 results from an amino acid change of 
Tyrosine (Y) to Histidine (H) in the HB-1 antigenic peptide due to a single 
nucleotide polymorphism in the HB-1 gene. The corresponding allelic variants 
were designated HB-1Y and HB-1H, respectively. Chapter 2 describes the 
development of a genotyping assay to determine the HB-1 allele and genotype 
frequencies. It was shown that the recipient disparity for HB-1H is 2.8%, 
whereas recipient disparity for the HB-1Y allelic variant is 12.4%. Therefore, 
we addressed the question whether the HB-1Y peptide is reciprocally 
immunogenic. For this, we investigated the effect of the HB-1 polymorphism on 
HLA-B44 peptide binding and proteasome digestion. Competition-based peptide 
binding analysis showed that the H/Y amino acid substitution did not change the 
binding affinity of the different variant peptides to HLA-B44. Furthermore, it 
was shown that the H/Y change has no influence on the generation of epitope 
precursor peptides by proteasome-mediated cleavage. These findings were 
confirmed by the autologous induction of a HB-1Y-specific CTL clone using 
peptide-loaded dendritic cells (DC). These CTL were able to efficiently 
recognize HB-1Y peptide-pulsed and cDNA transfected target cells. TCR-
specificity analysis of HB-1H and HB-1Y-specific CTL clones revealed that 
differential recognition of the HB-1 peptide variants is the result of TCR 
discrimination. These data indicate that mHAg HB-1 can induce bi-directional 
CTL responses, and that both allelic variant peptides may play a role in the GVT 
response after allogeneic SCT. 
In a previous study, we have shown that the HB-1 mRNA is differentially 
expressed in all B-ALL subtypes. Therefore, we investigated the potential use of 
the HB-1 antigen as an autologous T cell target for immunotherapy. In Chapter 
3 the generation of autologous cytotoxic and helper T cell responses against B-
ALL-associated mHAg HB-1 is described. In vitro CTL induction experiments 
using mature monocyte-derived DC resulted in the generation of several anti-
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HB-1H CD8+ T cell lines, which showed cytotoxicity against peptide-pulsed 
target cells. Furthermore, one of the in vitro-induced CTL lines displayed 
specific reactivity against target cells which presented the endogenously 
processed HB-1H epitope. Interestingly, this CTL also significantly recognized 
HB-1H+ primary B-ALL cells. In parallel, HB-1-specific CD4+ helper T cell 
clones were also generated using mature HB-1 protein-loaded DC. The 
molecular nature of two novel HLA-DR-restricted epitopes was identified. 
These data implicate that HB-1 is a suitable target antigen for cellular 
immunotherapy to treat B-ALL patients in the autologous setting.  
cDNA library screening and genetic linkage analysis are proven genetic 
methods for the identification of novel human CTL-defined mHAg. However, 
each approach has its specific drawbacks that may lead to mis-identification of 
the mHAg of interest. In Chapter 4, both approaches were refined to facilitate 
more robust molecular characterization of novel hematopoietic-restricted 
mHAg. First, the cDNA library screening was adapted by using a 293T cell line 
that was stably transfected with HLA class I, CD80 and CD54 molecules. Usage 
of this stable 293T mammalian expression system resulted in extremely efficient 
CTL activation, which improved the reliability of cDNA library screening. 
Despite this improvement, we failed to identify a novel HLA-B7-restricted 
mHAg. Second, the genetic linkage analysis was optimized to accurately 
pinpoint the chromosomal location of the mHAg-encoding gene. Single 
nucleotide polymorphism genotyping provided additional information about the 
genetic position of the mHAg-encoding gene. We believe that application of 
these optimized genetic methods will lead to more rapid and reliable molecular 
identification of hematopoietic-restricted mHAg. 
Using the optimized genetic linkage approach combined with gene expression 
profiling, a novel human HLA-B7-restricted mHAg, designated lymphoid-
restricted histocompatibility antigen-1 (LRH-1), was molecular identified as 
described in Chapter 5. We showed that the P2X5 gene, located on 
chromosome 17p13.2, encodes the 9-mer epitope TPNQRQNVC which is 
recognized by CTL in the context of HLA-B*0702. Interestingly, we 
demonstrated that the immunogenicity for LRH-1 is due to differential protein 
expression between recipient and donor as a result of a homozygous frameshift 
polymorphism in the P2X5 gene. Expression analysis of P2X5 using real-time 
quantitative RT-PCR showed selective expression in leukemic and normal 
CD34+ progenitor cells, lymphoid cells and lymphoid tissues. Furthermore, we 
constructed a HLA-B7 tetramer using the 9-mer antigenic peptide to 
longitudinally follow-up the LRH-1-specific CD8+ T cells in the peripheral 
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blood of the CML patient from which the LRH-1-specific CTL was originally 
isolated. This analysis showed a clear correlation between the emergence of 
CTL and complete remission of the CML. These findings clearly demonstrate 
that the leukemia-restricted mHAg LRH-1 is a promising candidate mHAg for 
the development of cellular immunotherapy of hematopoietic malignancies.  
Cells of the lymphoid lineage selectively express mHAg HB-1 and LRH-1. In 
Chapter 6, the mRNA level of HB-1 and P2X5 in primary cells and cell lines of 
several lymphoid malignancies is investigated using real-time quantitative RT-
PCR. It is shown that P2X5 is highly expressed in tumor cells from all stages of 
lymphoid development. In contrast, HB-1 is predominantly expressed in B-ALL, 
T-ALL and some B-cell lymphoma samples. In addition, LRH-1-specific CTL 
efficiently recognizes and kills LRH-1+ lymphoid tumor cell lines in vitro 
implicating a possible role for LRH-1 mismatches in GVT reactivity. These 
results indicate that LRH-1-specific immunotherapy after allogeneic SCT is 
feasible to eradicate residual tumor cells in patients with LRH-1+ lymphoid 
malignancies.  
mHAg HB-1 and LRH-1 represent potent antigens to specifically induce 
CTL-mediated immune responses against hematopoietic malignancies due to 
their significant expression in malignant CD34+ progenitor cells and lymphoid 
malignancies. The combined mHAg and HLA class I phenotypic frequencies of 
mHAg HB-1H, HB-1Y and LRH-1 results in an overall applicability of 0.7%, 
2.9% and 2.2%, respectively. Therefore, these mHAgs are suitable to induce 
specific GVL reactivity in a significant number of patients in the setting of 
mHAg-based immunotherapy. In conclusion, the studies described in this thesis 
provide novel insights and perspectives in mHAg immunobiology. In the future, 
this knowledge provides a solid basis for the development of specific cellular 
immunotherapeutic strategies to successfully treat patients with relapsed 
hematopoietic malignancies after allogeneic SCT.  
 
 
 
 
 
 
 
 
 
 
Chapter 7 
 
 152
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samenvatting 
 
 153
Samenvatting 
 
Tegenwoordig worden verschillende hematologische maligniteiten met succes 
behandeld door middel van een humane leukocyt antigeen (HLA)-identieke 
allogene hematopoïetische stamceltransplantatie. Voor patiënten met chronische 
myeloide leukemie (CML) is dit de enige kans op genezing. Bovendien kan 
allogene SCT leiden tot langdurige remissies bij patiënten met acute myeloide 
leukemie, acute lymfatische leukemie (ALL), non Hodgkin’s lymfoom en 
multipel myeloom. De therapeutische werkzaamheid is grotendeels te danken 
aan een immuun-gemedieerd anti-tumor effect, de zogenaamde graft-versus-
tumor (GVT) reactiviteit. Deze GVT-reactiviteit maakt de achtergebleven 
maligne cellen van de ontvanger onschadelijk. Helaas gaat deze gunstige GVT-
reactiviteit vaak gepaard met graft-versus-host-ziekte (GVHD) wat grote schade 
veroorzaakt aan normale weefsels zoals huid, lever en darmen. Zowel GVHD 
als GVT worden veroorzaakt door cytoxische T cellen (CTL) afkomstig van de 
donor die zogenaamde minor histocompatibiliteits-antigenen (mHAg) herkennen 
op cellen van de ontvanger. Deze mHAg zijn afkomstig van cellulaire eiwitten 
welke verschillen tussen donor en ontvanger als gevolg van genetische 
polymorfismen. Dit heeft als gevolg dat alloreactieve donor CTL via hun T-cel 
receptoren ontvangerspecifieke mHAg herkennen als lichaamsvreemde 
antigenen gebonden aan HLA-moleculen.  
Ondanks het grote succes van HLA-identieke allogene stamceltransplantatie 
in de behandeling van hematopoïetische maligniteiten reageert een groot aantal 
patiënten niet voldoende waardoor de ziekte uiteindelijk terugkeert. Daarom is 
ontwikkeling van nieuwe cellulaire immuuntherapeutische behandelingen 
noodzakelijk om achtergebleven tumor cellen onschadelijk te maken om zo de 
terugkeer van de ziekte te voorkomen of tegen te gaan. Om specifieke anti-
tumor T cel reactiviteit op te wekken is een scheiding tussen GVT en GVHD 
een vereiste. Dit kan worden bereikt door CTL van de donor te richten tegen 
mHAg die exclusief door hematopoïetische cellen, waaronder tumor cellen, tot 
expressie worden gebracht. Om deze nieuwe hematopoïetische-gerestricteerde 
mHAg te identificeren zijn vele onderzoeken uitgevoerd met behulp van 
verschillende technieken die gebruik maken van mHAg-specifieke CTL. 
Technieken als cDNA-bank screening, genetische koppelings analyse en peptide 
elutie gecombineerd met HPLC en massa-spectrometrie, zijn met succes 
toegepast om nieuwe CTL-gedefinieerde mHAg moleculair te karakteriseren. 
In de afgelopen tien jaar is een panel van 23 mHAg, inclusief hun coderende 
genen, geïdentificeerd en dit aantal neemt sterk toe. Bovendien hebben 
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aanvullende studies gedetailleerde informatie opgeleverd met betrekking tot hun 
genetische achtergrond, biochemische structuur, mechanisme van 
immunogeniciteit en weefsel distributie. Tot nu toe vertoont de meerderheid van 
de geïdentificeerde mHAg een brede weefsel distributie waardoor deze 
waarschijnlijk betrokken zijn bij de inductie van zowel GVHD als GVT. Echter 
een klein aantal hematopoïetische-gerestricteerde mHAg zijn attractief voor 
ontwikkeling van specifieke immuuntherapie. In eerdere studies hebben wij een 
leukemie-geassocieerde mHAg geïdentificeerd door middel van cDNA-bank 
screening. Dit 10-meer polymorfe peptide EEKRGSLHVW wordt gecodeerd 
door het HB-1 gen met een nog onbekende functie op chromosoom 5q32 en 
wordt gepresenteerd door HLA-B44. Het HB-1 antigeen vertegenwoordigt door 
zijn gerestricteerde gen expressie in B-ALL en Epstein-Barr virus 
getransformeerde B cellen een veelbelovend antigeen om een specifieke anti-
tumor respons te induceren. Aanvullende studies werden uitgevoerd om 
gegevens te verkrijgen over de potentie van HB-1 als een T cel target voor 
cellulaire immuuntherapie. 
De immunogeniciteit van mHAg komt tot stand door een aminozuur 
verandering in het HB-1 peptide als gevolg van een nucleotide polymorfisme in 
het HB-1 gen. De verschillende allel varianten worden HB-1Y en HB-1H 
genoemd. Hoofdstuk 2 beschrijft de ontwikkeling van een genomische 
typerings test om de HB-1 allel- en genotype-frequenties te bepalen. Met behulp 
van de ontwikkelde test hebben we aangetoond dat het ontvanger verschil voor 
het HB-1H allel 2,8% bedraagt, terwijl dit 12,4% bedraagt voor het HB1Y allel. 
Vervolgens hebben we het effect van het HB-1 polymorfisme op de HLA-B44 
peptide binding en proteasome digestie onderzocht en de vraag gesteld of het 
HB-1Y peptide wederzijds immunogeen is. Een competitie-gebaseerde peptide 
bindings test toonde aan dat de H/Y aminozuur substitutie de bindingsaffiniteit 
van verschillende peptide-varianten aan het HLA-B44 niet verandert. Bovendien 
bleek de H/Y substitutie geen invloed te hebben op de generatie van epitoop 
voorloper peptiden door proteasome-gemedieerde klieving. Deze bevindingen 
werden bevestigd door het feit dat HB-1Y specifieke CTL kunnen worden 
geïnduceerd door gebruik te maken van peptide-beladen dendritische cellen 
(DC). Deze HB-1Y specifieke CTL zijn in staat om efficiënt HB-1Y-peptide 
beladen en cDNA getransfecteerde doelwitcellen te herkennen. Het is gebleken 
dat de differentiële herkenning van de HB-1 peptide varianten door HB-1H en 
HB-1Y specifieke CTL klonen tot stand komt door het discriminerende 
vermogen van de T-cel receptor. Deze resultaten tonen aan dat mHAg HB-1 in 
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staat is bi-directionele CTL responsen te induceren en dat beide varianten een 
rol kunnen spelen in de GVT respons na allogene stamceltransplantatie. 
In een vorige studie hebben we aangetoond dat het HB-1 mRNA differentieel 
tot expressie wordt gebracht in alle B-ALL subtypen. We onderzochten 
vervolgens het gebruik van het HB-1 antigeen als een autologe T-cel target voor 
immuuntherapie. Hoofdstuk 3 beschrijft de generatie van autologe cytotoxische 
en helper T-cel responsen tegen het B-ALL geassocieerde mHAg HB-1. In vitro 
CTL inductie experimenten met uit monocyten gekweekte DC resulteerde in de 
generatie van anti-HB-1H CD8+ T-cellijnen, welke cytotoxisch zijn tegen 
peptide-beladen doelwitcellen. Bovendien vertoonde één van de in vitro 
geïnduceerde CTL-lijnen specifieke reactiviteit tegen doelwitcellen, welke het 
endogeen geproduceerde HB-1H epitoop presenteren. Deze CTL herkende 
tevens HB-1H-positieve primaire B-ALL cellen. Tegelijkertijd werden ook HB-
1-specifieke CD4+ T-cel klonen gegenereerd door middel van stimulatie met 
mature DC beladen met gehele HB-1 eiwit. De moleculaire identiteit van twee 
nieuwe HLA-DR-gerestricteerde epitopen werd opgehelderd. Deze gegevens 
impliceren dat HB-1 een geschikt tumor antigen is voor cellulaire 
immuuntherapie om B-ALL patiënten in de autologe setting te behandelen. 
cDNA bank screening en genetische koppelings analyse zijn bewezen 
genetische methoden om nieuwe humaan CTL-gedefinieerde mHAg te 
identificeren. Elke methode heeft echter zijn eigen specifieke beperkingen die 
kunnen leiden tot een misidentificatie van een mHAg. Hoofdstuk 4 beschrijft de 
verfijning van beide methoden om de moleculaire karakterisatie van nieuwe 
hematopoïetische-geresticteerde mHAg te optimaliseren. De cDNA-bank 
screening werd verbeterd door een 293T-cellijn te gebruiken met stabiel 
getransfecteerde HLA klasse I, CD80 en CD54 moleculen. Toepassing van dit 
stabiele 293T expressie systeem resulteerde in een zeer efficiënte CTL-activatie, 
welke de betrouwbaarheid van cDNA-bank screening verbeterde. Ondanks deze 
verbetering slaagden we er niet in om een nieuwe HLA-B7-gerestricteerde 
mHAg te identificeren. Daarna hebben we genetische koppeling analyse 
geoptimaliseerd om de chromosomale locatie van een mHAg-coderend gen 
nauwkeurig vast te stellen. Genotypering van nucleotide polymorfismen 
verschafte aanvullende informatie over de genetische locatie van het mHAg-
coderende gen. We zijn van mening dat toepassing van deze geoptimaliseerde 
genetische methoden in de toekomst zal leiden tot een snellere en betrouwbare 
moleculaire identificatie van hematopoïetische-gerestricteerde mHAg. 
Hoofdstuk 5 beschrijft de moleculaire identificatie van een nieuwe humane 
HLA-B7-gerestricteerde mHAg, lymfoid-gerestricteerd histocompatibiliteits 
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antigeen 1 (LRH-1) genoemd, middels de geoptimaliseerde genetische 
koppeling analyse in combinatie met gen expressie profilering. We hebben 
aangetoond dat het P2X5 gen, gelocaliseerd op chromosoom 17p13.2, codeert 
voor een 9-meer epitoop TPNQRQNVC die door een CTL in de context van 
HLA-B*0702 herkend wordt. De immunogeniciteit van LRH-1 komt door een 
differentiële eiwit expressie tussen ontvanger en donor als gevolg van een 
homozygoot frameshift polymorfisme in het P2X5 gen. Expressie-analyse 
middels real-time kwantitatieve RT-PCR toont aan dat P2X5 selectief tot 
expressie komt in leukemische en normale CD34+ voorloper cellen, lymfoide 
cellen en in lymfoide weefsels. Met behulp van een HLA-B7/LRH-1 tetrameer 
analyseerde we bovendien op verschillende tijdstippen de hoeveelheid LRH-1-
specifieke CD8+ T-cellen in het bloed van de CML patiënt waaruit de LRH-1-
specifieke CTL oorspronkelijk geïsoleerd is. Deze analyse liet een duidelijke 
correlatie zien tussen de opkomst van de CTL en de complete remissie van 
CML. Deze gegevens tonen aan dat de leukemie-gerestricteerde mHAg LRH-1 
een veelbelovend mHAg is voor de ontwikkeling van cellulaire immuuntherapie 
voor hematopoïetische-maligniteiten.  
Minor HAg HB-1 en LRH-1 komen selectief tot expressie in lymfoide cellen. 
Hoofdstuk 6 beschrijft de analyse van HB-1 en P2X5 mRNA expressie in 
primaire cellen en cellijnen van verschillende lymfoide maligniteiten middels 
real-time kwantitatieve RT-PCR. We hebben aangetoond dat P2X5 een hoge 
expressie heeft in tumor cellen afkomstig van alle stadia van de lymfoide 
ontwikkeling. HB-1 wordt echter voornamelijk tot expressie gebracht in B-ALL, 
T-ALL en sommige B-cel lymfoom cellen. Bovendien herkennen en doden 
LRH-1-specifieke CTL LRH-1+ lymphoide tumor cellijnen in vitro, wat een 
mogelijke rol impliceert voor LRH-1 verschillen in GVT reactiviteit. Deze 
resultaten geven aan dat LRH-1-specifieke immuuntherapie na allogene 
stamceltransplantatie haalbaar is om achtergebleven tumor cellen in patiënten 
met LRH-1+ lymfoide maligniteiten onschadelijk te maken. 
mHAg HB-1 en LRH-1 zijn, door hun significante expressie in leukemische 
CD34+ voorloper cellen en lymfoide maligniteiten, potente antigenen om 
specifieke CTL-gemedieerde immuun responsen tegen hematopoïetische 
maligniteiten te induceren. De gecombineerde mHAg- en HLA klasse I fenotype 
frequenties van mHAg HB-1H, HB-1Y and LRH-1 resulteren in een globale 
toepasbaarheid van respectievelijk 0,7%, 2,9% en 2,2%. Deze mHAg zijn dus 
zeer geschikt om specifieke GVL reactiviteit te induceren in een groot aantal 
patiënten door middel van mHAg-gebaseerde immuuntherapie. De studies 
beschreven in dit proefschrift verschaffen nieuwe inzichten en perspectieven in 
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de mHAg immunobiologie. In de toekomst zal deze kennis leiden tot de 
ontwikkeling van specifieke cellulaire immuuntherapeutische strategieën om 
patiënten met hematopoïetische maligniteiten met succes te behandelen.  
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Björn de Rijke, de auteur van dit proefschrift, werd op 16 maart 1977 geboren te 
de Bilt. In 1995 behaalde hij zijn VWO diploma aan het Mondriaan College te 
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begeleiding van Prof. dr. Henk Stunnenberg en Dr. Anneke Braks, gevolgd door 
een stage op het Centraal Hematologisch Laboratorium van het Radboud 
Universitair Medisch Centrum Nijmegen onder begeleiding van Dr. Harry 
Dolstra. In 2000 behaalde hij het doctoraalexamen Medische Biologie met als 
specialisatie moleculaire biologie en immunologie.  
Aansluitend begon hij als assistent in opleiding (AIO) op het Centraal 
Hematologisch Laboratorium van het Radboud Universitair Medisch Centrum 
Nijmegen onder supervisie van Prof. dr. Theo de Witte, Dr. Harry Dolstra en Dr. 
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de moleculaire identificatie van tumor-geassocieerde minor histocompatibiliteits 
antigenen, zoals beschreven in dit proefschrift.  
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7AAD  7-amino-actinomycin D 
Ag   antigen 
ALL   acute lymphoblastic leukemia 
AML   acute myeloid leukemia 
APC   antigen presenting cell 
BL   Burkitt’s lymphoma 
CEPH  Centre d’Etude Polymorphism Humain 
CFSE   carboxy-fluorescein diacetate succinimidyl ester 
CML   chronic myeloid leukemia 
CMV   cytomegalovirus 
CsA   cyclosporin A 
Ct   cycle threshold 
CTL   cytotoxic T lymphocyte 
DC   dendritic cell 
DLBCL  diffuse large B-cell lymphoma 
DLI   donor lymphocyte infusion 
DMSO  dimethyl sulfoxide 
Do   donor 
EBV-LCL  Epstein-Barr virus lymphoblastoid cell line 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
ER   endoplasmic reticulum 
FCS   fetal calf serum 
FITC   fluorescein isothiocyanate 
FL   follicular lymphoma 
GFP   green fluorescent protein 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
GVHD  graft-versus-host disease 
GVL   graft-versus-leukemia 
HBSS  Hanks balanced salt solution 
HLA   human leukocyte antigen 
HPLC  high pressure liquid chromatography 
HS   human serum 
HSV-TK  herpes simplex virus-thymidine kinase 
HUVEC  human umbilical vein endothelial cell 
IFN-γ   interferon γ 
Ig   immunoglobulin 
IL   interleukin 
IMDM  Iscove’s modified Dulbecco’s medium 
LFA   leukocyte function-associated antigen 
Lod   log odds ratio 
MCL   mantle cell lymphoma 
MCM   monocyte-conditioned medium 
MFI   mean fluorescence intensity 
mHAg  minor histocompatibility antigen 
MHC   major histocompatibility antigen 
MM   multiple myeloma 
MZL   marginal zone lymphoma 
NHL   non-Hodgkin’s lymphoma 
NK   natural killer 
Pbgd   porphobilinogen deaminase 
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PBMC  peripheral blood mononuclear cells 
PBS   phosphate-buffered saline 
PE   phycoerythrin 
PGE2   prostaglandin E2 
Ph   Philadelphia chromosome 
PHA   phytohemaglutinin 
PLL   prolymphocytic leukemia 
PTEC   proximal tubular epithelial cells 
RT   reverse transcriptase  
Rt   recipient 
SCT   stem cell transplantation 
SMZL  splenic marginal zone lymphoma 
SNP   single nucleotide polymorphism  
TAA   tumor-associated antigen 
TAP   transporter associated with antigen processing 
TCR   T cell receptor 
Th   T helper 
TNF-α  tumor necrosis factor α 
TRP   tyrosinase-related protein 
WT-1   Wilms tumor-1 
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Little things I should have said and done 
I just never took the time 
You were always on my mind 
 
- Elvis Presley, Always on my mind (1972) 
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